# EDGAR Filing Document

**Accession Number:** 0001803737
**File Stem:** 0001803737-26-000018
**Filing Date:** 2026-3
**Character Count:** 508072
**Document Hash:** d6457f446757eb06c9d28ffc9fba4d0f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001803737-26-000018.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001803737-26-000018

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 110

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260304

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enhabit, Inc.
- **CENTRAL INDEX KEY:** 0001803737
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472409192
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41406
- **FILM NUMBER:** 26723561

**BUSINESS ADDRESS:**
- **STREET 1:** 6688 N. CENTRAL EXPRESSWAY, SUITE 1300
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75206
- **BUSINESS PHONE:** 4696216419

**MAIL ADDRESS:**
- **STREET 1:** 6688 N. CENTRAL EXPRESSWAY, SUITE 1300
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75206

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Encompass Health Home Health Holdings, Inc.
- **DATE OF NAME CHANGE:** 20200218

?xml version='1.0' encoding='ASCII'? ehab-20251231

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K**

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the fiscal year ended December 31, 2025** 

**or**

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _________ to ________**

**Commission file number 001-41406** 

**Enhabit, Inc.**

**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**47-2409192** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |

---

---

| | |
|:---|:---|
| **6688 N. Central Expressway, Suite 1300,** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**75206** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Dallas, TX** | (Zip code) |
| (Address of principal executive offices) | |

---

**214-239-6500**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.01 per share** | **EHAB** | **New York Stock Exchange** |

---

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes □ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No □

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes □ No ☒

The aggregate market value of the voting stock held by non-affiliates of the registrant as of the last business day of the registrant's most recently completed second fiscal quarter was $480.1 million (based on the last reported sale price on the New York Stock Exchange as of such date).

The registrant had outstanding 50,723,245 shares of common stock as of February 26, 2026.

**Documents Incorporated By Reference**

Portions of the registrant's proxy statement for its 2026 Annual Meeting of stockholders are incorporated by reference into Part III.

------

**ENHABIT, INC.**

**FORM 10-K**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| [PART I](#i37ed9800c8d04a6988fc71aea423e4a2_16) | [PART I](#i37ed9800c8d04a6988fc71aea423e4a2_16) | [PART I](#i37ed9800c8d04a6988fc71aea423e4a2_16) |
| [Item 1](#i37ed9800c8d04a6988fc71aea423e4a2_19) | [Business](#i37ed9800c8d04a6988fc71aea423e4a2_19) | [1](#i37ed9800c8d04a6988fc71aea423e4a2_19) |
| [Item 1A](#i37ed9800c8d04a6988fc71aea423e4a2_61) | [Risk Factors](#i37ed9800c8d04a6988fc71aea423e4a2_61) | [16](#i37ed9800c8d04a6988fc71aea423e4a2_61) |
| [Item 1B](#i37ed9800c8d04a6988fc71aea423e4a2_82) | [Unresolved Staff Comments](#i37ed9800c8d04a6988fc71aea423e4a2_82) | [31](#i37ed9800c8d04a6988fc71aea423e4a2_82) |
| [Item 1C](#i37ed9800c8d04a6988fc71aea423e4a2_85) | [Cybersecurity](#i37ed9800c8d04a6988fc71aea423e4a2_85) | [32](#i37ed9800c8d04a6988fc71aea423e4a2_85) |
| [Item 2](#i37ed9800c8d04a6988fc71aea423e4a2_88) | [Properties](#i37ed9800c8d04a6988fc71aea423e4a2_88) | [32](#i37ed9800c8d04a6988fc71aea423e4a2_88) |
| [Item 3](#i37ed9800c8d04a6988fc71aea423e4a2_91) | [Legal Proceeding](#i37ed9800c8d04a6988fc71aea423e4a2_91)s | [33](#i37ed9800c8d04a6988fc71aea423e4a2_91) |
| [Item 4](#i37ed9800c8d04a6988fc71aea423e4a2_94) | [Mine Safety Disclosures](#i37ed9800c8d04a6988fc71aea423e4a2_94) | [34](#i37ed9800c8d04a6988fc71aea423e4a2_94) |
| [PART II](#i37ed9800c8d04a6988fc71aea423e4a2_97) | [PART II](#i37ed9800c8d04a6988fc71aea423e4a2_97) | [PART II](#i37ed9800c8d04a6988fc71aea423e4a2_97) |
| [Item 5](#i37ed9800c8d04a6988fc71aea423e4a2_100) | [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#i37ed9800c8d04a6988fc71aea423e4a2_100) | [35](#i37ed9800c8d04a6988fc71aea423e4a2_100) |
| [Item 6](#i37ed9800c8d04a6988fc71aea423e4a2_103) | [\[Reserved\]](#i37ed9800c8d04a6988fc71aea423e4a2_103) | [36](#i37ed9800c8d04a6988fc71aea423e4a2_103) |
| [Item 7](#i37ed9800c8d04a6988fc71aea423e4a2_106) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#i37ed9800c8d04a6988fc71aea423e4a2_106) | [36](#i37ed9800c8d04a6988fc71aea423e4a2_106) |
| [Item 7A](#i37ed9800c8d04a6988fc71aea423e4a2_124) | [Quantitative and Qualitative Disclosures About Market Risks](#i37ed9800c8d04a6988fc71aea423e4a2_124) | [50](#i37ed9800c8d04a6988fc71aea423e4a2_124) |
| [Item 8](#i37ed9800c8d04a6988fc71aea423e4a2_127) | [Financial Statements and Supplementary Data](#i37ed9800c8d04a6988fc71aea423e4a2_127) | [50](#i37ed9800c8d04a6988fc71aea423e4a2_127) |
| [Item 9](#i37ed9800c8d04a6988fc71aea423e4a2_130) | [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#i37ed9800c8d04a6988fc71aea423e4a2_130) | [50](#i37ed9800c8d04a6988fc71aea423e4a2_130) |
| [Item 9A](#i37ed9800c8d04a6988fc71aea423e4a2_133) | [Controls and Procedures](#i37ed9800c8d04a6988fc71aea423e4a2_133) | [50](#i37ed9800c8d04a6988fc71aea423e4a2_133) |
| [Item 9B](#i37ed9800c8d04a6988fc71aea423e4a2_136) | [Other Information](#i37ed9800c8d04a6988fc71aea423e4a2_136) | [51](#i37ed9800c8d04a6988fc71aea423e4a2_136) |
| [Item 9C](#i37ed9800c8d04a6988fc71aea423e4a2_139) | [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#i37ed9800c8d04a6988fc71aea423e4a2_139) | [51](#i37ed9800c8d04a6988fc71aea423e4a2_139) |
| [PART III](#i37ed9800c8d04a6988fc71aea423e4a2_142) | [PART III](#i37ed9800c8d04a6988fc71aea423e4a2_142) | [PART III](#i37ed9800c8d04a6988fc71aea423e4a2_142) |
| [Item 10](#i37ed9800c8d04a6988fc71aea423e4a2_145) | [Directors, Executive Officers and Corporate Governance](#i37ed9800c8d04a6988fc71aea423e4a2_145) | [52](#i37ed9800c8d04a6988fc71aea423e4a2_145) |
| [Item 11](#i37ed9800c8d04a6988fc71aea423e4a2_148) | [Executive Compensation](#i37ed9800c8d04a6988fc71aea423e4a2_148) | [52](#i37ed9800c8d04a6988fc71aea423e4a2_148) |
| [Item 12](#i37ed9800c8d04a6988fc71aea423e4a2_151) | [Security Ownership of Certain Beneficial Owners and Management](#i37ed9800c8d04a6988fc71aea423e4a2_151) and Related Stockholder Matters | [52](#i37ed9800c8d04a6988fc71aea423e4a2_151) |
| [Item 13](#i37ed9800c8d04a6988fc71aea423e4a2_154) | [Certain Relationships and Related Transactions, and Director Independence](#i37ed9800c8d04a6988fc71aea423e4a2_154) | [52](#i37ed9800c8d04a6988fc71aea423e4a2_154) |
| [Item 14](#i37ed9800c8d04a6988fc71aea423e4a2_157) | [Principal Accountant Fees and Services](#i37ed9800c8d04a6988fc71aea423e4a2_157) | [52](#i37ed9800c8d04a6988fc71aea423e4a2_157) |
| [PART IV](#i37ed9800c8d04a6988fc71aea423e4a2_160) | [PART IV](#i37ed9800c8d04a6988fc71aea423e4a2_160) | [PART IV](#i37ed9800c8d04a6988fc71aea423e4a2_160) |
| [Item 15](#i37ed9800c8d04a6988fc71aea423e4a2_163) | [Exhibit and Financial Statement Schedules](#i37ed9800c8d04a6988fc71aea423e4a2_163) | F-[1](#i37ed9800c8d04a6988fc71aea423e4a2_163) |
| [Item 16](#i37ed9800c8d04a6988fc71aea423e4a2_280) | [Form 10-K Summary](#i37ed9800c8d04a6988fc71aea423e4a2_280) | [53](#i37ed9800c8d04a6988fc71aea423e4a2_280) |
|  | [SIGNATURES](#i37ed9800c8d04a6988fc71aea423e4a2_283) | [54](#i37ed9800c8d04a6988fc71aea423e4a2_283) |

---

i

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**NOTE TO READERS**

As used in this Annual Report on Form 10-K (the "Annual Report"), the terms "Enhabit," "we," "us," "our," and the "Company" refer to Enhabit, Inc. and its consolidated subsidiaries, unless otherwise stated or indicated by context.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This Annual Report contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, our future financial performance, our projected business results, or our projected capital expenditures. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "targets," "potential," or "continue" or the negative of these terms or other comparable terminology. Any forward-looking statement speaks only as of the date of this Annual Report, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, disruption from the proposed Merger (as defined herein) with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement (as defined herein) or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that certain regulatory approvals for the proposed Merger are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed Merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on Merger-related issues; the risk that termination fees may be payable by us in the event that the Merger Agreement is terminated under certain circumstances; reputational risk related to the proposed Merger; the risk of litigation or regulatory action related to the proposed Merger; our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payers, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors', payers', and other contract counterparties' information systems; the outcome of litigation; quality performance and ratings; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; our ability to control costs, particularly labor and employee benefit costs; and such other factors as are discussed throughout Part I, Item 1A, "*Risk Factors*," of this Annual Report.

ii

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**PART I**

**ITEM 1. BUSINESS**

**Overview**

We are a leading provider of home health and hospice services in the United States. We strive to provide our patients with superior clinical care, where our patients prefer it: in their homes. For over 25 years, we have provided care in the low-cost home setting while achieving high-quality clinical outcomes and demonstrating a consistent ability to innovate during varying economic and regulatory climates. As of December 31, 2025, we operated 249 home health and 117 hospice locations across 34 states.

We operate our business in two segments, Home Health and Hospice. Each provides a comprehensive range of high-quality, Medicare-certified services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our Home Health segment provides skilled home health services, including nursing care, physical, occupational and speech therapy, medical social work, and home health aide services. For the year ended December 31, 2025, our Home Health segment had an average daily census of 41,786 and generated $813.8 million in *Net service revenue*, or 76.8% of Enhabit's total *Net service revenue*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our Hospice segment provides skilled hospice services, including nursing care, pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and family member bereavement to terminally ill patients and their families. For the year ended December 31, 2025, our Hospice segment had an average daily census of 3,985 patients and generated $246.2 million in *Net service revenue*, or 23.2% of Enhabit's total *Net service revenue*.

Enhabit is a Delaware corporation, founded in 1998 and headquartered in Dallas, Texas. We operated as a reporting segment of Encompass Health Corporation ("Encompass") from December 2014 to July 1, 2022, when we became an independent public company through the distribution of all outstanding shares of our common stock, par value $0.01 per share, to the stockholders of Encompass. Our common stock is listed under the symbol "EHAB" on the New York Stock Exchange. See Note 1, *Summary of Significant Accounting Policies—Separation from Encompass*, to the accompanying consolidated financial statements.

**Available Information**

Our Internet website address is www.ehab.com, which we use as a channel for routine distribution of important information, including news releases, investor presentations and financial information. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K are available on our website, as soon as reasonably practicable after providing such reports to the Securities and Exchange Commission ("SEC"). The website also contains links to the charters of our four board-level committees, the (i) Audit & Finance Committee, (ii) Compensation & Human Capital Committee, (iii) Care, Compliance, & Cybersecurity Committee, and (iv) Nominating & Corporate Governance Committee, our Corporate Governance Guidelines, Standards of Business Conduct and Ethics, Insider Trading Policy, Incentive Compensation Recoupment Policy, Amended and Restated Bylaws, Amended and Restated Certificate of Incorporation and information regarding certain of our investor presentations, press releases and shareholder communications. Print versions of these materials are available free of charge to any shareholder who provides a written request to the Corporate Secretary at 6688 North Central Expressway, Suite 1300, Dallas, Texas 75206. The contents of our website are not intended to be incorporated by reference into this Annual Report or any other report or document we file, and any reference to our website is intended to be an inactive textual reference only.

Our electronically filed reports can also be obtained on the SEC's internet site at http://www.sec.gov.

**Our Industries**

The home health and hospice industries are large, growing, and highly fragmented. According to the Centers for Medicare and Medicaid Services ("CMS") provider catalogs published in January 2026 and November 2025, there were approximately 12,200 home health agencies and 7,000 hospice agencies nationwide in 2025, respectively. These industries serve an aging U.S. population by providing care in the lowest-cost setting – the patients' homes. Many home health and virtually all hospice patients are eligible for Medicare benefits (federal health insurance for seniors).

The National Health Expenditures published by CMS in 2025 projected approximately $174 billion to be spent on broader home health expenditures, which includes Medicare payments for home health and hospice services. These

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

expenditures are expected to grow to approximately $317 billion by 2033, representing a 7.8% compound annual growth rate. The Medicare Payment Advisory Commission ("MedPAC") reports that Medicare spending for hospice care, which we believe represents the vast majority of total expenditures in the hospice market, increased from $3.0 billion in 2000 to $25.7 billion in 2023, reflecting a compound annual growth rate of 9.8%. The market our industries serve is expected to continue to expand, with Medicare eligible citizens expected to increase from approximately 65.1 million in 2023 to 78.0 million by 2033, according to CMS, positioning both the home health and hospice industries for growth.

***Growing Senior Population Driving Increased Demand***

According to estimates from the U.S. Census Bureau and the 2023 Profile of Older Americans published May 2024 by the Administration for Community Living and the Administration on Aging, the 65 and older population increased from 43.1 million in 2012 to 57.8 million in 2022, or an increase of approximately 34%. The 65 and older population is projected to reach 78.3 million by 2040 and 88.8 million by 2060. Growth in the elderly population in the United States is expected to significantly outpace the expected growth in facility-based beds, driving an ongoing shift from facility-based care to home-based care where clinically appropriate.

***Increasing Focus on Shifting Care to Lower Cost Settings***

The growing senior population puts pressure on an already strained healthcare system, contributing to rising healthcare costs in the United States. The Medicare cost per patient day, as of 2024 (the most current information available), in home health and hospice is $64 and $191, respectively, compared to a skilled nursing facility cost of $683 per day, highlighting home health care's savings potential for the healthcare system. We believe health care payers will increasingly encourage the treatment of patients in their homes and other low-cost settings where clinically appropriate.

***Patient Preference for Home-Based Care***

The COVID-19 pandemic significantly accelerated the demand for high-quality home-based care. Based on a 2024 American Association of Retired Persons survey, 75% of those over age 50 want to stay in their residence as long as possible. Similarly, a 2017 study by KFF (formerly known as the Kaiser Family Foundation) found that seven in ten Americans would prefer to spend their last days at home as opposed to any other care setting.

***Shift From Medicare Fee-for-Service to Medicare Advantage***

Medicare Advantage, also known as Medicare Part C, is a capitated program through which eligible Medicare beneficiaries may receive Medicare Part A and Part B benefits from private health plans that contract with CMS. Medicare Advantage plans receive fixed, risk-adjusted monthly payments from CMS and are responsible for delivering all Medicare-covered services to enrolled members.

According to KFF, in 2025, more than half of eligible Medicare beneficiaries were enrolled in Medicare Advantage plans, with Medicare Advantage enrollment as a share of the eligible Medicare population growing from 19% in 2007 to 54% in 2025. Between 2024 and 2025, total Medicare Advantage enrollment grew by about 1.3 million beneficiaries, or 4%, and the Congressional Budget Office projects that the share of all Medicare beneficiaries enrolled in Medicare Advantage plans will rise to 64% by 2034. As a result, Medicare Advantage penetration is a significant factor influencing demand for home health services in the markets we serve.

Unlike traditional Medicare fee-for-service ("FFS"), Medicare Advantage plans typically negotiate reimbursement rates directly with home health providers and shift financial risk, control and the administrative burden onto them. Medicare Advantage plans typically pay materially less than FFS Medicare for comparable home health episodes. Our home health industry is responding to Medicare Advantage pressure by becoming disciplined and selective in contract negotiations with payors. Successful providers can command increased reimbursement by delivering quality outcomes and highly satisfactory patient experience (often referred to as value-based purchasing, or "VBP").

When a Medicare Advantage beneficiary chooses hospice, traditional Medicare administers the hospice benefit, while Medicare Advantage covers unrelated services.

***Emphasis on Value-Based Payment Models***

In recent years, VBP models have become increasingly prevalent in contract negotiations between home health providers and payers, including Medicare Advantage plans, commercial insurers, and large Accountable Care Organizations ("ACOs"). For home health, VBP is fully integrated into the Medicare system through the nationwide Home

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Health Value-Based Purchasing ("HHVBP") Model, and many non-governmental payers have adopted similar quality- and outcome-based reimbursement structures. In the hospice sector, while there is currently no formal, nationwide VBP program, CMS has indicated interest in advancing VBP-aligned initiatives such as the development of new quality measurement tools and pilot programs that may inform future payment models.

**Our Competitive Strengths**

We believe we differentiate ourselves from our competitors by the scale and density of our footprint in targeted markets, our consistent and disciplined operating model emphasizing the use of technology, our clinical expertise and high-quality outcomes, and our people and award-winning culture, among other factors. We also believe that our competitive strengths make us an attractive partner to health systems, payers, and other risk-bearing entities. Additionally, we believe these strengths allow us to adapt and succeed in a healthcare industry facing continuing regulatory changes focused on improving outcomes and reducing costs.

***Scale and Density***

Our footprint reflects our multi-decade effort to establish scale and density, positioning us as a leading provider in key markets with attractive demographic and regulatory profiles. Since 2015, we have deployed over $798 million of capital on 42 home health and hospice acquisitions, which we have fully integrated into our business. Over that same period, we have opened 54 de novo locations (24 home health and 30 hospice) across 23 states. Our strategic presence in these markets helps us increase operating efficiency and brand awareness.

These operating efficiencies help us reduce our home health cost per patient day and increase capacity. For example, our scale in key markets allows for shorter drive time between patient visits, reducing unproductive time on the road. See Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations*—*Segment Results of Operations*," for our home health cost per patient day for the years ended December 31, 2025, 2024, and 2023.

We cross-market our home health and hospice services primarily by delivering high quality care and timely education about home health and hospice services with patients and families. This approach increases brand awareness and positions us as the preferred provider in markets where we have overlap and scale and density. Many home health patients and their friends and family members eventually require home health services or are eligible for hospice benefits and choose our services where we have scale and density.

As of December 31, 2025, 111 of our 117 hospice locations were co-located within our home health markets. We believe the overlap of our home health and hospice locations and our opening of hospice locations in markets with existing home health locations creates a unique growth opportunity. See "—*Our Strategy*—*Execute on De Novo Strategy in New and Existing Markets*."

***Consistent and Disciplined Operating Model***

Our operating model emphasizes consistency and the disciplined use of technology, driving our industry leadership in both clinical quality and cost-effectiveness. We leverage our comprehensive technology capabilities and centralized administrative functions to define best practices, streamline staffing models, and identify supply chain efficiencies across our platform. We invest significant time and training resources teaching our operators to use technology to drive timely decisions in the field. Our pairing of technology with a culture that emphasizes well-established operating protocols helps us deliver superior results.

***Clinical Expertise and High-Quality Outcomes***

We have developed standardized best practices and protocols based on our extensive home-based clinical experience. We believe these best practices and protocols, when combined with our technology and well-trained, mission-motivated clinicians, help deliver consistently high-quality healthcare services, reduce inefficiencies, and improve performance across a spectrum of operational areas. We believe our efforts have yielded meaningful results that surpass the national averages based on the metrics we utilize to measure our success.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

In the Home Health segment, we focus on hospital readmission and acute care hospitalization rates as our primary indicators of clinical quality. We believe this focus results in superior clinical outcomes for patients, providers, and payers. On a non-risk adjusted basis, our 30-day hospital readmission rate was 14.4% in 2025, 20.0% lower than the national average of 18.0% in 2024. As of January 2026, the last publicly reported Star ratings from the Home Health Care Consumer Assessment of Healthcare Providers and Systems, we averaged 3.9 stars, higher than the national average of 3.7 stars.

In the Hospice segment, we focus on providing patients the highest quality of care throughout their hospice tenure and especially within the last days of life, when physical and mental symptoms frequently intensify. We believe this focus has resulted in increased symptom mitigation for patients and their loved ones. Our percentage of patients who received in person visits from registered nurses or medical social workers on at least two out of the final three days of the patients' life was 63.8% in 2025, 32.1% higher than the national average of 48.3% reported in January 2026. As of November 2025, the last publicly reported Star ratings from the Consumer Assessment of Healthcare Providers and Systems Hospice Survey, we averaged 3.9 stars, higher than the national average of 3.6 stars.

For additional discussion of CMS's Star ratings, see Item 1A, "*Risk Factors*—*Risks Related to Our Business*—*Other Operational and Financial Risks*."

***Execution of Payer Innovation Strategy***

Our contracting strategy includes four primary tenets: (i) building relationships with payers and conveners; (ii) obtaining new agreements with favorable rates and terms; (iii) renegotiating existing agreements to provide more favorable rates and terms; and (iv) whenever possible, negotiating to include value-based incentives in our agreements. Collectively, we refer to these efforts as Payer Innovation. We continue to evaluate new models and opportunities to collaborate with both existing and new payers along with potential strategic partners. Our industry-leading capabilities and clinical results, including our low acute care hospitalization and hospital readmission rates, position us to bring value to payers focused on managing and reducing the total cost of care.

***People and Award-Winning Culture***

In 2025, we continued our efforts to support our clinical and support staff in receiving the necessary education and training to deliver the highest quality care in the most cost-effective manner. We maintained our certification as a "Great Place to Work" and were recognized as a USA TODAY Top Workplace USA company. We believe our award-winning culture is crucial for attracting and retaining talent as the demand for our services grows.

**Our Strategy**

Our growth strategy includes organic growth through existing operations, opening new locations, increasing our Payer Innovation contracts and shifting Medicare Advantage business to contracts that pay us improved rates, leveraging our expertise in care transitions, and, consistent with the terms of our credit facilities, pursuing strategic acquisitions.

***Drive Organic Growth at Existing Operations***

We strive for organic growth in existing markets by consistently increasing the number of referrals and referral sources we serve. To achieve this growth, we (i) educate healthcare providers about the scope and benefits of our services, (ii) position our agencies to add value in their communities by avoiding unnecessary hospitalizations, (iii) focus on high-quality care and related outcomes for our patients, (iv) identify related products and services needed by our patients and their communities, and (v) provide a superior work environment for our employees as part of our focus to recruit and retain our clinical staff. As we continue to grow organically, our scale and density will increase, further reinforcing our ability to deliver cost-effective care.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Execute on De Novo Strategy in New and Existing Markets***

Since 2015, we have opened 54 de novo locations, of which 24 are home health and 30 are hospice locations. De novos are an attractive supplement to our organic growth strategy because we have relative control over the start-up process, including location choice, capital costs and timelines. Depending on the market, de novos are an efficient use of capital, with expected costs ranging from approximately $250,000 to $350,000 per location. Based on historical performance and market dynamics, de novos generally achieve profitability within approximately 18 to 24 months of opening.

There are opportunities for us to open strategically located high-growth potential de novos that leverage existing leadership, brand recognition and referral networks to build patient census. We have approximately 80 home health locations without an accompanying hospice location in states that do not have certificate of need ("CON") laws or where we have the required CON. See Item 2, "*Properties*," for a listing of CON states in which we have operations. In 2026, we anticipate opening three to six home health and nine to twelve hospice de novos.

***Strategic Mix Management Through Referral Source Proposition and Payer Innovation Execution***

Medicare Advantage has become an increasingly prevalent payer source for skilled home health services. See "*—Our Industries—Shift from Medicare Fee-for-Service to Medicare Advantage"*. Although Medicare Advantage billings and collections are generally more labor intensive than traditional Medicare and typically involve discounted reimbursement rates, we believe strategic participation with these payers is important given the continued shift of Medicare-eligible beneficiaries from Medicare FFS to Medicare Advantage plans.

Over the past three years, we have successfully negotiated numerous Medicare Advantage contracts through our Payer Innovation efforts, resulting in improved reimbursement rates and Medicare Advantage revenue growth. These contracts enable us to accept a broad range of patients and serve as a full-service provider for our referral sources. As a preferred provider of high-quality care, we leverage our portfolio of local, regional, and national payer contracts to strategically manage our payer mix, which we believe provides a competitive advantage in our markets. Our teams focus on educating our referral sources on our high quality and our ability to accept a large number of payers.

***Leverage Care Transitions Expertise***

Our track record of performance and quality enables us to develop strong relationships with health systems and facility-based providers. We believe we are an attractive provider for patients transitioning from a facility-based setting due to the quality of our outcomes, data management, scale and market density, and proven ability to safely transition high acuity and/or chronically ill patients to the home. Our deep understanding of care transitions and ability to achieve industry-leading low hospital readmission rates make us the provider of choice for many facility-based referral sources. These relationships are integral to realizing positive outcomes from transitions of care.

***Strategic Acquisitions***

Historically, our growth strategy partially relied on acquisitions, and although we have not recently completed acquisitions due to prior restrictions under our credit facility, they remain part of our long-term growth strategy. We have a proven history spanning over 20 years of consummating and fully integrating acquisitions culturally, technologically, and operationally. We did not complete any acquisitions during the years ended December 31, 2025 and 2024, and the one acquisition made in 2023, for a total purchase price of $3.1 million, was not material to the Company's consolidated financial statements.

In the second quarter of 2025, the acquisition restrictions in our credit agreement were lifted. In 2026, we plan to invest $25 to $50 million in strategic acquisitions. We focus on acquisition opportunities where we believe we can accelerate top-line growth while also expanding profit margins.

**Our Services**

***Home Health***

Our home health operations provide a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. Our patients are typically older adults with chronic conditions and significant functional limitations who are on multiple

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

medications. We work closely with patients, families, caregivers, and physicians to deliver data-driven, evidence-based care plans focused on patient needs and goals.

Our home health services are prescribed by a physician, typically following an episode of acute illness or surgical intervention, an exacerbation or worsening of a chronic disorder, or a patient's discharge from an acute care hospital, skilled nursing facility, rehabilitation hospital or other facility-based settings. Our patients are also referred to us by assisted living and other long-term care facilities and community physicians. In 2025, approximately 38% of our home health patient admissions were from physician offices or other community referral sources, and approximately 62% were from facility-based sources.

Our nurses provide a variety of medically necessary services to homebound patients who are suffering from acute or chronic illness, recovering from injury or surgery, or who otherwise require care or monitoring. These services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment. We also have designed best practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases. Through our medical social workers, we counsel patients and their families with regard to financial, personal, and social concerns that arise from a patient's health-related problems.

Our physical, occupational, and speech therapists provide therapy services to patients in their homes. Our therapists coordinate multi-disciplinary treatment plans with physicians, nurses, and social workers to restore patients' basic mobility skills, such as getting out of bed, walking safely (with assistive devices if needed), and restoring range of motion to specific joints. Our therapists also assist patients and their families with improving and maintaining functional activities of daily living such as dressing, cooking, cleaning, and managing other activities safely in the home environment. Our speech and language therapists provide corrective and rehabilitative treatment to patients who suffer from physical or cognitive deficits or disorders that create difficulty with verbal communication or swallowing.

For the year ended December 31, 2025, our home health business had an average daily census of 41,786 home health patients. As of December 31, 2025, we operated 249 home health agencies in 33 states. See Item 1, "*Business*—*Sources of Revenue*—*Home Health*," in this Annual Report.

***Hospice***

Individuals with a terminal illness may be eligible for hospice care if they have a life expectancy of six months or less and have chosen to forego curative treatment.

Hospice care focuses on the quality of life for patients experiencing an advanced, life limiting illness by treating the symptoms of the disease, rather than the disease itself. Our hospice operations provide a comprehensive range of Medicare-certified skilled hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and family member bereavement counseling, as required by law, all of which are designed to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families.

For the year ended December 31, 2025, our hospice business had an average daily census of 3,985 hospice patients. As of December 31, 2025, we operated 117 hospice provider locations in 25 states. See Item 1, "*Business*—*Sources of Revenue*—*Hospice*," in this Annual Report.

***Operations***

Each of our home health and hospice locations is staffed with clinicians who are experienced in providing a wide range of patient care services, as well as administrative professionals. Our operations consist of field- and branch-level operations, business development operations, and corporate support operations. We believe organizing our operations in this way allows our clinical and administrative professionals to focus on patient care, while our business development team focuses on referral development.

Our branches are managed locally by branch directors who oversee branch clinical and office teams. Branch directors report to an administrator who oversees one or more branches. Our field-level operations use branch operating metrics provided by our technology platforms to monitor performance and quality, including volumes, clinician productivity and efficiency, and cost per patient day.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Our corporate support operations provide centralized services in support of our operations, including information technology, human resources, recruiting, finance, and regulatory and legal support services, among others. Our corporate support operations include a central clinical auditing group that performs audits on medical records, care plans, and core patient documentation to optimize proper, complete care plans toward achieving the highest quality outcomes. This corporate support operations team also develops, monitors, and deploys operating policies, allowing for consistency of operations measurement and ease of deploying productivity metrics.

**Business Development**

We assign teams to all aspects of the referral and patient onboarding process. We believe this high-touch approach enables our business development teams to develop deep-rooted relationships and build density in the markets they serve, increasing patient referrals to our home health and hospice locations.

Our business development team has access to a variety of technology platforms that provide real-time market intelligence and analysis. These tools allow team members to quickly identify and prioritize referral sources and share with potential referral sources clinical outcome performance indicators that highlight our clinical expertise. Our web-based portal allows referring physicians to easily monitor the care and progress of their patients and to sign orders electronically, building loyalty with our referral sources.

**Technology** 

We believe our use of technology enhances our competitive position in the markets we serve. Our systems also emphasize interoperability with referral sources and other providers to coordinate care. We have devoted substantial resources, effort, and expertise to leveraging technology to create solutions that improve patient care and operating efficiencies. We deploy and utilize new technologies to improve patient care and achieve operational efficiencies.

We use an electronic medical records system that we license from a home-based care software solution. The system manages the entire patient workflow and provides field clinicians with access to patient records, diagnostic information, and notes from prior visits via a mobile application. Real-time, customized feedback and instructions are provided to field clinicians on-site. The system enhances patient data capture and database management, which aids in the development of algorithms that can improve the plan of care.

Our IT systems provide management access to relevant data needed to make timely, accurate decisions. The data systems feature rules-based algorithms that promote accountability by escalating tasks and notifying management when processes are delayed.

We use technology to provide real-time market intelligence to members of our sales team, allowing them to prioritize particular referral sources to align with strategic directives. Specialty programs integrate individual physician protocols into the system. We believe this creates loyalty for physicians and facilities, generating greater consistency in future referrals. Additionally, a web-based portal allows referring physicians to easily monitor the care and progress of patients and to sign orders electronically.

We also work with a predictive analytics platform to improve our data analysis of patient care. We use this platform to help identify patients at risk for unplanned hospitalizations. The platform recommends a patient-centered visit utilization plan to promote discharge without hospitalization and prompts continued touch points with discharged patients to identify and prevent post-discharge hospitalizations.

**Sources of Revenue**

We receive payment for patient care services from the federal government (primarily under the Medicare program), managed care plans and private insurers, and, to a lesser degree, state governments (under their respective Medicaid or similar programs), as well as directly from patients. Revenues and receivables from Medicare are significant to our operations. The federal and state governments establish payment rates as described in more detail below. We negotiate payment rates with non-governmental group purchasers of healthcare services that are included in "Managed Care" in the table below, including private insurance companies, employers, health maintenance organizations ("HMOs"), preferred provider organizations ("PPOs"), and other managed care plans. Patients are generally not responsible for the difference between established gross charges and amounts reimbursed for such services under Medicare, Medicaid, and other private insurance plans, HMOs, or PPOs, but patients are responsible to the extent of any exclusions, deductibles, co-payments, or coinsurance features of their coverage. Medicare, through its Medicare Advantage program, offers Medicare-eligible

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

individuals an opportunity to participate in managed care plans. For the year ended December 31, 2025, revenues from Medicare and Medicare Advantage represented 89.7% of total *Net service revenue*.

The following table identifies the sources and relative mix of our revenues for the periods stated for our consolidated business:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
| | **2025** | **2024** | **2023** |
| Medicare<sup>(1)</sup> | **65.8%** | 66.8% | 71.5% |
| Medicare Advantage | **23.9%** | 23.0% | 19.0% |
| Managed Care | **9.1%** | 9.1% | 8.2% |
| Medicaid | **0.8%** | 0.9% | 1.2% |
| Other | **0.4%** | 0.2% | 0.1% |
| Total | **100.0%** | 100.0% | 100.0% |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;The decline in Medicare revenue as a percentage of our total *Net service revenue* and corresponding increase in Medicare Advantage revenue is primarily the result of the impact on Home Health *Net service revenue* from the continued national enrollment increases in Medicare Advantage plans by Medicare beneficiaries.

***Medicare Reimbursement***

Medicare is a federal program that provides hospital and medical insurance benefits to persons aged 65 and over, qualified disabled persons, and persons with end-stage renal disease. Medicare establishes reimbursement methodologies and rates for various types of healthcare providers, facilities, and services. Each year, MedPAC, an independent agency that advises Congress on issues affecting Medicare, makes policy recommendations to Congress for a variety of Medicare payment systems. These recommendations, along with other considerations including the policy focuses of the current U.S. presidential administration, may result in notable modifications to Medicare payments applicable to our business, namely in updates to the annual Home Health Prospective Payment System ("HH-PPS") and the Hospice Payment System ("Hospice-PS").

CMS makes annual adjustments to Medicare payment rates in prospective payment systems, including the HH-PPS and Hospice-PS, by what is commonly known as a "market basket update." According to CMS, market basket updates reflect inflation and other changes in price over time of goods and services used by providers to deliver care. Market basket updates are produced for various payment systems to accurately measure the price changes facing each provider. Medicare home health has its own market basket, while hospice is based on the Inpatient Prospective Payment System Hospital Market Basket. The impact of recent annual home health and hospice adjustments to our business are discussed below, see "—*Home Health*" and "—*Hospice*."

From time to time, Medicare regulations, including reimbursement methodologies and rates, can be further modified by CMS. In some instances, CMS's modifications can have a substantial impact on healthcare providers. For example, home health agencies and hospice provider locations are required to submit quality data to CMS each year, and the failure to do so in accordance with the rules will result in a 2% and 4% reduction, respectively, in their market basket annual payment update. Additionally, commencing in 2025, under the nationwide HHVBP Model, home health agencies began to receive increases or decreases to their Medicare FFS payments of up to 5% based on performance against specific quality measures relative to the performance of other home health providers. Data collected in each performance year impacts Medicare payments two years later.

Congress also periodically changes Medicare statutes. For example:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In 2010, President Obama signed the Patient Protection and Affordable Care Act ("2010 Healthcare Reform Laws"). The 2010 Healthcare Reform Laws provided specific reductions to healthcare providers' annual market basket updates and other payment policy changes for Medicare reimbursement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In 2011, President Obama signed into law the Budget Control Act of 2011 providing for an automatic 2% reduction, or "sequestration," of Medicare program payments for all healthcare providers. Sequestration took effect in April 2013 and, as a result of subsequent legislation, will continue through fiscal year 2030 unless Congress and the President take further action.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In 2018, President Trump signed into law the Bipartisan Budget Act of 2018 (the "2018 Budget Act"), which included several provisions affecting Medicare reimbursement, such as the Patient-Driven Groupings Model ("PDGM").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In 2025, President Trump signed into law the One Big Beautiful Bill Act (the "OBBBA"). The OBBBA affects a number of Medicare-related statutes, including those related to the Medicare Savings Program and the Statutory Pay-As-You-Go Act of 2010.

In the future, concerns about the federal deficit and national debt levels could result in enactment of further federal spending reductions or sequestration, further entitlement reform legislation affecting the Medicare program, or both. The future of the aforementioned regulations as well as the nature and substance of any other healthcare legislation remain uncertain.

We cannot predict the adjustments to Medicare payment rates Congress or CMS may make in the future. Congress, MedPAC, and CMS will continue to address reimbursement rates for a variety of healthcare settings. For additional discussion of the risks associated with our concentration of revenues from the federal government or potential changes to the statutes or regulations governing Medicare reimbursement, see Item 1A, "*Risk Factors*—*Risks Related to Our Business*—*Reimbursement Risks*."

Our operations are also affected by other rules and regulations that indirectly affect reimbursement for our services, such as data coding rules and patient coverage rules and determinations. For example, Medicare providers like us can be negatively affected by the adoption of coverage policies, either at the national or local level, which determine whether an item or service is covered and under what clinical circumstances it is considered to be reasonable and necessary. For additional discussion of the risks associated with potential changes in regulations, see Item 1A, "*Risk Factors*—*Risks Related to Our Business*—*Other Regulatory Risks*."

Medicare contractors processing claims for CMS make coverage determinations regarding medical necessity that can represent restrictive interpretations of CMS coverage rules. Those interpretations are not made through a notice and comment review process. We cannot predict how future CMS coverage rule interpretations or any new local coverage determinations will affect us.

We undertake significant efforts through training, education, and documentation to comply with coding and medical necessity coverage rules to maximize the successful processing of our claims for payments. Any denial of a claim for payment, either as a result of an audit or ordinary course payment review by Medicare Administrative Contractors ("MACs"), is subject to an appeals process that is slow and unpredictable in outcome. For additional discussion of these audits and the risks associated with them, see Item 1A, "*Risk Factors—Risks Related to Our Business—Reimbursement Risks*."

A basic summary of current Medicare reimbursement in our business segments follows:

**Home Health** 

Medicare pays home health benefits for patients discharged from a hospital or patients otherwise suffering from chronic conditions that require ongoing but intermittent skilled care. As a condition of participation under Medicare, patients must be homebound (meaning unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, or have a continuing need for occupational therapy, and receive treatment under a plan of care established and periodically reviewed by a physician. A physician must document that he or she or a qualifying nurse practitioner has had a face-to-face encounter with the patient and then certify to CMS that a patient meets the eligibility requirements for the home health benefit.

As of January 2020, Medicare began reimbursing home health providers under the PDGM. PDGM replaced a 60-day episode of payment methodology with a 30-day payment period and relies more heavily on clinical characteristics and other patient information (such as principal diagnosis, functional level, referral source, and timing), rather than the therapy service-use thresholds under the prior system, to determine payments. Under PDGM, the initial certification remains valid for 60 days. If a patient remains eligible for care after the initial period as certified by a physician, a new treatment period may begin. There are currently no limits to the number of home health treatment periods a Medicare patient may receive, assuming there is eligibility for each successive period.

Prior to 2022, providers were required to submit requests for anticipated payment ("RAP") in accordance with each 30-day period of care. In a departure from earlier policy, CMS in 2021 eliminated early payments received through the RAP process. Failure to submit required RAP documentation in a timely fashion resulted in reimbursement penalties.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Beginning in 2022, home health providers were required to submit a one-time Notice of Admission ("NOA") within five days of the start of the initial treatment period. A NOA covers contiguous 30-day periods of care until the patient is discharged. There is no upfront payment associated with the submission of an NOA. Reimbursement penalties for failure to timely submit a NOA can be significant, as the penalties may apply to a longer period, rather than the 30-day periods associated with RAP.

Home health Medicare payments are adjusted based on each patient's condition and clinical treatment ("case-mix adjustment"). In addition to the case-mix adjustment, payments for periods of care may be adjusted for other reasons, including patients whose care is unusually expensive (commonly known as outliers), low utilization patients ("LUPAs"), and geographic differences in wages. Outlier payments are capped at 10.0% of total reimbursement per provider number. Payments are also made for non-routine medical supplies that are used in treatment.

In November 2023, CMS released its notice of final rulemaking for calendar year 2024 for home health agencies under the HH-PPS (the "2024 HH Rule"). The 2024 HH Rule implemented a net 3.0% market basket increase (market basket update of 3.3% reduced by 0.3% for a productivity adjustment) and updated the fixed-dollar loss ratio for outlier payments. The 2024 HH Rule also implemented a permanent negative behavioral adjustment of 5.78% to the calendar year 2024 base payment rate, which was phased in at 2.89% for 2024.

In November 2024, CMS released its notice of final rulemaking for calendar year 2025 for home health agencies under the HH-PPS (the "2025 HH Rule"). The 2025 HH Rule implemented an overall 0.5% increase relative to 2024 levels (market basket update of 2.7%, reduced by 1.8% for negative behavioral adjustment, and a 0.4% for fixed dollar loss negative adjustment).

In November 2025, CMS issued the 2026 Home Health Prospective Payment System Update final rule (the "2026 HH Rule"). The 2026 HH Rule reflects an estimated 1.3% aggregate decrease to Medicare payments as compared to 2025 payments. This update represents a 2.4% increase to the market basket, reduced by a 0.9% decrease that reflects the net impact of the finalized permanent behavior adjustment, a 2.7% decrease that reflects the net impact of the finalized temporary adjustment, and an estimated decrease of 0.1% that reflects the effects of a proposed update to the fixed-dollar loss ratio. Based on our analysis, which utilizes, among other things, our patient mix for 2025, our specific geographic coverage area, and other factors, we expect the impact to us to be in line with the 1.3% decrease, effective for services provided beginning January 1, 2026.

**Hospice**

For a Medicare beneficiary to qualify for the Medicare hospice benefit, a hospice physician and a patient-designated attending physician (if the patient has one), must certify that, in their clinical judgment, the beneficiary has a life expectancy of six months or less, assuming the beneficiary's terminal illness runs its normal course, and providers must establish a plan of care. Under Medicare rules, patients seeking hospice benefits must agree to forgo curative treatment for their terminal medical conditions after being given a full understanding of the palliative nature of hospice care. Medicare hospice reimbursements are subject to a number of conditions of participation, including the use of volunteers and onsite visits to evaluate aides. Volunteers provide day-to-day administrative and direct patient care services in an amount that, at a minimum, equals 5.0% of the total patient care hours of all paid Hospice employees and contract staff. A registered nurse conducts an on-site visit every 14 days to assess the quality of care and to evaluate whether the services meet the patient's needs. The Consolidated Appropriations Act, 2021 (the "2021 Budget Act") created a new Medicare survey program for hospice provider locations that requires a survey at least once every three years. The 2021 Budget Act also created the Special Focus Program. Hospices that are found to be out of program compliance could be subjected to civil monetary penalties that accrue for each day out of compliance, as well as other forms of corrective action. In February 2025, CMS announced it was pausing the Special Focus Program for calendar year 2025 pending further evaluation.

For each day a patient elects hospice benefits, Medicare pays an adjusted daily rate based on patient location, and payments represent a prospective per diem amount tied to one of four different required levels of care: routine home care; continuous home care; inpatient respite care; and general inpatient care. Payments are adjusted by a wage index to reflect differences in health care labor costs across the country and are established annually through federal legislation. Adjustments for eligibility and technical billing requirements may be made to Medicare claims if we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation and other reasons unrelated to credit risk. Medicare hospice reimbursements to each provider are also subject to two annual caps: the aggregate cap, which limits total hospice payments based on the average annual payment per beneficiary, and the inpatient cap, which limits payment based on the number of days of inpatient care billed by the hospice provider. There are currently no limits to the number of

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

hospice benefit periods an eligible Medicare patient may receive, assuming compliance with Medicare requirements, and a patient may revoke the benefit at any time.

Both the aggregate and inpatient caps on Medicare hospice reimbursement are calculated at the end of the hospice cap period, based on the 12 month period beginning on October 1st of each year, which determines the maximum allowable payments per provider. The "80-20 rule" applies to the inpatient cap. Under that rule, if the number of inpatient care days of hospice care furnished by us to Medicare hospice beneficiaries under a unique provider number exceeds 20% of the total days of hospice care furnished by us to all Medicare hospice beneficiaries for both inpatient and in home care, Medicare payments to us for inpatient care days exceeding the inpatient cap will be reduced to the routine home care rate, with excess amounts due back to Medicare.

In July 2023, CMS released its notice of final rulemaking for calendar year 2024 for hospice provider locations under the Hospice-PS (the "2024 Hospice Rule"). The 2024 Hospice Rule implemented a net 3.1% market basket increase (market basket update of 3.3% reduced by 0.2% for a productivity adjustment).

In July 2024, CMS released its notice of final rulemaking for calendar year 2025 for hospice provider locations under the Hospice-PS (the "2025 Hospice Rule"). The 2025 Hospice Rule implemented a 2.9% net increase to reimbursement rates (market basket update of 3.4% reduced by a 0.5% productivity adjustment).

In August 2025, CMS issued its final rule for hospice payments for fiscal year 2026 (the "2026 Hospice Rule"). Effective October 1, 2025, CMS implemented a 2.6% net increase to reimbursement rates, resulting from a 3.3% update to the market basket reduced by a 0.7% productivity adjustment. Based on our analysis of the 2026 Hospice Rule, we expect the impact to us to be in line with the 2.6% increase for services provided beginning October 1, 2025.

***Managed Care and Other Discount Plans***

We negotiate payment rates with certain large group purchasers of healthcare services, including Medicare Advantage, managed care plans, private insurance companies, and third-party benefit administrators. Managed care contracts typically have terms between one and three years, although we have a number of managed care contracts that automatically renew each year (with pre-defined rates) unless a party elects to terminate the contract. In 2025, typical rate increases for our renewed home health and hospice contracts ranged from 3-5%. Our Payer Innovation team focuses on establishing and renegotiating contracts that provide equitable reimbursement for the services provided.

***Medicaid Reimbursement***

Medicaid is a jointly administered and funded federal and state program that provides hospital and medical benefits to qualifying individuals who are deemed unable to afford healthcare. As the Medicaid program is administered by the individual states under the oversight of CMS, there are substantial differences in reimbursement methodologies and coverage policies from state to state. Many states have experienced shortfalls in their Medicaid budgets and are implementing significant cuts in Medicaid reimbursement rates. Additionally, certain states control Medicaid expenditures through restricting or eliminating coverage of some services. Continuing downward pressure on Medicaid payment rates could cause a decline in that portion of our *Net service revenue*. In certain states, we are experiencing an increase in Medicaid patients, partially as a result of expanded coverage consistent with the intent of the 2010 Healthcare Reform Laws. In July 2025, President Trump signed into law the OBBBA, which included new requirements for Medicaid eligibility and may result in a decrease in the number of persons eligible for Medicaid coverage. However, for the year ended December 31, 2025 Medicaid payments represented only 0.8% of our consolidated *Net service revenue*.

***Cost Reports***

Because of our participation in Medicare and Medicaid, we are required to meet certain financial reporting requirements. Federal and, where applicable, state regulations require the submission of annual cost reports covering the revenue, costs, expenses, and other data associated with the services provided by home health and hospice providers to Medicare beneficiaries and Medicaid recipients. These annual cost reports are subject to routine audits that may result in adjustments to the amounts determined to be due to us under these reimbursement programs. These audits are used to determine if any under- or over-payments were made to these programs and to set payment levels for future years.

**Our Competition**

Providers of home health and hospice services include both for-profit and not-for-profit organizations. Our competitors include large home health and hospice providers, as well as publicly traded and privately owned freestanding agencies,

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

facility-based home health agencies, visiting nurse associations and government-owned agencies. In the last three years, national payers have acquired the three largest providers of home health and hospice services in the United States. We are the largest publicly traded standalone home health and hospice organization in the country.

Our primary competition varies from market to market. The primary competitive factors in any given market include the quality and cost of care and service provided, the treatment outcomes achieved, the relationship and reputation with managed care and other private payers and the acute care hospitals, physicians, and other referral sources in the market, and the regulatory barriers to entry in CON states. Home health providers with scale, which include the other public companies and those integrated with national payers, may have competitive advantages, including professional management, efficient operations, sophisticated information systems, brand recognition, and large referral bases.

**Regulation**

The healthcare industry is subject to significant federal, state, and local regulations that affect our business by controlling our reimbursement rates, requiring operational licenses or certification, regulating our relationships with physicians and other referral sources, regulating our properties, and controlling our growth. State and local healthcare regulations may cover additional matters such as nurse staffing ratios, healthcare worker safety, marijuana legalization, and medical aid in dying. These laws and regulations are extremely complex, and, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation or consistent enforcement approaches. Regulations and policies frequently change, and we monitor these changes through trade and governmental publications and associations.

We have developed a compliance program to help facilitate meeting regulatory and legal requirements applicable to our business. Our compliance program is overseen primarily by our board of directors' Care, Compliance, & Cybersecurity Committee, whose function is to assist the board in fulfilling its fiduciary responsibilities relating to our regulatory compliance. Our Chief Compliance Officer provides quarterly reports to the Care, Compliance, & Cybersecurity Committee on compliance efforts and related matters. At the management level, we have established an executive compliance committee, chaired by the Chief Compliance Officer; an inter-departmental compliance operations committee responsible for identifying key compliance risks and mitigation strategies; and an inter-departmental privacy and security committee that oversees programs and initiatives designed to protect and secure our data and systems. For additional discussion of the regulatory risks associated with our business, see Item 1A, "*Risk Factors—Risks Related to Our Business—Other Regulatory Risks*."

***Licensure and Certification***

Our home health agencies and hospice provider locations are each licensed under applicable law, certified by CMS for participation in the Medicare program, and generally certified by the applicable state Medicaid agencies to participate in those programs.

***Certificates of Need***

In some states the acquisition of existing agencies or the introduction of new home health and hospice services may be subject to review by and prior approval of state regulatory bodies under a CON law or similar permit of approval. Currently, state health authorities in 11 states where we operate require a CON to establish and operate a home health agency, and state health authorities in 4 states where we operate require a CON to operate a hospice provider. As of December 31, 2025, approximately 31% of our home health and hospice locations are in states that have CON laws.

CON laws require a reviewing authority or agency to determine the public need for additional or expanded healthcare agencies, locations, or services. CON laws in some states require us to abide by certain charity care commitments as a condition for approving a CON. In any state where we are subject to a CON law, we must obtain such certificate before acquiring, opening, reclassifying, or expanding a home health agency or hospice provider.

***False Claims***

The federal civil False Claims Act ("FCA") imposes liability for the knowing presentation of a false claim to the U.S. government and provides for damages equal to three times the actual amount of any overpayments plus additional penalties per claim. Federal civil penalties are adjusted to account for inflation each year. In addition, the FCA allows private persons ("relators") to file complaints under seal (also known as whistleblower complaints) and provides a period of time for the government to investigate such complaints and determine whether to intervene in them and take over the handling of all or part of such complaints.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

The government and relators may also allege violations of the FCA for the knowing and improper failure to report and refund amounts owed to the government in a timely manner following identification of an overpayment ("reverse false claim"). In 2025, CMS implemented updated regulations regarding overpayment reporting requirements, including by incorporating the definition of "knowingly" under the FCA and modifying internal investigation timelines. The government deems identification of the overpayment to occur when a person "knowingly" receives or retains an overpayment, defined to include whenever a person has actual knowledge of the overpayment, acts in deliberate ignorance of the truth or falsity of information regarding overpayment, or acts in reckless disregard of such. By law, a person must report and return the overpayment by the later of 60 days after the date of identification or the date any corresponding cost report is due absent specific enumerated exceptions, including a maximum 180 day deadline suspension for qualifying, timely, good faith investigations.

Because we furnish thousands of services a year for which we are reimbursed by Medicare and other federal payers and for which there is a relatively long statute of limitations, a coding or billing error, cost reporting error or disagreement over physician medical judgment could result in significant civil damages and penalties under the FCA and penalties under criminal fraud equivalents. Many states have also adopted similar laws relating to state government payments for healthcare services. The 2010 Healthcare Reform Laws and similar amendments to the FCA along with related federal initiatives and pilot programs, have effectively expanded the definition of a false claim, facilitated government investigations, increasingly incentivized relators with monetary rewards where prosecutions are ultimately successful, and extended the statute of limitations on claims by the government. The federal government appears to have become increasingly aggressive in asserting that incidents of erroneous billing or record keeping represent FCA violations and in challenging the medical judgment of independent physicians as the basis for FCA allegations.

In 2025, the U.S. Department of Justice ("DOJ") made significant announcements regarding its enforcement priorities. For instance, the DOJ launched the Civil Rights Fraud Initiative, which will utilize the FCA to investigate and pursue claims against recipients of federal funding, such as by way of Medicare payments, that knowingly violate federal civil rights laws. In July 2025, the DOJ and the U.S. Department of Health and Human Services ("HHS") declared six priority enforcement areas: Medicare Advantage; drug, device, or biologics price; barriers to care; kickbacks related to products; defective medical devices; and manipulation of electronic health records. DOJ enforcement priorities may continue to evolve.

***Relationships between Physicians and Other Providers***

State and federal laws regulate relationships between physicians and certain healthcare providers. Certain examples material to our business are discussed below.

***Anti-Kickback Statute.*** Federal law prohibits individuals or entities from offering, paying, soliciting, or receiving remuneration to induce referrals of patients for services reimbursed under federal health care programs like the Medicare or Medicaid programs (the "Anti-Kickback Statute"). Violators of the Anti-Kickback Statute may be subject to civil monetary penalties and damages for improper claims, FCA enforcement, imprisonment, and exclusion from federal health care programs like the Medicare and Medicaid programs. Federal civil penalties are adjusted to account for inflation each year.

The HHS Office of Inspector General (the "HHS-OIG") has published "safe harbors" that protect certain enumerated practices from enforcement action under the Anti-Kickback Statute, including, without limitation, bona-fide employment relationships, contracts for the rental of space or equipment, and personal service arrangements and management contracts, among others. Protection under a safe harbor requires strict compliance with the elements set forth by federal regulation.

Anti-Kickback Statute violations can be the basis for other claims and may result in increased scrutiny. Additionally, many states separately enforce state-law anti-kickback prohibitions, which may differ in scope and applicability. State and federal regulators may increase anti-kickback investigation and enforcement efforts across the healthcare industry, including home health and hospice providers, under both the Anti-Kickback Statute and state-law analogues.

***Physician Self-Referral Law.*** The federal law commonly known as the "Stark law" and CMS regulations promulgated under the Stark law prohibit physicians from making referrals for "designated health services," including, among other things, separately billable physical and occupational therapy, and home health services, to an entity in which the physician (or an immediate family member) has an investment interest or other financial relationship, subject to certain exceptions. The Stark law also prohibits those entities from filing claims or billing Medicare for those referred services. Violators of the Stark law and regulations may be subject to recoupments, civil monetary penalties, FCA enforcement, and exclusion from any federal, state, or other governmental healthcare program. The statute also provides significant penalties for circumvention schemes. Federal civil penalties are adjusted to account for inflation each year.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

There are statutory and regulatory exceptions to the Stark law for many of the customary financial arrangements between physicians and providers, including, without limitation, personal services contracts and leases. However, the Stark law is a strict liability statute, and the requirements of Stark law exceptions are closely scrutinized. Additionally, many states separately enforce state-law anti-self-referral prohibitions and other restrictions on practitioner relationships, such as fee-splitting prohibitions, which limit our ability to form arrangements with practitioners and other persons.

We have carefully structured our relationships to meet one or more exceptions to the Stark law, but the regulations implementing the exceptions are detailed and complex. Additionally, adherence to a safe harbor under the Anti-Kickback Statute does not obviate the need for compliance with the elements applicable to any exception under the Stark law. Government investigation and enforcement efforts under both the Stark law and state-law analogues may increase in the home health industry.

***Health Insurance Portability and Accountability Act-Anti-Fraud Regulations***

The Health Insurance Portability and Accountability Act of 1996 ("HIPAA") broadened the scope of certain fraud and abuse laws by adding criminal provisions for certain healthcare fraud offenses. HIPAA also prohibits certain incentives intended to influence a Medicare or Medicaid beneficiary's choice of provider. In addition, HIPAA created new enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program, an incentive program under which individuals can receive a monetary reward for providing information on Medicare fraud and abuse that leads to the recovery of at least a portion of the Medicare funds. Violating HIPAA may result in civil and criminal penalties. The HHS Office for Civil Rights ("HHS-OCR") implemented a HIPAA audit program for healthcare providers nationwide in 2016. As of December 31, 2025, we have not been selected for audit.

***Health Insurance Portability and Accountability Act-Administrative Simplification and Privacy***

HIPAA and related HHS regulations require the use of uniform electronic data transmission standards for certain healthcare claims and payment transactions submitted or received electronically. HIPAA also regulates the use and disclosure of protected health information ("PHI"), whether communicated electronically, on paper, or orally. The regulations provide patients with significant rights related to understanding and controlling how their health information is used or disclosed and require covered healthcare providers to implement administrative, physical, and technical practices to protect the security of PHI.

The Health Information Technology for Economic and Clinical Health ("HITECH") Act modified and expanded the privacy and security requirements of HIPAA. The HITECH Act applies certain HIPAA privacy and security requirements directly to business associates of covered entities. The modifications to existing HIPAA requirements included expanded accounting requirements for electronic health records, tighter restrictions on marketing and fundraising, and heightened penalties and enforcement associated with noncompliance.

In addition, there are numerous legislative and regulatory initiatives at the federal and state levels addressing patient privacy concerns. Increasingly, state governments have implemented comprehensive and health-specific privacy statutes that add an additional layer of compliance complexity. HHS-OIG and other regulators have also increasingly interpreted laws and regulations to increase exposure of healthcare providers to allegations of noncompliance. For additional discussion regarding the risks related to HIPAA compliance, see Item 1A, "*Risk Factors—Risks Related to Our Business—Other Operational and Financial Risks*," in this Annual Report.

***Civil Monetary Penalties Law***

Under the Civil Monetary Penalties Law, HHS may impose civil monetary penalties on healthcare providers for knowingly presenting, or causing to be presented, false or fraudulent claims for reimbursement; knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim for payment under a federal healthcare program; transferring remuneration or offering to transfer remuneration that the provider knows or should know will induce a beneficiary to use a particular provider or service; knowing of an overpayment and failing to report and return such overpayment as required; violating certain federal laws, including the Anti-Kickback Statute or Stark law; hiring or contracting with individuals or entities excluded from federal healthcare programs; or committing certain other acts of misconduct. Failure to comply with the Civil Monetary Penalties Law may result in exclusion from federal healthcare programs such as Medicare and Medicaid in addition to monetary damages. The penalties are adjusted annually by HHS to account for inflation and are subject to further changes.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Governmental Review, Audits, Surveys, and Investigations***

Medicare and Medicaid reimbursement claims submitted by healthcare providers, including home health agencies and hospice provider locations, are subject to audit from time to time by governmental payers and their agents, such as MACs that act as fiscal intermediaries for all Medicare billings, auditors contracted by CMS, and insurance carriers, as well as the HHS-OIG, CMS, and state Medicaid programs.

CMS has developed and instituted various audit programs under which CMS contracts with private companies to conduct claims and medical record audits. These audits are in addition to those conducted by existing MACs. Some contractors are paid a percentage of the overpayments recovered. One type of audit contractor, Recovery Audit Contractors ("RACs"), may receive claims data directly from MACs, for example, on a monthly or quarterly basis, and are authorized to review previously paid claims. RACs are paid on a contingency basis tied to the amount of improper payments the RACs identify. CMS has authorized RACs to conduct complex reviews of medical records associated with home health and hospice reimbursement claims.

CMS also has established contractors known as Uniform Program Integrity Contractors ("UPICs"). These contractors conduct audits with a focus on potential fraud, waste, and abuse issues. Like RACs, UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error. We have, from time to time, received record requests from UPICs which have resulted in claim denials on paid claims and associated refunds of overpayments.

MACs also conduct Targeted Probe and Educate ("TPE") audits, which are designed to help providers reduce claim denials and appeals with one-on-one education focused on the documentation and coding of the services they provide. Providers with high error rates in their billing practices or providers that bill for items with high error rates nationally can be required to participate in a TPE audit. While the outcome of most TPE audits is improved claims reporting, if providers fail to improve after three rounds of education sessions they will be referred to CMS for next steps which may include prepay review, extrapolation, referral to a RAC, or other action.

***The Improving Medicare Post-Acute Care Transformation Act***

In October 2014, the Improving Medicare Post-Acute Care Transformation Act ("IMPACT Act") was signed into law requiring the reporting of standardized patient assessment data for quality improvement, payment, and discharge planning purposes across the spectrum of post-acute care providers ("PACs"), including skilled nursing facilities and home health agencies. The IMPACT Act requires PACs to report: (i) standardized patient assessment data at admission and discharge; (ii) quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls and patient preference regarding treatment and discharge; and (iii) resource use measures, including Medicare spending per beneficiary, discharge to community and hospitalization rates of potentially preventable readmissions. Failure to report such data when required could subject a facility to a reduction in market basket prices then in effect.

The IMPACT Act also includes provisions impacting Medicare-certified hospices, including: (i) increasing survey frequency for Medicare-certified hospices to once every 36 months; (ii) imposing a medical review process for facilities with a higher percentage of stays in excess of 180 days; and (iii) updating the annual aggregate Medicare payment cap.

***Review Choice Demonstration ("RCD") for Home Health Services***

In 2024, CMS extended the Review Choice Demonstration for home health services for an additional five years in Illinois, Ohio, Texas, North Carolina, Florida, and Oklahoma. RCD is intended to test, among other things, whether pre-claim review improves methods for the identification, investigation, and prosecution of Medicare fraud and whether the pre-claim review helps reduce expenditures while maintaining or improving quality of care.

We operate agencies in the six RCD states. This demonstration project requires us to incur additional administrative and staffing costs and may impact the timeliness of claims payments.

**Human Capital Management** 

***Overview of Our Employees***

As of December 31, 2025, we employed approximately 10,800 individuals, none of whom was represented by a labor union.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

The increase in demand for clinicians continues to generate pressure in our labor markets. In 2025, our human capital management strategy focused on, among other things, increasing net full-time nursing and therapy headcount to support Home Health growth and increasing net full-time nursing headcount to support Hospice growth, increasing business development direct selling headcount, leadership development, and employee engagement targeted at reducing turnover and increasing retention. We undertook numerous studies and employee surveys, held conferences and trainings, and implemented other initiatives and programs targeted at recruitment, retention, and engagement. Additionally, turnover reduction goals are embedded into our incentive compensation plans.

***Human Capital Objectives***

To recruit and retain our employees, we maintain a total rewards program that combines the tangible components of pay and benefits with the intangible components of a culture that encourages learning, development, and a supportive work environment. We focus on the following strategic human capital objectives:

**Compensation and Benefits**

Maintaining competitive compensation and benefit programs that reward and recognize employee performance furthers our goal to attract, retain, and motivate employees who will help us deliver high-quality patient care. We strive to provide comprehensive benefit options that will allow our employees and their families to live healthier and more secure lives.

**Employee Development and Engagement**

We believe that promoting employee development and engagement can increase our ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment. We support the long-term career aspirations of our employees through education and professional development.

To aid in employee development, we have invested in what we believe to be best-in-class technology to offer on demand learning and development programs, including podcasts and a broadcast studio for enhanced virtual learning. Another important aspect of employee development is succession planning. We annually review our talent to identify potential successors for key positions and to identify candidates for accelerated development based on their performance and potential. The annual process includes an assessment of each employee's promotability based on a set of leadership core competencies defined as part of our talent strategy.

We believe aligning our organizational values—People, Integrity, Compassion, Excellence, Teamwork, and Communication—with our business strategy creates a business differentiator that leads to improved patient care and outcomes, higher-employee engagement and satisfaction, lower turnover, effective communication, and better teamwork.

**ITEM 1A. RISK FACTORS**

*You should carefully consider the following risks and uncertainties, together with all the other information in this Annual Report, including our consolidated financial statements and the related notes, in evaluating Enhabit and Enhabit common stock ("our stock" or "our common stock"). This section does not describe all risks that may be applicable to us, our industry, or our business, and it is intended only as a summary of material risk factors. Additional risks and uncertainties we have not or cannot foresee may also adversely affect us in the future. If any of the risks below or other risks or uncertainties discussed elsewhere in this Annual Report are realized, our business and financial condition, results of operations, and cash flows could be adversely affected.*

**Risks Related to the Proposed Merger with Kinderhook**

***The proposed Merger is subject to the satisfaction of certain closing conditions, including government consents and approvals, some or all of which may not be satisfied or completed within the expected timeframe, if at all.***

On February 22, 2026, we entered into an Agreement and Plan of Merger (the "Merger Agreement") with Anchor Parent, LLC ("Parent"), a Delaware limited liability company affiliated with the private equity firm Kinderhook Industries, LLC ("Kinderhook"), and Anchor Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), providing for our acquisition by Kinderhook in an all-cash transaction valued at approximately $1.1 billion (the "Merger"). Completion of the Merger is subject to a number of closing conditions, including (i) obtaining the approval of our stockholders, (ii) the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (iii) obtaining consents or the expiration or

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

termination of any applicable waiting periods pursuant to certain other regulatory requirements, (iv) no governmental authority having jurisdiction over any party to the Merger Agreement having issued any order or other action that is in effect (whether temporary, preliminary or permanent) restraining, enjoining or otherwise prohibiting the consummation of the Merger and (v) no applicable law having been adopted that makes consummation of the Merger illegal or otherwise prohibited. We can provide no assurance that all required consents and approvals will be obtained or that all closing conditions will otherwise be satisfied (or waived, if applicable), and, even if all required consents and approvals can be obtained and all closing conditions are satisfied (or waived, if applicable), we can provide no assurance as to the terms, conditions and timing of such consents and approvals or the timing of the completion of the Merger. Many of the conditions to completion of the Merger are not within our control, and we cannot predict when or if these conditions will be satisfied (or waived, if applicable). Any adverse consequence of the pending Merger could be exacerbated by any delays in completion of the Merger or termination of the Merger Agreement.

Each party's obligation to consummate the Merger is also subject to the accuracy of the representations and warranties of the other party (subject to certain exceptions) and performance by each party of its respective obligations under the Merger Agreement, including an agreement by us to conduct our business in all material respects in the ordinary course and to comply with certain operating covenants during the period between execution of the Merger Agreement and completion of the Merger. In addition, the Merger Agreement may be terminated under certain specified circumstances, including, but not limited to, if our board of directors changes its recommendation in favor of the Merger prior to the receipt of stockholder approval. As a result, we cannot assure you that the Merger will be completed, or that, if completed, it will be exactly on the terms set forth in the Merger Agreement or within the expected time frame.

***We may not complete the proposed Merger within the time frame we anticipate or at all, which could have an adverse effect on our business, financial position, results of operations, and cash flows.***

The proposed Merger may not be completed within the expected timeframe, or at all, as a result of various factors and conditions, some of which may be beyond our control. If the Merger is not completed for any reason, our stockholders will not receive any payment for their shares of our common stock in connection with the Merger. Instead, we will remain a public company, our common stock will continue to be listed and traded on the New York Stock Exchange and registered under the Exchange Act, and we will be required to continue to file periodic reports with the SEC. Moreover, our ongoing business may be materially adversely affected, and we would be subject to a number of risks, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may experience negative reactions from the financial markets, including negative impacts on our stock price, and it is uncertain when, if ever, the price of our shares would return to the prices at which our shares currently trade;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may experience negative publicity, which could have an adverse effect on our ongoing operations including, but not limited to, retaining and attracting employees, customers, partners, suppliers and others with whom we do business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we will still be required to pay certain significant costs relating to the Merger, such as legal, accounting, financial advisory, printing and other professional services fees, which may relate to activities that we would not have undertaken other than in connection with the Merger;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may be required to pay a termination fee to Parent of approximately $24.5 million, as required under the Merger Agreement under certain circumstances;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• while the Merger Agreement is in effect, we are subject to covenants prohibiting us from taking certain actions during such period without the consent of Parent (which consent may not be unreasonably withheld, conditioned or delayed);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• matters relating to the Merger require substantial commitments of time and resources by our management, which could result in the distraction of management from ongoing business operations and pursuing other opportunities that could have been beneficial to us; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may commit significant time and resources to defending against litigation related to the Merger.

If the Merger is not consummated, the risks described above may materialize, and they may have a material adverse effect on our business, financial position, results of operations, cash flows and stock price, particularly to the extent that the current market price of our common stock reflects an assumption that the Merger will be completed. Even if the Merger is successfully completed, our stockholders will forego the opportunity to realize the potential long-term value of the successful execution of our current strategy as an independent company.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***We will be subject to various uncertainties while the Merger is pending that may cause disruption and may make it more difficult to maintain relationships with employees, patients, providers, and payers.***

Our efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, our business, which may materially adversely affect our results of operations and our business. Uncertainty as to whether the Merger will be completed may affect our ability to recruit prospective employees or to retain and motivate existing employees. Employee retention may be particularly challenging while the Merger is pending because employees may experience uncertainty about their roles following the Merger. A substantial amount of our management's and employees' attention is being directed toward the completion of the Merger and thus is being diverted from our day-to-day operations. Uncertainty as to our future could adversely affect our business and our relationship with customers and potential customers. For example, providers and payers may defer decisions concerning working with us or seek to change existing business relationships with us. Changes to or termination of existing business relationships could adversely affect our business, financial position, results of operations, and cash flows. The adverse effects of the pendency of the Merger could be exacerbated by any delays in completion of the Merger or termination of the Merger Agreement.

***We have incurred, and will continue to incur, direct and indirect costs as a result of the Merger.***

We have incurred, and will continue to incur, significant costs and expenses, including regulatory costs, fees for professional services and other transaction costs in connection with the Merger, for which we will have received little or no benefit if the Merger is not completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses. Many of these fees and costs will be payable by us even if the Merger is not completed and may relate to activities that we would not have undertaken other than to complete the Merger.

***Litigation challenging the Merger Agreement may prevent the Merger from being consummated within the expected timeframe or at all.***

Lawsuits may be filed against us, our board of directors or other parties to the Merger Agreement, challenging the Merger or making other claims in connection therewith. Such lawsuits may be brought by our purported stockholders and may seek, among other things, to enjoin consummation of the Merger. One of the conditions to the consummation of the Merger is the absence of any order or other action that is in effect (whether temporary, preliminary or permanent) restraining, enjoining or otherwise prohibiting the consummation of the Merger. As such, if the plaintiffs in such lawsuits are successful in obtaining an injunction prohibiting the defendants from completing the Merger on the agreed upon terms, then such injunction may prevent the Merger from becoming effective, or from becoming effective within the expected timeframe.

**Risks Related to Our Business**

***Reimbursement Risks***

***Reductions or changes in reimbursement rates from government programs, or new government regulations, could adversely affect our Net service revenue and other operating results.***

We derive a substantial portion of our *Net service revenue* from the Medicare program. In addition to reimbursement rate changes resulting from CMS's annual rulemaking processes, Congress and certain state legislatures periodically propose significant changes in laws and regulations governing the healthcare system, which have resulted in, and may result in future, limitations on increases and, in some cases, significant reductions in the levels of payments to healthcare providers. For example:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In July 2025, President Trump signed into law the OBBBA, which provided for significant changes to Medicare and Medicaid aimed at reducing overall federal spending, including certain work mandates for Medicaid eligibility. With the pending eligibility changes, enrollees could lose health care coverage, leading to increased demand for more affordable, non-institutional care options, such as home health and hospice services. The OBBBA also introduced significant financial and operational challenges for the services we provide, however. These challenges include, but are not limited to, reduced Medicaid funding, potential increases in uncompensated care, and semi-annual eligible redeterminations with stricter documentation verification for enrollees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Beginning in 2020, PDGM replaced the prior 60-day episode payment methodology with a 30-day payment period and eliminated therapy usage as a factor in setting payments. CMS was required to make assumptions about potential behavior changes caused by the implementation of the 30-day unit of payment and the PDGM. Through 2026, CMS must annually determine the impact on estimated aggregate expenditures of differences between assumed and actual behavior changes and make permanent and temporary increases or decreases to the

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

30-day payment amount to account for such differences. Applying this methodology, CMS implemented a 3.925%, 2.89%, 1.975%, and 0.9% permanent adjustment reduction to the home health base rate for 2023, 2024, 2025, and 2026, respectively, and implemented a temporary reduction to the home health base rate for 2026 of 2.7%. CMS may make future permanent or temporary adjustments based on analysis of estimated aggregate expenditures, which could significantly impact reimbursement for our services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For Medicare providers like us, the 2010 Healthcare Reform Laws provide that CMS will make annual adjustments to Medicare reimbursement rates, commonly known as a "market basket update," that in recent years has been largely offset by adjustment reductions to the home health base rate. For calendar year 2026, for example, CMS implemented a 1.3% payment update percentage decrease for home health reimbursement rates and, for fiscal year 2026, a 2.6% payment update percentage increase to hospice reimbursement rates, each as compared to 2025 reimbursement rates. There is no assurance that future market basket updates will result in increases, or that such updates will be sufficient to offset increases in operating costs or the effects of other adjustments to the home health or hospice base rates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other federal legislation can also have a significant direct impact on our Medicare reimbursement. For example, the Budget Control Act of 2011 provided for an automatic 2% reduction of Medicare program payments, known as sequestration. In August 2025, the Congressional Budget Office estimated that required limits on spending connected to the OBBBA may result in a 4% sequestration under the Statutory Pay-As-You-Go Act of 2010 ("Statutory PAYGO"). In November 2025, President Trump signed the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, setting the Statutory PAYGO to zero for the year and reducing the risk of such sequestration. Concerns held by federal policymakers about the federal deficit, national debt levels, or healthcare spending specifically, including solvency of the Medicare trust fund, could result in enactment of further federal spending reductions or limitations, further entitlement reform legislation affecting the Medicare program, and further reductions to provider payments. State policymakers may consider similar measures relating to Medicaid in response to potential reductions associated with the OBBBA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Each year, MedPAC advises Congress on issues affecting Medicare, including, among others, the HH-PPS and the Hospice payment systems, which can affect the rates we are paid for our services. For example, CMS incorporated some of MedPAC's recommendations into the PDGM system mandated by the 2018 Budget Act and set out in the 2019 final rule for the HH-PPS. MedPAC has also recommended that, for fiscal year 2026, Congress should reduce the home health base rate by 7% and eliminate the hospice base payment update.

There can be no assurance that the government will not enact future initiatives that result in pricing freezes, reimbursement reductions, or levels of reimbursement increases that are less than the increases we may experience in our costs of operations, which could have material adverse effects on our business, financial position, results of operations, and cash flows. For additional discussion of how we are reimbursed by Medicare, see Item 1, "*Business—Sources of Revenue—Medicare Reimbursement*," in this Annual Report.

***An increase in Medicare Advantage patients and resulting change in our payer mix could adversely affect our Net service revenue or our profitability.***

Although the reimbursement rates we receive from traditional Medicare FFS are generally higher than those received from other payers, an increasing percentage of Medicare eligible individuals are choosing to enroll in a Medicare Advantage plan. Medicare Advantage, however, presents a number of challenges with respect to reimbursement rates and collection of fees. Not only do Medicare Advantage and managed care payers generally pay less than Medicare FFS, under Medicare Advantage claims processes we may experience increased bad debt and longer collection cycles for services we provide. Additionally, in May 2025, CMS announced increased audits for Medicare Advantage Plans and deployment of enhanced technology to review medical records of Medicare Advantage patients. These additional audits may affect the claims processing practices of Medicare Advantage plans. For additional discussion of how we are reimbursed by Medicare Advantage payers, see Item 1, *"Business - Our Strategy - Create Revenue Opportunities in Medicare Advantage Through Improved Contracts,"* in this Annual Report.

As our payer mix shifts to a greater portion of Medicare Advantage patients, our ability to collect higher reimbursement rates will become increasingly difficult, and we may not be able to sufficiently increase the volume of patients to offset the impact. Additionally, as the volume of Medicare Advantage patients continues to increase, any payer negotiations that impact payment rates, narrow the scope of covered services, or increase case management review of services and pricing, as well as any delays in such negotiations, could have a material adverse effect on our business, financial position, results of operations, and cash flows.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Efforts to reduce payments to healthcare providers undertaken by third-party payers, conveners, and referral sources could adversely affect our revenues and profitability.***

Many third-party payers are exerting pressure on our industry to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. These efforts include, but are not limited to, lowering payment rates, narrowing the scope of covered services, increasing case management review of services, and negotiating pricing. Our relationships with managed care and non-governmental third-party payers are generally governed by negotiated agreements. Our *Net service revenue* and our ability to grow our business with these payers could be adversely affected if we are unable to negotiate and maintain favorable agreements with them.

In addition, CMS's 2030 goal is for all traditional Medicare and most Medicaid beneficiaries to be in an accountable care relationship. CMS has established several ACO programs, the largest of which is the Medicare Shared Savings Program, a voluntary ACO program in which hospitals, physicians, and other care providers pursue the delivery of coordinated healthcare on a more efficient, patient-centered basis. While the ACO rules are extremely complex and remain subject to further refinement by CMS, ACOs generally receive a portion of any savings generated from care coordination as long as benchmarks for the quality of care are maintained. It is possible, however, that ACOs may seek to reduce costs by discouraging referrals to post-acute care altogether.

Health insurers and managed care companies, including Medicare Advantage plans, may also utilize certain third parties, known as conveners, to attempt to control costs. Conveners offer patient placement and care transition services to those payers with the intent of managing post-acute utilization and associated costs. Conveners may influence referral source decisions on which post-acute setting to recommend, as well as how long to remain in a particular setting.

As a result of various alternative payment models, many referral sources—such as physicians, acute care hospitals, and other healthcare providers in the communities we serve—are increasingly focused on reducing post-acute costs by eliminating post-acute care referrals.

***We face periodic and routine reviews, audits, and investigations under our contracts with federal and state government agencies and private payers, and these audits could have adverse findings that may negatively impact our business.***

As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental reviews, audits, and investigations to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various federal and state government programs in which third-party firms engaged by CMS, the HHS-OIG, and private payers conduct extensive reviews of claims data and medical and other records to identify potential improper payments. If billing errors are identified in the sample of reviewed claims, these reviewers sometimes extrapolate the billing error to all claims filed, which could result in a larger alleged overpayment than originally identified in the sample. Our costs to respond to and defend reviews, audits and investigations may be significant and could have a material adverse effect on our business, financial position, results of operations, and cash flows. Moreover, an adverse review, audit or investigation could, among other things, result in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• required refunding or retroactive adjustment of amounts we have been paid by federal or state programs or private payers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• state or federal agencies imposing fines, penalties, and other sanctions on us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• loss of our ability to participate in federal programs like Medicare, state programs or one or more private payer networks; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• damage to our business and reputation in various markets.

For additional discussion of the reviews, audits, and investigations to which we are subject, see Item 1, "*Business—Regulation—Governmental Review, Audits, Surveys, and Investigations*," in this Annual Report.

***The administration of billings and collections is complex, and our estimates of accounts receivable require us to exercise judgment. Delays in reimbursement due to administrative issues or inadequate reserve estimates may cause financial reporting issues or liquidity problems.***

The billing and collection of our accounts receivable is subject to numerous and complex administrative processes and requires a significant amount of time and effort, including, but not limited to, the assessment of patient eligibility, the process of pre-authorization, the recording and collection of provider documentation, the timely and complete submission of claims for reimbursement, the application of cash receipts to patient accounts, the timely response to payer denials, and

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

the conduct of collection activities. Additional administrative processes are also required when patients elect to change their third-party payers, such as when patients switch from Medicare to Medicare Advantage. If we incorrectly estimate our *Accounts receivable, net of allowances*, or the timing of those collections, it may result in adjustments to our financial statements. Future delays in reimbursement, the future inability to collect aged accounts, or inadequate reserve estimates could have a material impact on our business, financial position, results of operations, or cash flows.

In addition, our accounts receivable with Medicare and Medicaid are subject to the complex regulations that govern Medicare and Medicaid reimbursement and rules imposed by non-government payers, and a portion of our accounts receivable are typically under medical review by payers. The amount collected may materially differ from the amount billed. Our inability to bill and collect on a timely basis pursuant to these regulations and rules could subject us to payment delays that could have a material adverse effect on our business, financial position, results of operations, and cash flows.

Further, if our reserve estimates are inadequate and we do not collect the amount of accounts receivable that we expect in a timely fashion, or at all, our financial position may materially differ from financial results that we have historically recorded.

In addition, timing delays in, or unrealized levels of, billings and collections may cause working capital shortages. Working capital management, including prompt and diligent billing and collection, is an important factor in our financial position, results of operations, and in maintaining liquidity. It is possible that Medicare, Medicaid, documentation support, system problems or other provider issues or industry trends may extend our collection period, which may materially adversely affect our working capital, and our working capital management procedures may not successfully mitigate this risk.

***Medicare reimbursement of hospice services is subject to caps, which may result in our having to reimburse Medicare for certain amounts previously paid to us.***

Payments made by Medicare to each hospice provider are subject to an inpatient cap amount and an overall payment cap amount, which are calculated and published by the Medicare fiscal intermediary on an annual basis covering the period from October 1 through September 30. If payments made to our hospice providers exceed either of these caps, we may be required to reimburse Medicare for excess payments received. See Item 1, "*Business—Sources of Revenues—Hospice*," in this Annual Report. For example, as of December 31, 2025 and 2024, we had accrued approximately $1.9 million and $3.1 million, respectively, for hospice cap exposure. There can be no assurance that future hospice cap exposure will not have a material adverse effect on our business, financial position, results of operations, and cash flows.

***Reimbursement from non-governmental payers can be delayed or inaccurate due to internal challenges that may cause financial reporting or liquidity impacts.***

The billing and collection of our accounts receivable is subject to the ability of non-governmental payers to timely and accurately pay claims we submit for adjudication. From time to time, these payers can experience delays in timely updating their claims systems for changes made to new contractual arrangements we enter into with them. Additionally, a change in payer ownership can introduce changes to systems and issue resolution and medical review processes. Such changes can further slow or stop our ability to collect on outstanding accounts receivable, leading to potential financial reporting or liquidity impacts on us.

***Other Regulatory Risks***

***The ongoing evolution of the healthcare delivery system, including alternative payment models and VBP initiatives, may significantly affect our business and results of operations.***

Government and private payers are increasingly looking for alternative payment models and VBP to contain costs. In May 2025, the Center for Medicare and Medicaid Innovation ("CMMI") announced its updated strategic approach to alternative payment models and value-based care, including, among other things, exploring additional waivers for ACOs and models focused on lifestyle education and services. CMMI may develop new models that directly affect our business.

The healthcare industry faces uncertainty around attempts to improve outcomes and reduce costs, including coordinated care and integrated delivery payment models. In an integrated payment delivery model, hospitals, physicians, and other care providers are incentivized to coordinate healthcare on a more efficient, patient-centered basis. While this is consistent with our goal of being a high-quality, cost-effective provider, broad-based implementation of a new delivery payment model could disrupt the healthcare industry, and may have a significant impact on our business and results of operations.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

In recent years, HHS has been studying the feasibility of bundling and episode-based care. CMS's Bundled Payments for Care Improvement ("BPCI") Advanced initiative, a voluntary, multi-year bundling program intended to test and evaluate alternative payment methodologies, ended December 31, 2025. The BPCI Advanced initiative covered 29 types of inpatient and three types of outpatient clinical episodes, including stroke and hip fracture, over a 90-day episode period. In January 2026, the Transforming Episode Accountability Model ("TEAM"), a five-year mandatory, episode-based payment model for certain acute care hospitals, will begin, requiring covered acute care hospitals to coordinate care for 30 days following one of five covered procedure episodes, including surgical hip femur fracture treatment. TEAM participants bill Medicare FFS but receive a target price based on certain Medicare items and services. TEAM participants will either, subject to quality performance adjustments, earn payments from CMS or owe payment to CMS depending on whether the participant's spending is below or above the target price. We may not be able to properly adjust to the end of the BPCI Advanced initiative or the beginning of TEAM, and effects on reimbursement remain uncertain. Additionally, as the number and types of bundling, direct contracting, and ACO models increase, the number of patients who are treated in these models likely increases as well. Our unwillingness or inability to participate in integrated delivery payment and other alternative payment models and the referral patterns of other providers participating in those models may limit our access to patients who would benefit from treatment by home health services.

Government and private payers' implementation of alternative payment models and VBP requirements could have a material adverse effect on our business. We may not be able to effectively adapt to such changes, or our competitors may be able to adapt more quickly, which would harm our ability to increase our volume of patients and revenue and harm our business, financial position, results of operations, and cash flows.

***Other legislative and regulatory initiatives and changes affecting the industry could adversely affect our business and results of operations.***

Other legislative and regulatory changes may affect healthcare providers like us from time to time by lowering reimbursements, increasing the cost of compliance, decreasing patient volumes, promoting frivolous or baseless litigation, and otherwise adversely affecting our business.

For example, the 2010 Healthcare Reform Laws provide for the expansion of the federal Anti-Kickback Law and the FCA and increased investigation and enforcement efforts in the healthcare industry generally. Changes include increased resources for enforcement, lowered burden of proof for the government in healthcare fraud matters, expanded definition of claims under the FCA, enhanced penalties, and increased rewards for relators in successful prosecutions. CMS may also suspend payment for claims prospectively if, in its opinion, credible allegations of fraud exist. While the initial suspension period may be up to 180 days, it can be extended almost indefinitely if the matter is under investigation by the HHS-OIG or the DOJ. Any such suspension would adversely affect our financial position, results of operations, and cash flows. Some states in which we operate have undertaken, or are considering, similar healthcare reform initiatives.

Shifts in policy in 2025 have increased, and will continue to increase, legislative, regulatory, and enforcement uncertainty in our industry. Recent changes in agency structure and staffing of government subsidized healthcare programs, including Medicare, may affect these programs by changing the number of people enrolled in or eligible for these programs, reducing or delaying funding, changing reimbursement rules or increasing our administrative and compliance costs. Enforcement priorities at both the federal and state level may also shift to align with emerging policy objectives, which may result in scrutiny of practices previously outside the focus of the relevant agencies.

In 2025, the OBBBA made several changes that may decrease the number of persons eligible for Medicaid. For instance, the OBBBA requires states to condition eligibility for Medicaid for certain individuals on demonstration of community engagement after December 31, 2026. This and other provisions in the OBBBA and further legislative or administrative actions at the federal level may impact *Net service revenue* relating to the Medicaid program or the structure of the Medicaid program at the state level. We cannot predict what legislative or regulatory reforms or changes, if any, will ultimately be enacted or the timing or effect any of those changes or reforms will have on our *Net service revenue*, financial position, results of operations, and cash flows.

For additional discussion of healthcare reform and other factors affecting reimbursement for our services, see Item 1, "*Business—Sources of Revenue—Medicare Reimbursement*," in this Annual Report.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Compliance with the extensive laws and government regulations applicable to healthcare providers requires substantial time, effort, and expense, and if we fail to comply with them, we could suffer penalties or be required to make significant changes to our operations.***

Healthcare providers are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• licensure, certification, enrollments, and accreditation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• policies, at either the national or local level, delineating what conditions must be met to qualify for reimbursement under federal programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• coding and billing for services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• quality of medical care;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• use and maintenance of medical supplies, equipment, and technology;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• implementation, maintenance, security, and privacy of patient information and medical records, including electronic health data and health system interoperability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• minimum staffing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acquisition and dispensing of pharmaceuticals and controlled substances; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disposal of medical and hazardous waste.

Any changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our equipment, personnel, services, capital expenditure programs, operating procedures, and contractual arrangements, as well as the way in which we deliver home health and hospice services. Those changes could also affect reimbursements as well as future costs related to compliance, training, and staffing.

Examples of regulatory changes that can affect our business, beyond direct changes to Medicare reimbursement rates, can be found from time to time in CMS's annual rulemaking. See Item 1A, "*Risk Factors*—*Risks Related to Our Business*—*Reimbursement Risks*," in this Annual Report. In addition, the use of sub-regulatory guidance, statistical sampling, and extrapolation by CMS, Medicare contractors, HHS-OIG, and DOJ to deny claims, expand enforcement, and advocate for changes in reimbursement policy increases our risk of experiencing reduced revenue, financial penalties, or significant required changes to our operations.

In 2025, there have been significant shifts in regulatory priorities in the federal government. For instance, the Hospice Special Focus Program ("HSFP") launched in December 2024, subjecting certain hospices to additional oversight and evaluation on selected quality indicators. On February 14, 2025, CMS announced that implementation of the HSFP had ceased for calendar year 2025. We cannot predict other potential shifts in policy or the continuation of preexisting programs.

Because our business is both highly regulated and dependent on payment from federal programs, failure to comply with applicable laws and regulations could materially and adversely affect us. As stated in Item 1, "*Business—Regulation*," we are required to comply with various federal anti-fraud and abuse laws, including the FCA, the federal Anti-Kickback Statute, the Stark or Physician Self-Referral Law, and Civil Monetary Penalties Law, as well as state laws and regulations. Settlements of alleged violations of applicable regulations or imposed reductions in reimbursements, substantial damages and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation and could cost us significant time and expense to defend.

***If any of our home health agencies or hospice provider locations fails to comply with the Medicare enrollment requirements or conditions of participation, that agency could be subject to sanctions or terminated from the Medicare program.*** 

Each of our home health agencies and hospice provider locations must comply with extensive enrollment requirements and conditions of participation for the Medicare program. Failure to comply with applicable requirements may make our agencies ineligible for reimbursement under government healthcare programs such as Medicare and Medicaid. A determination by a regulatory authority that one of our care centers is not in compliance with applicable requirements could also lead to the assessment of fines or other penalties, loss of licensure, exclusion from participation in Medicare and

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Medicaid, and the imposition of requirements that the offending agency or provider take corrective action. In addition, Medicare or Medicaid may seek retroactive reimbursement from noncompliant providers or otherwise impose sanctions for noncompliance.

Non-governmental payers often have the right to terminate provider contracts if the provider loses its Medicare or Medicaid certification. Termination of one or more of our care centers from the Medicare or Medicaid program for failure to satisfy the program's conditions of participation, or the imposition of alternative sanctions, could disrupt operations, require significant attention by management, or have a material adverse effect on our business, financial position, results of operations, and cash flows.

***Other Operational and Financial Risks***

***Pressures relating to downturns in the economy, including increased inflation, could adversely affect our business and consolidated financial statements.***

Adverse developments in the United States could lead to a reduction in federal expenditures, including governmentally funded programs in which we participate, such as Medicare and Medicaid. In addition, if at any time the federal government is not able to meet its debt payments unless the federal debt ceiling is raised, and legislation increasing the debt ceiling is not enacted, the federal government may stop or delay making payments on its obligations, including funding for government programs in which we participate, such as Medicare and Medicaid. Failure of the government to make payments under these programs could have a material adverse effect on our business, financial position, results of operations and cash flows. Further, any failure by Congress to complete the federal budget process and fund government operations may result in a federal government shutdown, potentially causing us to incur substantial costs without timely reimbursement under the Medicare program, which could have a material adverse effect on our business, financial position, results of operations, and cash flows.

Sustained unfavorable economic conditions could also result in reduced payment rates and could have a material adverse effect on our business, financial position, results of operations, and cash flows. For example, general levels of inflation and specific inflationary pressures that we have experienced in areas such as labor, transportation and medical supplies may continue to persist due to events outside of our control, such as potential pandemic events, supply chain disruptions, and the broader macro-economic environment. During 2023 to 2025, for example, inflation increased throughout the U.S. economy. The sustained or continued rise of inflation may adversely impact our business, financial position, results of operations, and cash flows.

***The proper function, availability, and security of our information systems are critical to our business, and failure to maintain them or to protect our data against unauthorized access could have a material adverse effect on our business, financial position, results of operations, and cash flows.***

We are required to comply with HIPAA regulations regarding the privacy and security of PHI, as well as state laws that focus on privacy, security, and notification requirements regarding personal information. The HIPAA regulations impose significant requirements on providers regarding how such PHI may be used and disclosed. Third-party vendors or "business associates," in the event the vendor creates, receives, transmits or maintains PHI on our behalf, are required to comply with substantially the same HIPAA requirements as the healthcare provider. This is accomplished using "Business Associate Agreements" with vendors. Further, the regulations include extensive and complex requirements to establish reasonable and appropriate administrative, technical, and physical safeguards to protect the confidentiality, integrity, and availability of PHI.

We are and will remain dependent on the proper function, availability, and security of our information systems, including systems provided by or hosted by business associates, external contractors, vendors and other businesses with whom we interact. For example, we depend upon our third parties' information systems and software for patient care, coding, accounting, billing, collections, quality assurance, human resources, payroll and other information considered to be sensitive and/or confidential, including PHI.

We expend capital to protect our information systems and the data maintained within those systems from security breaches, including cyber-attacks, email phishing schemes, malware, and ransomware, and we periodically test the adequacy of our security and disaster recovery measures. We have implemented administrative, technical, and physical controls to prevent unauthorized access to that data, which includes patient information and other sensitive information, but we routinely identify attempts to gain unauthorized access to our systems. We, and third parties whose systems we rely on, have faced such attacks in the past and are likely to face such attacks in the future.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Given the rapidly evolving nature and proliferation of cyber threats, there can be no assurance our training and network security measures or other controls will detect, prevent, or remediate security or data breaches in a timely manner or otherwise prevent unauthorized access to, damage to, or interruption of our systems and operations. A security breach, or threat thereof, could require that we expend significant resources to repair or improve our information systems and infrastructure and could distract management and other key personnel from performing their primary operational duties. In the case of a material breach or cyber-attack, the associated expenses and losses may exceed our current insurance coverage for such events. Some adverse consequences may not be insured, such as reputational harm and third-party business interruption.

In recent years, several hospitals have reported being victims of ransomware attacks in which they lost access to their systems, including clinical systems, during the course of the attacks. There have been other recent significant incidents of software vendor compromises. Threat actors continue to attempt to exploit commonly used software and services to gain remote access to a large number of information systems.

The occurrence of any information system failure, breach or security incident, or those of business associates or other vendors and businesses with whom we interact, which results in confidential, protected health or personal information being accessed, obtained, damaged or used by unauthorized persons or unavailability of systems necessary to the operation of our business, could impact patient care, harm our reputation, and expose us to significant remedial costs as well as regulatory actions (fines and penalties) and claims from patients, financial institutions, regulatory and law enforcement agencies, and other persons, any of which could have a material adverse effect on our business, financial position, results of operations, and cash flows.

***Quality of care reporting requirements could adversely affect our business, our referrals, and the Medicare reimbursement we receive.***

Clinical quality is becoming increasingly important within our industry. For example, Medicare imposes a financial penalty upon hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge. In addition, VBP under HHVBP may negatively impact Medicare reimbursement for home health providers. Under HHVBP, home health agencies receive increases or decreases to their Medicare FFS payments of up to 5% based on performance against specific quality measures relative to the performance of other home health providers. Performance on these quality measures in a specified year (performance year) impacts payment adjustments in a later year (payment year). CMS may also create a similar plan for hospices in the future.

The focus on alternative payment models and VBP of healthcare services has led to more extensive quality of care reporting requirements. In many cases, our reimbursement is conditioned upon, or qualified by, our satisfaction of CMS quality of care reporting requirements. For example, home health agencies and hospice provider locations are required to submit quality of care data to CMS each year, and failure to comply with these requirements may result in a 2% penalty to our home health agencies reimbursement and 4% for hospices reimbursement.

Additionally, Medicare has established consumer-facing websites, Home Health Compare and Hospice Compare, that present data regarding our performance on certain quality measures compared to state and national averages. Failure to achieve or exceed these averages may affect our ability to generate referrals, which could have a material adverse effect upon our business, financial position, results of operations, and cash flows.

The adoption of additional quality reporting measures will require more time and expense to track and report and could affect reimbursement in the future. In healthcare generally, the burdens associated with collecting, recording, and reporting quality data are increasing. Currently, for example, CMS requires home health providers to track and submit patient assessment data to support the calculation of quality of care reporting measures. We, like other healthcare providers, are likely to incur additional expenses to comply with changing quality reporting requirements.

There can be no assurance that all our agencies will meet quality performance expectations (including Star ratings) or quality reporting requirements in the future, which may result in one or more of our agencies seeing a reduction in its Medicare reimbursements or patient referral volume. If we fail to attain our goals regarding acute care hospital readmission rates and other quality metrics, we expect our ability to generate referrals and our Medicare reimbursements to be adversely impacted, which could have a material adverse effect upon our business, financial position, results of operations, and cash flows.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***We face intense competition for patients from other healthcare providers.***

We operate in the highly competitive and fragmented home health and hospice industries. Some of our competitors have greater financial and other resources, advantages of scale and more established presences in their respective communities than we do.

Competing companies may offer newer or different services from those we offer or have better relationships with referring physicians and may thereby attract patients who are presently, or would be candidates for, receiving our services. Other companies, including hospitals and other healthcare organizations that are not currently providing competing services, may expand their services to include home health, hospice care, or similar services. In several states in which we operate, a majority of the Medicare Advantage patients are insured by two large managed care companies that currently offer home health services. The managed care companies have substantial resources and existing relationships with customers, which may serve as a large patient base for their current or future home health services. Competition by these managed care companies in home health services may adversely affect our ability to capture Medicare Advantage volumes.

In addition, from time to time, there are efforts in states with CON laws to weaken those laws, which could potentially increase competition in those states. Conversely, competition and statutory procedural requirements in some CON states may inhibit our ability to expand our operations in those states. For a breakdown of the CON status of the states and territories in which we have operations, see Item 2, "*Properties*," in this Annual Report. There can be no assurance current or future competition will not adversely affect our business, financial position, results of operations, or cash flows.

***If we are unable to maintain or develop relationships with patient referral sources, our growth and profitability could be adversely affected.***

Our success depends in large part on referrals from physicians, hospitals, case managers and other patient referral sources in the communities we serve. By law, referral sources cannot be contractually obligated to refer patients to any specific provider. However, there can be no assurance that our competitors will not attempt to steer patients to other post-acute providers or otherwise limit our access to potential referrals. Our ability to attract patients could be adversely affected if any of our home health agencies fails to provide or maintain a reputation for providing high-quality care on a cost-effective basis as compared to other providers. The establishment of joint ventures or networks between referral sources, such as acute care hospitals, and other post-acute providers may hinder patient referrals to us. The growing emphasis on integrated care delivery across the healthcare continuum increases that risk.

We cannot provide assurance that we will be able to maintain our existing referral source relationships or that we will be able to develop and maintain new relationships in existing or new markets. Our loss of, or failure to maintain, existing relationships or our failure to develop new relationships could adversely affect our ability to grow our business and operate profitably.

***Our business depends on the ability of our employees to travel via fleet vehicles or their personal vehicles, and our business operations may be impacted by rising costs of fuel and access to fleet vehicles.***

Our employees drive to our patients using either company fleet vehicles or personal vehicles. For the company fleet vehicles, we reimburse our employees' out-of-pocket expenses, including fuel cost, and we reimburse our employees using their personal vehicles for mileage pursuant to an established reimbursement methodology. Fluctuations in fuel prices affect our cost per visit and per patient day, and in an environment of increasing fuel prices, our cost per visit and per patient day can increase due to factors beyond our control. If the costs associated with fuel, repair expenses, and new fleet vehicles continue to rise, our future operations and financial results may be adversely affected, and our profits and profit margins will likely be reduced.

***Competition for staffing, shortages of qualified personnel or other factors may increase our staffing costs and reduce profitability.***

Our operations depend on the efforts, abilities, and experience of our medical personnel, such as physical therapists, occupational therapists, speech pathologists, nurses, and other healthcare professionals. We compete with other healthcare providers for qualified personnel responsible for the daily operations of each of our locations. Our ability to attract and retain qualified personnel depends on several factors, including our ability to provide competitive wages and benefits. In some markets, the lack of available medical personnel is a significant operating issue facing all healthcare providers, including us. A shortage may require us to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel. A failure to recruit and retain qualified medical personnel could cause the quality of our services to decline or constrain our ability to grow.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

If our staffing costs increase, we may not experience reimbursement rate or pricing increases to offset these additional costs. Because a significant percentage of our revenues consists of fixed, prospective payments, our ability to pass along increased staffing costs is limited. In particular, if staffing costs continue to rise at an annual rate greater than the annual net impact of reimbursement rates from Medicare, or we experience a significant shift in our payer mix to lower rate payers such as Medicare Advantage, our results of operations and cash flows will be adversely affected. Conversely, decreases in reimbursement revenues, such as with sequestration, may limit our ability to increase compensation or benefits to the extent necessary to retain key employees, increasing our turnover and associated costs.

***The transition of management or unexpected departure of our key officers could harm our business.***

We depend on the efforts of our senior management. The transition of management, the unforeseen loss or limited availability of the services of any of our executive leaders, or our inability to recruit and retain qualified personnel in the future, could, at least temporarily, create uncertainty and involve a diversion of resources and management attention, be disruptive to our daily operations or impact public or market perception, any of which could negatively impact our ability to operate effectively or execute our strategies, which could result in a material adverse impact on our business, financial position, results of operations, and cash flows.

On August 6, 2025, we announced the transition of our Chief Executive Officer ("CEO"), Barb Jacobsmeyer. Failure to successfully manage our CEO transition could adversely impact our business, financial position, and operating results. The change in leadership introduces a retention risk for other members of senior management, and risks the continuity of business initiatives, plans, and strategies through the transition period. If we are unable to execute an orderly transition, our business may be adversely affected.

***We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation, the outcome of which could have a material adverse effect on us.***

We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. Various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are a defendant in a number of lawsuits, most of which are general and professional liability matters inherent in treating patients with medical conditions.

On any given day, we have thousands of care providers driving to and from the homes of patients where we provide services and administer care to individuals with a variety of serious, sometimes terminal, medical conditions. We cannot predict the impact any claims arising out of the travel, the home visits or the care being provided (regardless of their ultimate outcomes) could have on our business or reputation or on our ability to attract and retain patients and employees.

Substantial damages, fines or other remedies assessed against us or agreed to in settlements could have a material adverse effect on our business, financial position, results of operations, and cash flows. Additionally, the costs of defending litigation and investigations, even if frivolous or non-meritorious, could be significant. We also cannot predict the adequacy of any reserves for such losses or recoveries from any insurance or re-insurance policies we maintain, and there can be no guarantee that our insurance policies cover all risks that our business may face.

***Although we are currently restricted under the terms of our credit agreement, we may incur additional indebtedness in the future, and that debt or the associated increased leverage may have negative consequences for our business. The restrictive covenants included in the terms of our indebtedness could affect our ability to execute aspects of our business plan successfully.***

We utilize a $400.0 million term loan A facility and a $220.0 million revolving credit facility for working capital purposes. Subject to specified limitations, the credit agreement governing this indebtedness generally restricts our ability to incur additional debt, other than additional draws on the revolving credit facility.

Our indebtedness and the limitations on incurring additional debt could have important consequences and exacerbate the following risks:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• limiting our ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy and other general corporate purposes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• making us more vulnerable to unfavorable economic, industry and competitive conditions and government regulation by limiting our flexibility in planning for, and reacting to, changing conditions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• placing us at a competitive disadvantage compared with competing providers that have less debt or better access to capital resources; and

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exposing us to risks inherent in interest rate fluctuations, which could result in higher interest expense, as discussed in Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations*," in this Annual Report.

Changes in our business or other factors could prevent us from satisfying our obligations under our credit agreement or other future debt instruments. If we are unable to generate sufficient cash flow from operations to service our debt and any other cash payment obligations, we may have to refinance all or a portion of our debt, obtain additional financing, reduce expenditures, or sell assets we deem necessary to our business. We cannot assure these measures would be possible or any additional financing could be obtained. The credit agreement also includes customary remedies, including the right of the lenders to take action with respect to the collateral securing the indebtedness, that would apply should we default or otherwise be unable to satisfy our obligations under the credit agreement.

In addition, the various restrictive covenants in our credit agreement could also adversely affect our ability to finance our future operations or capital needs and pursue available business opportunities. Further, we are required to maintain compliance with certain financial tests and ratios under the credit agreement. If we become concerned that we may not be in compliance with such financial tests and ratios, we may seek to negotiate a waiver or amendment of the applicable covenant. However, there can be no assurance we will be able to obtain such waiver or amendment on commercially acceptable terms or at all. Various risks, uncertainties and events beyond our control could affect our ability to comply with the covenants and financial tests and ratios in the credit agreement.

Failure to comply with any of the covenants in our existing or future financing agreements could result in a default under those agreements and under any other agreements containing cross-default provisions. A default that occurs and is not cured within any applicable cure period, or is not waived, would permit lenders to accelerate the maturity of the debt under these agreements and to foreclose upon any collateral securing the debt. Under these circumstances, we might not have sufficient funds or other resources to satisfy all of our obligations.

For additional discussion of our indebtedness, see Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources*," in this Annual Report, and Note 8, *Long-Term Debt*, to the accompanying consolidated financial statements.

***A pandemic, public health catastrophe or other unforeseen event, including natural disasters, could materially impact our operations.***

Our operations are vulnerable to disruption from the occurrence of pandemics and other public health catastrophes. For example, future federal, state, or local laws, regulations, orders or other governmental or regulatory actions addressing a pandemic or a future public health catastrophe, including without limitation vaccine mandates, shelter-in-place orders, and other government-mandated business closures, could limit our ability to operate efficiently and adversely affect our financial condition, results of operations, and cash flows. A pandemic or a future public health catastrophe could also, among other things, exacerbate staffing shortages, increase our costs, decrease institutional referrals, reduce elective health care procedures, restrict in-home visits and visits in assisted living facilities, or reduce patient volumes. Because the majority of our patients have complex medical challenges, they may be more vulnerable than the general public during a pandemic or other public health catastrophe, and our employees are at greater risk of contracting contagious diseases due to their increased exposure to vulnerable patients. In addition, supply chain disruptions caused by a pandemic or a future public health catastrophe, or by the economic impact of foreign or domestic tariffs, could increase our expenses for necessary equipment, pharmaceuticals, and medical supplies, including without limitation, personal protective equipment. All these potential effects would have a negative impact on our business, financial condition, and operations results.

Several of our locations were impacted by natural disasters in 2024, including Hurricanes Helene and Milton. If the intensity of individual hurricanes or the number of hurricanes that occur each year increases, we may experience considerable disruptions in our operations due to property damage or electrical outages experienced in storm-affected areas, whether these affect our locations and staff, or whether they impact our patients, referral sources, vendors, and others. Further, long-term adverse weather conditions and natural disasters may cause an outmigration of people from the communities we serve. If any of the circumstances described above occur, there could be a harmful effect on our business and our results of operations could be adversely affected.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***If we fail to maintain effective internal control over financial reporting, we may be unable to accurately or timely report our financial condition or results of operations, which may adversely affect our business, financial condition, results of operations, and cash flows.***

As a public company, we are required to document and test our internal control over financial reporting in order to satisfy the rules and regulations of the SEC, which require annual management assessments of the effectiveness of our internal control over financial reporting and a report by our independent registered public accounting firm that addresses the effectiveness of internal control over financial reporting. A "material weakness" is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We have identified, and subsequently remediated, material weaknesses in our control environment in previous years. There can be no assurance that other internal control issues will not be identified in the future.

If we fail to implement and maintain effective internal control over financial reporting, our ability to record, process, summarize, and report financial information accurately, and to prepare the consolidated financial statements within the time periods specified by the rules and regulations of the SEC could be adversely affected. An inability to record, process, summarize, and report financial information accurately could cause our investors to lose confidence in our publicly reported information, cause the market price of our stock to decline, expose us to sanctions or investigations by the SEC or other regulatory authorities, or impact our financial condition and results of operations.

***The carrying value of our Goodwill or other intangible assets, net, is subject to impairment testing and may result in the incurrence of impairment charges and adversely impact our results of operations and financial condition.***

As of December 31, 2025, we had *Goodwill* of $855.3 million and *Intangible assets, net*, of $38.5 million. The net carrying value of *Goodwill* represents the fair value of acquired businesses in excess of identifiable assets and liabilities as of the acquisition date or subsequent impairment date, if applicable. The carrying value of *Intangible assets, net*, represents the fair value of certificates of need, licenses, noncompete agreements, internal-use software, and other acquired intangibles as of the acquisition date or subsequent impairment date, if applicable, net of accumulated amortization, if applicable. *Goodwill* and other acquired intangibles expected to contribute indefinitely to our cash flows are not amortized, and therefore must be evaluated by management at least annually for impairment or when events occur or circumstances change that could potentially reduce the fair value of the reporting unit or intangible asset. Amortized intangible assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amounts of these assets may not be recoverable. For example, as a result of the quantitative impairment analysis performed, we recorded impairment charges totaling $44.7 million and $161.7 million for the Home Health reporting unit for the years ended December 31, 2025 and 2024, respectively, and $85.8 million for the Hospice reporting unit for the year end December 31, 2023. Impairments to *Goodwill* and other intangible assets, net, may also be caused by factors outside our control, such as increasing competitive pricing pressures, lower than expected revenue and profit growth rates, changes in industry earnings before interest, taxes, depreciation and amortization ("EBITDA") multiples or changes in discount rates based on changes in cost of capital and interest rates.

Any additional impairment to goodwill or other intangible assets in future periods could adversely impact our results of operations and financial condition. See Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates*," in this Annual Report.

***We may make investments or complete transactions that could expose us to unforeseen risks and liabilities. Further, we may not be able to successfully integrate acquisitions or realize the anticipated benefits of any acquisitions or investments, including opening de novo locations.***

Historically, we selectively pursued strategic acquisitions of, and in some instances joint ventures with, other healthcare providers. Acquisitions remain part of our long-term growth strategy. In both the home health and hospice industries, there is significant competition to acquire companies that have a large number of locations. We may face limitations on our ability to identify sufficient acquisitions or other development targets and to complete those transactions to meet goals.

Any acquisitions, joint ventures and investments, including de novo locations, involve numerous risks, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal and regulatory limitations on our ability to complete acquisitions, particularly those involving not-for-profit providers, on terms, timelines, and valuations reasonable to us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• obtaining financing for acquisitions at a cost reasonable to us;

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal and regulatory limitations on our ability to obtain approval to operate de novo locations on anticipated timeframes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties integrating acquired operations, personnel, and information systems, and in realizing projected revenues, efficiencies, and cost savings, or returns on invested capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• entry into markets, businesses, or services in which we may have little or no experience;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• diversion of business resources or management's attention from ongoing business operations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exposure to undisclosed or unforeseen liabilities of acquired operations, including liabilities for failure to comply with healthcare laws and anti-trust considerations in specific markets, successor liability imposed by Medicare, and risks and liabilities related to previously compromised information systems.

We may face substantial difficulties, costs, and delays involved in the integration of acquired businesses or de novo locations. In some cases, the acquired business has itself grown through acquisitions, and there may be legacy systems, operating policies and procedures, and financial and administrative practices yet to be fully integrated. To the extent we are attempting to integrate multiple businesses at the same time, we may not be able to do so as efficiently or effectively as we initially anticipate. Additionally, approval of de novo locations is controlled by local regulatory agencies and may take longer than anticipated. The failure to successfully integrate on a timely basis any acquired business or de novo locations could have an adverse effect on our business, financial position, results of operations, and cash flows.

In addition, acquired businesses and de novo locations may not contribute to our revenues or earnings to the extent anticipated, and any expected synergies may not be realized. If the acquired businesses and de novo locations underperform, we may be required to take an impairment charge. Failure to achieve the anticipated benefits could also divert management's time and energy and could have an adverse effect on our business, financial position, results of operations, and cash flows.

***We use, and may continue to expand our use of, machine learning and AI technologies to deliver our services and operate our business.***

The use or offering of AI technologies may result in new or expanded risks and liabilities, including enhanced government or regulatory scrutiny, litigation, compliance issues, ethical concerns, confidentiality, reputational harm and security risks. It is not possible to predict all the risks related to the use of AI, and changes in laws, rules, directives, and regulations governing the use of AI may adversely affect our ability to develop and use AI or subject us to legal liability. The cost of complying with laws and regulations governing AI could be significant and would increase our operating expenses, which could adversely affect our business, financial condition and results of operations. Further, market demand and acceptance of AI technologies are uncertain, and we may be unsuccessful in efforts to further incorporate AI into our processes.

At the same time, if we fail to successfully integrate AI into our platform and business processes, or if we fail to keep pace with rapidly evolving AI technological developments, including attracting and retaining talented AI developers and programmers, we may face a competitive disadvantage.

***Risks Related to Industry Consolidation***

***Consolidation in the healthcare industry and the actions of activist stockholders could materially affect our business, financial position, results of operations, and cash flows and our ability to operate as an independent entity.***

The healthcare industry faces strong competition and consistent pressure to grow revenues while containing escalating costs. In recent periods, these aspects of our industry have caused some consolidation.

Additionally, our business could be negatively affected by the actions of activist stockholders. While we value constructive input from investors and regularly engage in dialogue with our stockholders, responding to actions by activist stockholders can be costly and time-consuming and divert management's attention from operations. Activist stockholder activity can create uncertainties as to our future direction and could lead to the perception of a change in the direction of our business or other instability. In such a case, our competitors or other activist stockholders could exploit these uncertainties and perceptions, which could have a material adverse impact on our business, financial position, results of operations, and cash flows.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Certain provisions in our amended and restated certificate of incorporation and amended and restated bylaws, and of Delaware law, may prevent or delay an acquisition of Enhabit, which could decrease the trading price of our common stock.*** 

We are party to the Merger Agreement, which will result in a change of control of the Company, if completed. The below anti-takeover provisions are inapplicable to the proposed Merger.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions consistent with Delaware law that are intended to deter coercive takeover practices and inadequate takeover bids by making such practices or bids unacceptably expensive to the bidder and to encourage prospective acquirers to negotiate with our board of directors rather than to attempt a hostile takeover. These provisions include, among others:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• rules regarding the number of votes of stockholders required to amend certain provisions of our amended and restated certificate of incorporation and approve a business combination;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• limitations on the ability of stockholders to call special meetings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the right of our board of directors to issue preferred stock without stockholder approval;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• rules regarding how stockholders may present proposals or nominate directors for election at stockholder meetings; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability of our directors, and not stockholders, to increase the number of directors constituting our board of directors and to fill vacancies on our board of directors.

In addition, because we have not elected to be exempt from Section 203 of the Delaware General Corporation Law, this provision could also delay or prevent a change of control. Section 203 provides that, subject to limited exceptions, persons that acquire, or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation (an "interested stockholder") shall not engage in any business combination with that corporation, including by merger, consolidation or acquisitions of additional shares, for a three-year period following the date on which the person became an interested stockholder, unless (i) prior to such time, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock; or (iii) after our board of directors approves the business consideration, it is authorized at a meeting of stockholders by the affirmative vote of at least two-thirds of our outstanding voting stock not owned by the interested stockholder.

Furthermore, our board of directors has the power, subject to applicable law, to issue series of preferred stock that could, depending on the terms of the series, impede the completion of a merger, tender offer or other takeover attempt that some, or a majority, of the stockholders may believe to be in their best interests or in which stockholders would have received a premium for their stock over the then-prevailing market price of the stock. For instance, subject to applicable law, a series of preferred stock may impede a business combination by including class voting rights, which would enable the holder or holders of such series to block a proposed transaction. Our board of directors will make any determination to issue shares of preferred stock based on its judgment as to our and our stockholders' best interests.

Although we believe these provisions will protect our stockholders from coercive or otherwise unfair takeover tactics, these provisions will apply even if the offer may be considered beneficial by some stockholders and could delay or prevent an acquisition that our board of directors determines is not in the best interests of Enhabit and its stockholders.

**ITEM 1B. UNRESOLVED STAFF COMMENTS**

Not applicable.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ITEM 1C. CYBERSECURITY**

We take a holistic, multi-layered approach to management and oversight of cybersecurity risks. Our board of directors has ultimate oversight responsibility but has delegated to the board's Care, Compliance, & Cybersecurity Committee focused and pertinent oversight duties, which have been integrated into our overall enterprise risk management program, as described below. Our Chief Information Officer provides quarterly reports on our cybersecurity program to the Care, Compliance, & Cybersecurity Committee. These reports include details and metrics on, among other things, our routine vulnerability assessments, internal and external threat intelligence, company-wide phishing exercises and training, device encryption, device patching, routine resilience efforts including quarterly disaster recovery exercises, tabletop incident response and business continuity exercises. The chairperson of the Care, Compliance, & Cybersecurity Committee briefs the full board of directors on such quarterly reports.

The Chief Information Officer and our Chief Information Security Officer also serve on management's Enterprise Risk Committee, along with our executive management team, the Chief Compliance Officer, and internal audit personnel. The Enterprise Risk Committee meets regularly during the year to assess various significant risks—including cybersecurity risks—and receives cybersecurity updates in connection with those assessments and the development and implementation of any risk mitigation plans. Our President and CEO presents the report of the Enterprise Risk Committee quarterly to the full board of directors.

We also maintain an inter-departmental privacy and security committee which oversees programs and initiatives to protect and secure patient information as well as our data and information systems. This committee reports to our executive management team and has responsibility for our IT-security incident response plan and various training and awareness programs that promote patient privacy and system security practices by employees.

We have structured our cybersecurity program around the National Institute of Standards and Technology ("NIST") Cybersecurity Framework as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business. Our cybersecurity strategy focuses on implementing effective and efficient controls, technologies, and processes to assess, identify and manage cybersecurity risks. Key components of our strategy include annual and ongoing security awareness training for employees, advanced detection and monitoring systems, and robust incident response and containment. We actively monitor and investigate both internally discovered and externally reported issues that may compromise our information systems, permitting quick and decisive action when necessary. We also have engaged third-party service providers and have implemented cybersecurity risk management protocols for such parties. For example, all vendors are required to complete our Ongoing Monitoring Assessment Questionnaire, which helps monitor each vendor's continuing compliance, and we subject our technology vendors to a separate vetting and approval process formally assessing each vendor from a cybersecurity perspective.

Our Chief Information Security Officer, who reports to our Chief Information Officer, brings to bear more than two decades of experience implementing NIST cybersecurity frameworks, including most recently five years as chief information security officer for a Fortune 200 company. He also holds multiple certifications including the globally recognized Certificate Information Systems Security Professional designation since 2006. The Chief Information Security Officer leads a dedicated team of internal IT employees, along with multiple long-term third-party security vendors. Our board of directors, and the Care, Compliance, & Cybersecurity Committee of the board, supports our Chief Information Officer and Chief Information Security Officer by leveraging members' experience with information technology and management, including information technology strategy and risks associated with cybersecurity matters, as part of its oversight function.

Our policies and procedures concerning cybersecurity matters apply to all employees. These policies and procedures address encryption standards, antivirus protection, remote access, multi-factor authentication, confidential information, and the use of the internet, social media, email and wireless devices.

We have experienced threats to our data and systems, including malware and computer virus attacks from time to time. To our knowledge, these threats have not materially affected us, our business, financial position, results of operations or cash flows to date. For more information about the cybersecurity risks we face, see Item 1A, "*Risk Factors—Other Operational and Financial Risks*."

**ITEM 2. PROPERTIES**

We maintain our principal executive office at 6688 N. Central Expressway, Ste. 1300, Dallas, Texas 75206, the lease for which was renewed in March 2023 for an 11 year term. See Note 6, *Leases*, to the accompanying consolidated financial statements for additional information about the renewal of the lease.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

In addition to our principal executive office, as of December 31, 2025, we leased through various consolidated entities 280 locations. Our home health and hospice locations are in the localities served by that business and are subject to relatively small space leases, primarily of 5,000 square feet or less. Those space leases are typically five years or less in term. Our principal executive office and other properties are suitable for their respective uses and are, in all material respects, adequate for our present needs.

The following table sets forth information regarding our home health and hospice locations as of December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| **State** | &nbsp;&nbsp;&nbsp;&nbsp;**Home Health<br> Locations** | &nbsp;&nbsp;&nbsp;&nbsp;**Hospice<br>Locations** | **Total** |
| Alabama+\* | 29 | 27 | 56 |
| Alaska | 1 | 1 | 2 |
| Arizona | 5 | 3 | 8 |
| Arkansas+\* | 3 | 2 | 5 |
| Colorado | 6 | 3 | 9 |
| Connecticut | 1 | 1 | 2 |
| Florida | 25 |  | 25 |
| Georgia+ | 18 | 5 | 23 |
| Idaho | 7 | 6 | 13 |
| Illinois | 3 | 1 | 4 |
| Indiana | 2 | 1 | 3 |
| Kansas | 4 | 2 | 6 |
| Kentucky+ | 3 |  | 3 |
| Louisiana |  | 2 | 2 |
| Maryland+ | 1 |  | 1 |
| Massachusetts | 5 |  | 5 |
| Mississippi+ | 9 | 11 | 20 |
| Missouri | 1 | 1 | 2 |
| Montana | 4 | 4 | 8 |
| Nevada | 3 | 1 | 4 |
| New Mexico | 5 | 4 | 9 |
| North Carolina+ | 6 |  | 6 |
| Ohio | 2 |  | 2 |
| Oklahoma | 17 | 3 | 20 |
| Oregon | 2 |  | 2 |
| Pennsylvania | 3 |  | 3 |
| Rhode Island+ | 1 |  | 1 |
| South Carolina+\* | 3 | 1 | 4 |
| Tennessee+\* | 7 | 1 | 8 |
| Texas | 52 | 26 | 78 |
| Utah | 5 | 5 | 10 |
| Virginia | 11 | 2 | 13 |
| Washington+\* | 1 | 1 | 2 |
| Wyoming | 4 | 3 | 7 |
|  | 249 | 117 | 366 |

---

+&nbsp;&nbsp;&nbsp;&nbsp;Home health certificate of need state.

\*&nbsp;&nbsp;&nbsp;&nbsp;Hospice certificate of need state.

**ITEM 3. LEGAL PROCEEDINGS**

We provide services in the highly regulated healthcare industry. In the ordinary course of our business, we are a party to various legal actions, proceedings, and claims as well as regulatory and other governmental audits and investigations. These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. Some of these matters have been material to us in the past, and others in the future may, either individually or in the aggregate, be

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

material and adverse to our business, financial position, results of operations, and liquidity. We do not believe any of our pending legal proceedings are material to us, but there can be no assurance our assessment will not change based on future developments.

Additionally, the FCA allows relators to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as "qui tam" actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys' fees, and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. For additional discussion regarding the FCA, see Item 1A, "*Risk Factors—Risks Relating to Our Business—Other Regulatory Risks*."

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**PART II**

**ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES**

**Market Information for Common Stock**

Our common stock is listed for trading on the New York Stock Exchange under the symbol "EHAB."

**Holders of Common Stock**

As of the close of business on February 26, 2026, approximately 5,300 holders of record held our common stock. This number of holders of record does not represent the actual number of beneficial owners of our common stock because shares are frequently held in "street name" by securities dealers and others for the benefit of individual owners who have the right to vote their shares.

**Dividend Policy**

We have not declared or paid any cash dividends on our common stock and do not expect to pay cash dividends for the foreseeable future. Future decisions concerning the payment of dividends will depend upon our results of operations, financial condition, capital expenditure plans, and debt service requirements, as well as such other factors that our board of directors, in its sole discretion, may consider relevant.

**Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities**

During the three months ended December 31, 2025, we purchased shares of our common stock as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total Number of Shares Purchased** <sup>(1)</sup> | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Plans** | **Approximate Dollar Value of Shares that May Yet be Purchased under our Share Repurchase Plans** |
| October 1 through October 31 | **—** | $**—** | **—** | **—** |
| November 1 through November 30 | **3080** | **7.99** | **—** | **—** |
| December 1 through December 31 | **49649** | **9.65** | **—** | **—** |
|  | **52729** | $**9.55** | **—** | **—** |

---

(1)Represents shares of common stock we repurchased in November and December 2025 to satisfy employee tax-withholding obligations in connections with the vesting of stock-based compensation awards.

**Securities Authorized for Issuance Under Equity Compensation Plans**

Information required by this item is incorporated by reference to our definitive proxy statement for our 2026 Annual Meeting of stockholders.

**Comparison of Total Stockholder Return**

The following graph compares the cumulative total stockholder returns of Enhabit's common stock with the cumulative total stockholder returns of the S&P Health Care Services Select Industry (the "S&P 500 Index and the S&P Health Care Services Index"). Data for the S&P 500 Index and S&P Health Care Services Index assume reinvestment of dividends. The graph assumes that $100 was invested at market close on July 1, 2022, which was the first day that our common stock began trading. The graph uses the closing market price on July 1, 2022 of $22.74 per share as the initial value of a share of our common stock.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

![2321](ehab-20251231_g1.jpg)

This performance graph and other information furnished under this Comparison of Total Stockholder Return section shall not be deemed to be "soliciting material" or to be "filed" with the SEC or subject to Regulation 14A or 14C, or to the liabilities of Section 18 of the Exchange Act.

**ITEM 6. [RESERVED]**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

This section is designed to provide a reader of our financial statements with a narrative from the perspective of management on our financial condition, results of operations, liquidity, and other factors that may affect our future results. The following discussion should be read in conjunction with the consolidated financial statements and related notes that appear in Item 15, "*Exhibit and Financial Statement Schedules*," in this Annual Report.

This discussion also contains forward-looking statements about our business, operations and industry that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, and intentions. Our future results and financial condition may differ materially from those we currently anticipate as a result of the factors we describe under the sections titled "*Cautionary Note Regarding Forward-Looking Statements*," and Item 1A, "*Risk Factors*," in this Annual Report.

For a comparison of our results of operations for the years ended December 31, 2024 to 2023, see Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations*," of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 6, 2025.

**Overview**

We are a leading provider of home health and hospice services in the United States. We strive to provide superior, cost-effective care where patients prefer it: in their homes. For over 25 years, we have provided care in the low-cost home setting while achieving high-quality clinical outcomes. As of December 31, 2025, our footprint comprised 249 home health and 117 hospice locations across 34 states.

Our operations are principally managed on a services basis and include two operating segments for financial reporting purposes: (i) Home Health; and (ii) Hospice. For additional information about our business and reportable segments, see Item 1, "*Business*," Item 1A, "*Risk Factors*," "—*Segment Results of Operations*," and Note 14, *Segment Reporting*, to the accompanying consolidated financial statements in this Annual Report.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**Factors Affecting Our Performance**

There are a number of factors that have impacted, and we believe will continue to impact, our results of operations and growth. These factors include:

***Pricing***

Generally, the pricing we receive for our services is based on reimbursement rates from payers. Because we derive a substantial portion of our *Net service revenue* from the Medicare program, our results of operations are heavily impacted by changes in Medicare reimbursement rates.

Medicare reimbursement rates are subject to change annually, with the potential for more sweeping changes from time to time as a result of Congressional or state legislation. See Item 1, "*Business*," and Item 1A, "*Risk Factors*," and "—S*egment Results of Operations*," in this Annual Report, as well as Note 14, *Segment Reporting*, to the accompanying consolidated financial statements.

We are also impacted by changes in reimbursement rates by other payers, and in particular, Medicare Advantage plans. See Item 1, "*Business*—*Sources of Revenue*," for a table identifying the sources and relative payer mix of our revenues.

***Volume***

The volume of services we provide has a significant impact on our *Net service revenue*. Various factors, including competition and increasing regulatory and administrative burdens, impact our ability to maintain and grow our Home Health and Hospice volumes. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages. Aggressive payment review practices by Medicare contractors, aggressive enforcement of regulatory policies by government agencies, and restrictive or burdensome rules, regulations, or statutes governing admissions practices may lead us not to accept patients who would be appropriate for, and would benefit from, the services we provide.

We expect the United States' aging population will continue to increase long-term demand for our services, which we believe will help us grow our Home Health and Hospice volumes. While we treat patients of all ages, most of our patients are 65 and older, and, due to the growth of this segment of the U.S. population, the number of Medicare enrollees is expected to continue to grow approximately 3% per year. More specifically, the average age of our home health patients and hospice patients is approximately 76 and 83, respectively. We believe the growing percentage of seniors experiencing chronic conditions will result in higher utilization of home health services in the future as patients require more care to support these conditions.

Due to the continued national enrollment increases in Medicare Advantage plans by Medicare beneficiaries, we expect the volume of third-party payers to shift and evolve. For example, in the year ended December 31, 2024, Medicare Advantage patients accounted for 23.0% of our revenue as compared to 23.9% for the year ended December 31, 2025.

In addition to organic growth, our strategy includes volume growth through de novo location openings and strategic acquisitions. See Item 1, "*Business*—*Our Strategy*."

***Efficiency***

Cost and operating efficiencies impact the profitability of the patient care services we provide. We use a number of strategies to drive cost and operating efficiencies within our business. We target markets for expansion and growth that allow us to leverage our existing operations to create operating efficiencies through scale and density. We also leverage technology to create operating and supply chain efficiencies throughout our organization. See Item 1, "*Business*—*Our Competitive Strengths*," for further discussion of the ways we seek to reduce costs while improving patient outcomes.

***Impact of Inflation***

Inflation has impacted us primarily with respect to our labor costs. The healthcare industry is labor intensive, and wages, and other expenses, may increase during periods of inflation, or when labor shortages occur in the marketplace. There can be no guarantee we will not experience increases in the cost of labor, as the need for clinical healthcare professionals is growing. In addition, increases in labor costs in the healthcare industry are typically higher than inflation and, as such, would impact our costs under employee benefit plans. Managing these costs remains a significant challenge and priority for us.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Suppliers may pass along rising costs to us in the form of higher prices. In addition, we have experienced higher prices for our medical supplies as a result of inflation and other factors. Our supply chain efforts and our continual focus on monitoring and actively managing medical supplies and pharmaceutical costs have enabled us to mitigate the effect of increased pricing related to supplies and other operating expenses over the past few years. However, we cannot predict the magnitude of future cost increases.

We have little or no ability to pass on these increased costs associated with providing service to Medicare and Medicaid patients due to federal and state laws that establish fixed reimbursement rates through the annual Medicare reimbursement rate updates for home health and hospice. Additionally, we have little or no ability to pass on these increased costs associated with providing service to Medicare Advantage and other third-party payer patients due to contractually negotiated rates.

***Recruiting and Retaining High-Quality Personnel***

Recruiting and retaining qualified personnel, including management, for our home health agencies and hospice provider locations remains a high priority for us. We attempt to maintain a comprehensive compensation and benefits package to compete in the current challenging staffing environment.

***Recent Developments***

***2026 Credit Agreement***

On February 26, 2026, the Company entered into an amended and restated credit agreement (the "2026 Credit Agreement") that consists of a $315.0 million senior secured term loan A facility (the "2026 Term Loan A Facility") and a $160.0 million senior secured revolving credit facility (the "2026 Revolving Credit Facility" and together with the 2026 Term Loan A Facility, the "2026 Credit Facilities"). The 2026 Credit Facilities mature on February 26, 2031. See Note 8, *Long-Term Debt* for additional information.

***Merger Agreement***

As previously disclosed, on February 22, 2026, we entered into the Merger Agreement with Parent and Merger Sub, providing for our acquisition by Kinderhook. If the Merger is completed, our stockholders will be entitled to receive $13.80 in cash for each share of common stock they hold as of the effective time of the Merger. The Merger is expected to close in the second quarter of 2026, subject to customary closing conditions, including approval by our stockholders and the receipt of certain regulatory approvals. See Note 17, *Subsequent Events*, to the accompanying consolidated financial statements for additional information regarding the Merger.

The consummation of the Merger remains subject to the satisfaction or, to the extent permitted under the Merger Agreement, waiver by each of us, Parent and Merger Sub, of closing conditions, including, but not limited to, stockholder approval. Our board of directors has approved the Merger Agreement and the transactions contemplated thereby.

If the Merger is consummated, our common stock will no longer be publicly listed and traded on the New York Stock Exchange, our common stock will be deregistered under the Exchange Act, we will no longer file periodic reports with the SEC and existing stockholders will cease to have any ownership interest in the Company.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**Results of Operations**

Our consolidated results of operations for the years ended December 31, 2025, 2024, and 2023 were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Percentage Change** | **Percentage Change** |
| **(in millions, except percentages)** | **2025** | **2024** | **2023** | **2025 vs 2024** | **2024 vs 2023** |
| Net service revenue | $**1060.0** | $1034.8 | $1046.3 | 2.4% | (1.1)% |
| Cost of service, excluding depreciation and amortization | **540.2** | 530.8 | 535.6 | 1.8% | (0.9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin, excluding depreciation and amortization | **519.8** | 504.0 | 510.7 | 3.1% | (1.3)% |
| General and administrative expenses | **433.5** | 425.9 | 441.6 | 1.8% | (3.6)% |
| Depreciation and amortization | **22.5** | 31.5 | 30.9 | (28.6)% | 1.9% |
| Impairment of goodwill | **44.7** | 161.7 | 85.8 | (72.4)% | 88.5% |
| Impairment of intangible assets | **3.0** |  |  | N/A | N/A |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) | **16.1** | (115.1) | (47.6) | 114.0% | (141.8)% |
| Interest income | **0.2** |  |  | N/A | N/A |
| Interest expense and amortization of debt discounts and fees | **34.0** | 42.9 | 43.0 | (20.7)% | (0.2)% |
| Other (income) expense | **(19.1)** |  | (0.2) | N/A | (100.0)% |
| &nbsp;&nbsp;&nbsp;Income (loss) before income taxes and noncontrolling interests | **1.4** | (158.0) | (90.4) | 100.9% | (74.8)% |
| Provision for (benefit from) income taxes | **4.0** | (4.0) | (11.4) | 200.0% | 64.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | **(2.6)** | (154.0) | (79.0) | 98.3% | (94.9)% |
| Less: Net income attributable to noncontrolling interests | **2.0** | 2.2 | 1.5 | (9.1)% | 46.7% |
| &nbsp;&nbsp;&nbsp;**Net income (loss) attributable to Enhabit, Inc.** | $**(4.6)** | $(156.2) | $(80.5) | 97.1% | (94.0)% |

---

The following table sets forth our consolidated results as a percentage of *Net service revenue*:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
| | **2025** | **2024** | **2023** |
| Cost of service, excluding depreciation and amortization | **51.0%** | 51.3% | 51.2% |
| General and administrative expenses | **40.9%** | 41.2% | 42.2% |
| Depreciation and amortization | **2.1%** | 3.0% | 3.0% |
| Interest expense and amortization of debt discounts and fees | **3.2%** | 4.1% | 4.1% |

---

***Net Service Revenue.*** For the year ended December 31, 2025, *Net service revenue* increased 2.4% compared to the prior year due to increased revenue in Hospice of 17.2% partially offset by decreased Home Heath segment revenues of 1.3%. See "—*Segment Results of Operations*."

***Cost of Service, Excluding Depreciation and Amortization.*** For the year ended December 31, 2025, *Cost of service, excluding depreciation and amortization*, increased 1.8% compared to the prior year due to increased *Cost of service, excluding depreciation and amortization* of 10.8% in the Hospice segment partially offset by decreased *Cost of service, excluding depreciation and amortization* of 0.4% in the Home Health segment.

*Cost of service, excluding depreciation and amortization*, represents the cost of operating our business, which primarily consists of payroll and related benefits, travel, supplies, including pharmacy for Hospice patients, and lease costs for our locations.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***General and Administrative Expenses.*** For the year ended December 31, 2025, *General and administrative expenses* increased 1.8% compared to the prior year primarily due to annual merit increases in the fourth quarter and increased incentive compensation partially offset by cost savings initiatives and lower benefit related expenses.

***Depreciation and Amortization.*** For the year ended December 31, 2025, *Depreciation and amortization* decreased compared to the prior year due to a number of intangible assets, including licenses and non-compete agreements, reaching the end of their useful lives in 2024.

***Impairment of Goodwill.*** For the year ended December 31, 2025, *Impairment of goodwill* resulted from impairment charges to reduce the carrying value of our Home Health reporting unit to its fair value. See Note 7, *Goodwill and Other Intangible Assets, Net*, to the accompanying consolidated financial statements for additional information.

***Impairment of Other Intangible Assets.*** For the year ended December 31, 2025, *Impairment of other intangible assets* resulted from the impairment of a portion of our certificates of need.

***Interest Expense and Amortization of Debt Discounts and Fees.*** For the year ended December 31, 2025, *Interest expense and amortization of debt discounts and fees* decreased compared to the prior year primarily due to a lower average borrowing level under our credit facilities and lower average interest rates. See "—*Liquidity and Capital Resources*" within this Item 5.

***Provision For (Benefit From) Income Taxes.*** Our effective tax rate in 2025 was 285.7% compared to an effective tax rate of 2.5% in 2024. The difference in the rate is primarily attributable to a larger rate impact from permanent differences attributable to the impairment of goodwill in 2025. See Note 11, *Income Taxes*, to the accompanying consolidated financial statements, and "*—Critical Accounting Estimates*."

***Adjusted EBITDA.*** Adjusted EBITDA is a non-GAAP measure of our financial performance. Management believes Adjusted EBITDA assists investors in comparing our operating performance across operating periods on a consistent basis by excluding items we do not believe are indicative of our operating performance.

We calculate Adjusted EBITDA as *Net income (loss)* adjusted to exclude (i) interest expense, net and amortization of debt discounts and fees, (ii) provision for or benefit from income taxes, (iii) depreciation and amortization, (iv) gains or losses on disposal or impairment of assets or goodwill, (v) stock-based compensation, (vi) net income attributable to noncontrolling interests, and (vii) unusual or nonrecurring items not typical of ongoing operations.

Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America ("GAAP"), and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for *Net income (loss)*. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, *Summary of Significant Accounting Policies*, to the accompanying consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

The following table reconciles *Net income (loss)* to Adjusted EBITDA for the years ended December 31, 2025, 2024, and 2023 (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
| | **2025** | **2024** | **2023** |
| **Net income (loss)** | $**(2.6)** | $(154.0) | $(79.0) |
| Interest expense, net and amortization of debt discounts and fees | **33.8** | 42.9 | 43.0 |
| Provision for (benefit from) income taxes | **4.0** | (4.0) | (11.4) |
| Depreciation and amortization | **22.5** | 31.5 | 30.9 |
| (Gain) loss on disposal of assets | **(19.1)** | (0.7) | (0.3) |
| Impairment of goodwill | **44.7** | 161.7 | 85.8 |
| Impairment of intangible assets | **3.0** |  |  |
| Stock-based compensation | **16.6** | 11.7 | 8.9 |
| Net income attributable to noncontrolling interests | **(2.0)** | (2.2) | (1.5) |
| Unusual or nonrecurring items not typical of ongoing operations | **7.6** | 13.2 | 21.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Adjusted EBITDA** | $**108.5** | $100.1 | $97.6 |

---

Unusual or nonrecurring items in the year ended December 31, 2025 include: (i) restructuring activities and severance costs; (ii) third-party legal fees associated with the suit Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al. and pending in the Chancery Court of Delaware, and in which the Company has asserted claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity arising from actions involving its former officers; and (iii) third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the year ended December 31, 2024 include: (i) third-party legal and advisory fees related to shareholder activism; (ii) third-party legal and advisory fees related to the strategic review process that concluded in May 2024; (iii) certain third-party legal fees associated with the Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al. lawsuit referenced above; and (iv) costs related to severance.

For additional information, see "—*Results of Operations*" and "—*Segment Results of Operations*."

**Segment Results of Operations**

Our segment and consolidated *Net service revenue* for the years ended December 31, 2025, 2024, and 2023 is provided in the table below.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| **(in millions, except percentages)** | **$ Amount** | **% of Consolidated Revenue** | **$ Amount** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**% of Consolidated**<br>**Revenue**  | **$ Amount** | **% of Consolidated Revenue** |
| Home Health segment net service revenue | $**813.8** | 76.8% | $824.8 | 79.7% | $850.1 | 81.2% |
| Hospice segment net service revenue | **246.2** | 23.2% | 210.0 | 20.3% | 196.2 | 18.8% |
| Consolidated net service revenue | $**1060.0** | 100.0% | $1034.8 | 100.0% | $1046.3 | 100.0% |

---

***Net Service Revenue.*** For the year ended December 31, 2025, *Net service revenue* increased 2.4% compared to the prior year due to increased revenue in Hospice of 17.2% partially offset by decreased Home Heath segment revenues of 1.3%. See "—*Segment Results of Operations*."

For additional information regarding our business segments, including a detailed description of the services we provide, financial data for each segment, and a reconciliation of total adjusted earnings before interest, taxes, depreciation, and amortization ("Segment Adjusted EBITDA") to *Income (loss) before income taxes and noncontrolling interests*, see Note 14, *Segment Reporting*, to the accompanying consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Home Health***

During the years ended December 31, 2025, 2024, and 2023, our Home Health segment derived its *Net service revenue* from the following payer sources:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
| | **2025** | **2024** | **2023** |
| Medicare | **55.9%** | 58.8% | 65.6% |
| Medicare Advantage | **31.1%** | 28.8% | 23.4% |
| Managed Care | **11.5%** | 11.1% | 9.5% |
| Medicaid | **0.9%** | 1.1% | 1.4% |
| Other | **0.6%** | 0.2% | 0.1% |
| Total | **100.0%** | 100.0% | 100.0% |

---

The decline in Medicare revenue as a percentage of our Home Health *Net service revenue* and corresponding increase in Medicare Advantage revenue is primarily the result of continued national enrollment increases in Medicare Advantage plans by Medicare beneficiaries.

Additional information regarding our Home Health segment's operating results for the years ended December 31, 2025, 2024, and 2023 is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended** <br>**December 31,**  | **Year Ended** <br>**December 31,**  | **Year Ended** <br>**December 31,**  | **Percentage Change** | **Percentage Change** |
| **(in millions, except percentages)** | **2025** | **2024** | **2023** | **2025 vs. 2024** | **2024 vs. 2023** |
| **Net service revenue:** |  |  |  |  |  |
| &nbsp;&nbsp;Medicare | $**455.2** | $484.6 | $557.4 | (6.1)% | (13.1)% |
| &nbsp;&nbsp;Non-Medicare | **350.8** | 331.2 | 283.0 | 5.9% | 17.0% |
| &nbsp;&nbsp;Private duty<sup>(1)</sup> | **7.8** | 9.0 | 9.7 | (13.3)% | (7.2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Home Health net service revenue** | **813.8** | 824.8 | 850.1 | (1.3)% | (3.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of service, excluding depreciation and amortization | **426.5** | 428.2 | 439.0 | (0.4)% | (2.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Gross margin, excluding depreciation and amortization** | **387.3** | 396.6 | 411.1 | (2.3)% | (3.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | **237.3** | 235.4 | 240.6 | 0.8% | (2.2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income | **—** |  | (0.2) | N/A | (100.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity earnings and noncontrolling interests | **1.5** | 1.8 | 1.4 | (16.7)% | 28.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Home Health Segment Adjusted EBITDA**<sup>(2)</sup> | $**148.5** | $159.4 | $169.3 | (6.8)% | (5.8)% |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Private duty represents long-term comprehensive hourly nursing medical care.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Segment Adjusted EBITDA is presented in conformity with ASC 280, *Segment Reporting*, as a measure reported to management for purposes of making decisions on allocating resources and addressing the performance of our segments. Segment Adjusted EBITDA is calculated similarly to consolidated Adjusted EBITDA but excludes corporate overhead costs that are not allocated to reportable segments because they are not considered when management evaluates segment performance. See Note 14, *Segment Reporting*, to the accompanying consolidated financial statements for additional information about Segment Adjusted EBITDA.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Percentage Change** | **Percentage Change** |
| | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Percentage Change** | **Percentage Change** |
| **(actual amounts)** | **2025** | **2024** | **2023** | **2025 vs. 2024** | **2024 vs. 2023** |
| **Medicare:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Admissions | **91603** | 96502 | 106805 | (5.1)% | (9.6)% |
| &nbsp;&nbsp;&nbsp;Recertifications | **62687** | 66692 | 78113 | (6.0)% | (14.6)% |
| &nbsp;&nbsp;&nbsp;Completed episodes | **153036** | 162761 | 185414 | (6.0)% | (12.2)% |
| &nbsp;&nbsp;&nbsp;Average daily census | **19605** | 20447 | 23597 | (4.1)% | (13.3)% |
| &nbsp;&nbsp;&nbsp;Visits | **2114926** | 2351316 | 2715380 | (10.1)% | (13.4)% |
| &nbsp;&nbsp;&nbsp;Visits per episode | **13.8** | 14.4 | 14.6 | (4.2)% | (1.4)% |
| &nbsp;&nbsp;&nbsp;Revenue per episode | $**2974** | $2977 | $3006 | (0.1)% | (1.0)% |
| **Non-Medicare:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Admissions | **132599** | 120850 | 100643 | 9.7% | 20.1% |
| &nbsp;&nbsp;&nbsp;Recertifications | **56915** | 55729 | 51767 | 2.1% | 7.7% |
| &nbsp;&nbsp;&nbsp;Average daily census | **22181** | 20540 | 18253 | 8.0% | 12.5% |
| &nbsp;&nbsp;&nbsp;Visits | **2249095** | 2239048 | 2020714 | 0.4% | 10.8% |
| **Total:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Admissions | **224202** | 217352 | 207448 | 3.2% | 4.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total admissions growth* |  |  |  | **3.1%** | 4.5% |
| &nbsp;&nbsp;&nbsp;Recertifications | **119602** | 122421 | 129880 | (2.3)% | (5.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total recertifications growth* |  |  |  | **(2.3)%** | (5.9)% |
| &nbsp;&nbsp;&nbsp;Average daily census | **41786** | 40987 | 41850 | 1.9% | (2.1)% |
| &nbsp;&nbsp;&nbsp;Visits | **4364021** | 4590364 | 4736094 | (4.9)% | (3.1)% |
| &nbsp;&nbsp;&nbsp;Visits per episode | **13.4** | 14.2 | 14.6 | (5.6)% | (2.7)% |
| &nbsp;&nbsp;&nbsp;Cost per visit | $**97.7** | $93.0 | $91.0 | 5.1% | 2.2% |
| &nbsp;&nbsp;&nbsp;Revenue per patient day | $**53.4** | $55.0 | $55.7 | (2.9)% | (1.3)% |
| &nbsp;&nbsp;&nbsp;Cost per patient day | $**28.0** | $28.6 | $28.7 | (2.1)% | (0.3)% |

---

**Expenses as a % of Net Service Revenue**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
| | **2025** | **2024** | **2023** |
| Cost of service, excluding depreciation and amortization | **52.4%** | 51.9% | 51.6% |
| General and administrative expenses | **29.2%** | 28.5% | 28.3% |

---

***Net Service Revenue.*** The decrease in Home Health *Net service revenue* for the year ended December 31, 2025 as compared to the prior year of 1.3% is due to a decrease in unit revenue per patient day of 2.9% primarily related to the growth in our non-Medicare patients, partially offset by an increase in average daily census in Home Health of 1.9%.

***Segment Adjusted EBITDA.*** The decrease in Home Health Segment Adjusted EBITDA of 6.8% for the year ended December 31, 2025 as compared to the prior year resulted primarily from the decrease in *Net service revenue* of 1.3% as discussed above, partially offset by decreased *Cost of service, excluding depreciation and amortization* of 0.4% attributable to improved clinical staff productivity in 2025. Home Health segment *General and administrative expenses* increased 0.8% as compared to the prior year due to annual merit increases in the fourth quarter of 2023 and 2024.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Hospice***

During the years ended December 31, 2025, 2024, and 2023, our Hospice segment derived its *Net service revenue* from the following payer sources:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
| | **2025** | **2024** | **2023** |
| Medicare | **98.2%** | 98.3% | 97.1% |
| Managed care | **1.1%** | 1.7% | 2.5% |
| Medicaid | **0.7%** | —% | 0.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | **100.0%** | 100.0% | 100.0% |

---

Additional information regarding our Hospice segment's operating results for the years ended December 31, 2025, 2024, and 2023 is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Percentage Change** | **Percentage Change** |
| **(in millions, except percentages)** | **2025** | **2024** | **2023** | **2025 vs. 2024** | **2024 vs. 2023** |
| **Hospice net service revenue** | $**246.2** | $210.0 | $196.2 | 17.2% | 7.0% |
| Cost of service, excluding depreciation and amortization | **113.7** | 102.6 | 96.6 | 10.8% | 6.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Gross margin, excluding depreciation and amortization** | **132.5** | 107.4 | 99.6 | 23.4% | 7.8% |
| General and administrative expenses | **72.2** | 65.5 | 63.4 | 10.2% | 3.3% |
| Equity earnings and noncontrolling interests | **0.5** | 0.4 | 0.1 | 25.0% | 300.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Hospice Segment Adjusted EBITDA**<sup>(1)</sup> | $**59.8** | $41.5 | $36.1 | 44.1% | 15.0% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Percentage Change** | **Percentage Change** |
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Percentage Change** | **Percentage Change** |
| **(actual amounts)** | **2025** | **2024** | **2023** | **2025 vs. 2024** | **2024 vs. 2023** |
| **Total:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Admissions | **12586** | 12025 | 11713 | 4.7% | 2.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total admissions growth* |  |  |  | **4.6%** | 0.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Patient days | **1454421** | 1304878 | 1256081 | 11.5% | 3.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Discharged average length of stay | **104** | 105 | 108 | (1.0)% | (2.8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average daily census | **3985** | 3565 | 3441 | 11.8% | 3.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenue per patient day | $**169.3** | $160.9 | $156.2 | 5.2% | 3.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost per patient day | $**78.2** | $78.6 | $76.9 | (0.5)% | 2.2% |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Segment Adjusted EBITDA is presented in conformity with ASC 280, *Segment Reporting*, as a measure reported to management for purposes of making decisions on allocating resources and addressing the performance of our segments. Segment Adjusted EBITDA is calculated similarly to consolidated Adjusted EBITDA but excludes corporate overhead costs that are not allocated to reportable segments because they are not considered when management evaluates segment performance. See Note 14, *Segment Reporting*, to the accompanying consolidated financial statements for additional information about Segment Adjusted EBITDA.

**Expenses as a % of Net Service Revenue**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,**  | **Year Ended December 31,**  | **Year Ended December 31,**  |
| | **2025** | **2024** | **2023** |
| Cost of service, excluding depreciation and amortization | **46.2%** | 48.9% | 49.2% |
| General and administrative expenses | **29.3%** | 31.2% | 32.3% |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Net Service Revenue.*** The increase in Hospice *Net service revenue* for the year ended December 31, 2025 as compared to the prior year of 17.2% was due to an increase in average daily census of 11.8%, as we continue to see the benefits of the maturing case management model and improved unit revenue per patient day of 5.2% on improved Medicare reimbursement rates, compared to the prior year.

***Segment Adjusted EBITDA.*** The increase in Hospice Segment Adjusted EBITDA of 44.1% for the year ended December 31, 2025 as compared to the prior year primarily resulted from the increase in *Net service revenue* of 17.2% discussed above with *Cost of service, excluding depreciation and amortization*, higher by 10.8% to support revenue growth, partially offset by improved clinical staff productivity with a decrease in cost per patient day of 0.5%. Hospice *General and administrative expenses* increased 10.2% due to increased selling-related and back office support expenses to support revenue growth.

**Liquidity and Capital Resources**

Our principal uses of cash include the funding of working capital requirements, servicing our debt, funding capital expenditures and supporting de novo locations. See "—*Contractual Obligations*" for more information about our material cash requirements from our contractual obligations at December 31, 2025.

As of December 31, 2025 and 2024, we had $43.6 million and $28.4 million, respectively, in *Cash and cash equivalents*. These amounts exclude $1.9 million in *Restricted cash*. Our *Restricted cash* pertains primarily to a joint venture in which our joint venture partner requested, and we agreed, the joint venture's cash not be commingled with other corporate cash accounts. See Note 1, *Summary of Significant Accounting Policies—Cash and Cash Equivalents and Restricted Cash*, to the accompanying consolidated financial statements. As of December 31, 2025, we also had $92.5 million available to us under the Revolving Credit Facility, as discussed below. For additional information regarding our debt, see Note 8, *Long-Term Debt*, to the accompanying consolidated financial statements and "*—Quantitative and Qualitative Disclosures about Market Risk*."

The following table shows the cash flows provided by or used in operating, investing, and financing activities for the years ended December 31, 2025, 2024, and 2023 (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Net cash provided by operating activities | $**70.7** | $51.2 | $48.4 |
| Net cash provided by (used) in investing activities | **16.7** | (2.4) | (5.3) |
| Net cash used in financing activities | **(72.2)** | (48.3) | (40.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase in cash, cash equivalents, and restricted cash | $**15.2** | $0.5 | $2.6 |

---

***Operating Activities*.** The increase in *Net cash provided by operating activities* for the year ended December 31, 2025 as compared to the prior year resulted primarily from the decrease in the net loss and changes in working capital.

***Investing Activities*.** The increase in *Net cash provided by (used) in investing activities* for the year ended December 31, 2025 as compared to the prior year resulted primarily from the sale of an investment. During the year ended December 31, 2024, *Net cash provided by (used) in investing activities* primarily resulted from purchases of property and equipment.

***Financing Activities*.** The increase in *Net cash used in financing activities* for the year ended December 31, 2025 as compared to the prior year resulted primarily from an increase in net repayments of debt in 2025.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Contractual Obligations***

Our consolidated contractual obligations as of December 31, 2025 are as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Total**  | **Current** | **Long-Term** |
| Long-term debt obligations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Long-term debt, excluding revolving credit facility and finance lease obligations<sup>(1)</sup> | $**328.7** | $**20.0** | $**308.7** |
| &nbsp;&nbsp;&nbsp;Revolving credit facility | **115.0** | **—** | **115.0** |
| Interest on long-term debt<sup>(2)</sup> | **77.4** | **25.8** | **51.6** |
| Finance lease obligations<sup>(1)</sup> | **4.9** | **2.5** | **2.4** |
| Operating lease obligations<sup>(3)</sup> | **62.0** | **15.5** | **46.5** |
| Purchase obligations<sup>(4)</sup> | **68.4** | **40.9** | **27.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $**656.4** | $**104.7** | $**551.7** |

---

(1)We lease automobiles under finance leases for our clinicians. Amounts include interest portion of future minimum finance lease payments. For more information, see Note 6, *Leases*, to the accompanying consolidated financial statements.

(2)Interest on long-term debt was calculated using the rate for the credit facilities as of December 31, 2025.

(3)In addition to our corporate headquarters office space, our Home Health and Hospice segments lease: (a) relatively small office spaces in the localities they serve; and (b) equipment in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note 6, *Leases*, to the accompanying consolidated financial statements.

(4)Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support. Purchase obligations are not recognized in our Consolidated Balance Sheets. For more information, see Note 13, *Contingencies and Other Commitments*, to the accompanying consolidated financial statements.

Our capital expenditures include costs associated with computer hardware and licensing software we utilize to run our business, as well as leasehold improvements. During the years ended December 31, 2025 and 2024, we made capital expenditures for property and equipment of $4.9 million and $3.8 million, respectively. During 2026, we expect to spend approximately $5 million for maintenance capital expenditures. Actual amounts spent will be dependent upon the timing of projects for our business.

As of December 31, 2025, we do not have any material off-balance sheet arrangements.

**Critical Accounting Estimates**

Our consolidated financial statements are prepared in accordance with GAAP. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and other factors we believe to be relevant at the time we prepared our consolidated financial statements. On a regular basis, we review the accounting policies, assumptions, estimates and judgments to ensure our consolidated financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Our significant accounting policies are discussed in Note 1, *Summary of Significant Accounting Policies*, to the accompanying consolidated financial statements. We believe the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported financial results, as they require our most difficult, subjective, or complex judgments resulting from the need to make estimates about the effect of matters that are inherently uncertain.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Revenue Recognition***

We recognize *Net service revenue* in the reporting period in which we perform the service based on our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances (principally for patients covered by Medicare, Medicare Advantage, Medicaid, and other third-party payers), potential adjustments that may arise from payment and other reviews, and uncollectible amounts. See Note 1, *Summary of Significant Accounting Policies—Net Service Revenue*, to the accompanying consolidated financial statements for a complete discussion of our revenue recognition policies.

Our patient accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payer. Certain other factors that are considered and could influence the estimated transaction price are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payer classes, and additional adjustments are provided to account for these factors.

Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. In addition, laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.

Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payers, which are often subject to interpretation and review, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. However, we continually review the amounts actually collected in subsequent periods in order to determine the amounts by which our estimates differed.

The collection of outstanding receivables from third-party payers and patients is our primary source of cash and is critical to our operating performance. Our primary collection risks relate to the increasing complexities of documentation requirements by payers and claims reviews conducted by MACs or other contractors.

The table below shows a summary of our total *Accounts receivable, net of allowances*, as of December 31, 2025 and 2024. Information on the concentration of total patient accounts receivable by payer class can be found in Note 1, *Summary of Significant Accounting Policies—Accounts Receivable, Net of Allowances*, to the accompanying consolidated financial statements.

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| **(in millions)** | **2025** | **2024** |
| Current |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;0 – 30 Days | $**98.6** | $92.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;31 – 60 Days | **13.8** | 16.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;61 – 90 Days | **10.9** | 8.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;91 – 120 Days | **4.8** | 6.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;120 + Days | **15.9** | 25.1 |
| Current accounts receivable, net of allowances | **144.0** | 149.2 |
| Noncurrent patient accounts receivable, net of allowances | **0.5** | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | $**144.5** | $149.7 |

---

Changes in general economic conditions (such as increased unemployment rates or periods of recession), business office operations, payer mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable. Our collection risks include payment denials by payers as a result of increasing complexities of documentation requirements, pre- and post-payment claim reviews by our respective MACs, and reimbursement claims audits by governmental or other payers and their agents. As of December 31, 2025 and 2024, the amount of our patient accounts receivable representing denials that were under review or audit in excess of reserves established for such denials was $0.6 million and $1.2 million, respectively, in our Home Health segment and $1.2 million and $1.5 million, respectively, in our Hospice segment. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. See Note 1, *Summary of Significant Accounting Policies—Net Service Revenue* and —*Accounts Receivable, Net of Allowances*, to the accompanying consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

***Goodwill***

We test *Goodwill* for impairment annually as of October 1<sup>st</sup> of each year. We may perform interim impairment tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount. We test *Goodwill* for impairment by performing either a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not the fair value of a reporting unit is less than its carrying amount, including goodwill. We may elect to bypass this qualitative assessment for its reporting units and perform a quantitative test as of the measurement date of the test.

We test *Goodwill* for impairment at the reporting unit level and are required to make certain subjective and complex judgments on a number of matters, including assumptions and estimates used to determine the fair value of our Home Health and Hospice reporting units. We assess qualitative factors in each reporting unit to determine whether it is necessary to perform the quantitative goodwill impairment test. The quantitative impairment test is required only if we conclude it is more likely than not a reporting unit's fair value is less than its carrying amount.

If, based on our qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of the applicable reporting unit using generally accepted valuation techniques including equal weighting of the income approach and the market approach. We would validate our estimates under the income approach by reconciling the estimated fair value of the reporting units determined under the income approach to our market capitalization and estimated fair value determined under the market approach. Values from the income approach and market approach would then be evaluated and weighted to arrive at the estimated aggregate fair value of the reporting units.

The income approach includes the use of each reporting unit's projected operating results and cash flows that are discounted using a weighted average cost of capital that reflects market participant assumptions. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. Other significant estimates and assumptions include cost-saving synergies and tax benefits that would accrue to a market participant under a fair value methodology. The market approach estimates fair value through the use of observable inputs, such as prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

See Note 1, *Summary of Significant Accounting Policies—Goodwill and Other Intangible Assets, Net*, and Note 7, *Goodwill and Other Intangible Assets, Net*, to the accompanying consolidated financial statements for additional information.

The following events and circumstances are certain of the qualitative factors we consider in evaluating whether it is more likely than not the fair value of a reporting unit is less than its carrying amount:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• macroeconomic conditions, such as deterioration in general economic conditions, limitations on accessing capital, or other developments in equity and credit markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• industry and market considerations and changes in healthcare regulations, including reimbursement and compliance requirements under the Medicare and Medicaid programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• cost factors, such as an increase in labor, supply, or other costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• overall financial performance, such as negative or declining cash flows or a decline in actual or forecasted revenue or earnings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other relevant company-specific events, such as material changes in management or key personnel or outstanding litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• material events, such as a change in the composition or carrying amount of each reporting unit's net assets, including acquisitions and dispositions; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• length of time since the most recent quantitative analysis.

Based on the sensitivity analysis performed at December 31, 2025 by reporting unit, it was determined that, assuming all other assumptions and inputs used in the discounted cash flow analysis are held constant, a 50 and 100 basis point increase in the discount rate assumption would result in decreases in the fair value of approximately $15 million for both Home Health and Hospice reporting units. We based our fair value estimates on assumptions management believed to be reasonable but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

See Note 7, *Goodwill and Other Intangible Assets, Net*, to the accompanying consolidated financial statements for additional information.

***Income Taxes***

We provide for income taxes using the asset and liability method. We also evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. See Note 1, *Summary of Significant Accounting Policies*—*Income Taxes*, and Note 11, *Income Taxes*, to the accompanying consolidated financial statements for a more complete discussion of income taxes and our policies related to income taxes.

The application of income tax law is inherently complex. Laws and regulations in this area are voluminous and are often ambiguous. We are required to make many subjective assumptions and judgments regarding our income tax exposures. Interpretations of and guidance surrounding income tax laws and regulations change over time. As such, changes in our subjective assumptions and judgments can materially affect amounts recognized in our consolidated financial statements.

The ultimate recovery of certain of our deferred tax assets is dependent on the amount and timing of taxable income we will ultimately generate in the future, as well as other factors. A high degree of judgment can be required to determine the extent a valuation allowance should be provided against deferred tax assets. Due to the pretax losses we have generated in recent years, we recorded a valuation allowance of $14.1 million in 2024. This negative evidence is more objectively verifiable than other subjective evidence, such as our projections for future growth and improvements in profitability. On a quarterly basis, we assess all available positive and negative evidence, and we recognize only the portion of our deferred tax assets that are more likely than not to be realized. The amount of the valuation allowance may be adjusted in future periods in the event of changes to these factors. This valuation allowance was reduced to $12.2 million in 2025. The reduction is primarily attributable to provisions of the OBBBA.

Our evaluation of any required liability for unrecognized tax benefits contains uncertainties because management is required to make assumptions and to apply judgment to estimate the exposures associated with our various filing positions which are periodically audited by tax authorities. In addition, our effective income tax rate is affected by changes in tax law, the tax jurisdictions in which we operate, and the results of income tax audits.

***Assessment of Loss Contingencies***

We provide for losses in situations where we have concluded it is probable a loss has been or will be incurred and the amount of loss is reasonably estimable. A significant amount of judgment is involved in determining whether a loss is probable and reasonably estimable due to the uncertainty involved in determining the likelihood of future events and estimating the financial statement impact of such events. If further developments or resolutions of a contingent matter are not consistent with our assumptions and judgments, we may need to recognize a significant charge in a future period related to an existing contingent matter.

***Business Combinations***

We account for acquisitions of entities that qualify as business combinations under the acquisition method of accounting. Under the acquisition method of accounting, the total consideration is allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair values of these identifiable assets and liabilities is recorded as goodwill. During the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.

In determining the fair value of assets acquired and liabilities assumed in a business combination, we primarily use the income and multi-period excess earnings approaches to estimate the value of our most significant acquired intangible assets. Both income approaches utilize projected operating results and cash flows and include significant assumptions such as base revenue, revenue growth rate, projected EBITDA margin, discount rates, rates of increase in operating expenses, and the future effective income tax rates. The valuations of our significant acquired businesses have been performed by a third-party valuation specialist under our management's supervision. We believe the estimated fair value assigned to the assets acquired and liabilities assumed is based on reasonable assumptions and estimates that marketplace participants would use. However, such assumptions are inherently uncertain and actual results could differ from those estimates. Future changes in our assumptions or the interrelationship of those assumptions may result in purchase price allocations that are different than those recorded in recent years.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Acquisition-related costs are not considered part of the consideration paid and are expensed as operating expenses as incurred. Contingent consideration, if any, is measured at fair value initially on the acquisition date as well as subsequently at the end of each reporting period until the contingency is resolved and settlement occurs. Subsequent adjustments to contingent considerations are recorded in our Consolidated Statements of Comprehensive Income. We include the results of operations of the businesses acquired as of the beginning of the acquisition dates.

See Note 2, *Business Combinations*, to the accompanying consolidated financial statements for additional information.

***Recent Accounting Pronouncements***

For information regarding recent accounting pronouncements, see Note 1, *Summary of Significant Accounting Policies*, to the accompanying consolidated financial statements.

**ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our primary exposure to market risk is to changes in interest rates on our variable rate long-term debt. We use sensitivity analysis models to evaluate the impact of interest rate changes on our variable rate debt. As of

December 31, 2025, our primary variable rate debt outstanding related to $115.0 million in advances under our Revolving Credit Facility and $330.0 million under our Term Loan A Facility.

Assuming outstanding balances were to remain the same a 1% increase in interest rates would result in an incremental negative cash flow of $4.5 million over the next 12 months, while a 1% decrease in interest rates would result in an incremental positive cash flow of $4.5 million over the next 12 months.

See Note 8, *Long-Term Debt*, to the accompanying consolidated financial statements for additional information regarding our long-term debt.

**ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

The financial statements and related notes required to be filed pursuant to this Item 8 are appended to this Annual Report. An index to those financial statements is found in Item 15, "*Exhibits and Financial Statements*," of Part IV of this Annual Report.

**ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES**

None.

**ITEM 9A. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

Our "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025. Based on the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

**Management's Report on Internal Control Over Financial Reporting**

Our management, under the supervision of our board of directors, is responsible for establishing and maintaining adequate "internal control over financial reporting," as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, our management conducted an assessment of our internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control – Integrated Framework* (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this evaluation, our management concluded our internal control over financial reporting was effective as of December 31, 2025, based on criteria in *Internal Control – Integrated Framework* (2013) issued by COSO.

PricewaterhouseCoopers LLP, an independent registered public accounting firm, has audited the effectiveness of our internal control over financial reporting as of December 31, 2025 and has expressed an unqualified opinion on the effectiveness of our internal control over financial reporting, as stated in their report, which is included herein.

**Changes in Internal Control Over Financial Reporting** 

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**ITEM 9B. OTHER INFORMATION**

On December 4, 2025, Julie D. Jolley, the Company's Executive Vice President of Home Health, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) to sell up to 5,586 shares of the Company's common stock over a period ending on March 10, 2026, subject to certain conditions.

No other director or Section 16 officer adopted or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended December 31, 2025.

**ITEM 9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS**

Not Applicable.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**PART III**

**ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**

The information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of stockholders and is incorporated herein by reference.

**Insider Trading Arrangements and Policies**

The Company has adopted an insider trading compliance policy that governs the purchase, sale, and/or other transactions of the Company's securities by its directors, officers, and employees, and has implemented processes for the Company, that the Company believes are reasonably designed to promote compliance with insider trading laws, rules and regulations, and applicable New York Stock Exchange listing standards.

**ITEM 11. EXECUTIVE COMPENSATION**

The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of stockholders and is incorporated herein by reference.

**ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of stockholders and is incorporated herein by reference.

**ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of stockholders and is incorporated herein by reference.

**ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES**

The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of stockholders and is incorporated herein by reference.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**PART IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

The following documents are filed as part of this Annual Report:

1. Index to Consolidated Financial Statements, Report of Independent Registered Public Accounting Firm, Consolidated Statements of Income for the Years Ended December 31, 2025, 2024, and 2023, Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2025, 2024, and 2023, Consolidated Balance Sheets as of December 31, 2025 and 2024, Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2025, 2024, and 2023 and Consolidated Statements of Cash Flows for the Years Ended December 31, 2025, 2024, and 2023.

2. Financial Statement Schedules: All other schedules for which provision is made in the applicable accounting regulations of the SEC are omitted because the required information is either not applicable, not required or is shown in the respective financial statements or in the notes thereto.

3. Exhibits: The exhibits required to be filed by this Item 15 are set forth in the Exhibit Index included below.

**INDEX TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| | **Page** |
| [Report of Independent Registered Public Accounting Firm](#i37ed9800c8d04a6988fc71aea423e4a2_169) (PCAOB Firm ID: 238) | F-[2](#i37ed9800c8d04a6988fc71aea423e4a2_169) |
| [Consolidated Statements of Income](#i37ed9800c8d04a6988fc71aea423e4a2_172) | F-[5](#i37ed9800c8d04a6988fc71aea423e4a2_172) |
| [Consolidated Statements of Comprehensive Income](#i37ed9800c8d04a6988fc71aea423e4a2_175) | F-[6](#i37ed9800c8d04a6988fc71aea423e4a2_175) |
| [Consolidated Balance Sheets](#i37ed9800c8d04a6988fc71aea423e4a2_178) | F-[7](#i37ed9800c8d04a6988fc71aea423e4a2_178) |
| [Consolidated Statements of Stockholders' Equity](#i37ed9800c8d04a6988fc71aea423e4a2_184) | F-[8](#i37ed9800c8d04a6988fc71aea423e4a2_184) |
| [Consolidated Statements of Cash Flows](#i37ed9800c8d04a6988fc71aea423e4a2_187) | F-[9](#i37ed9800c8d04a6988fc71aea423e4a2_187) |
| [Notes to Consolidated Financial Statements](#i37ed9800c8d04a6988fc71aea423e4a2_193) | F-[10](#i37ed9800c8d04a6988fc71aea423e4a2_193) |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Stockholders of Enhabit, Inc.

***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of Enhabit, Inc. and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of income, of comprehensive income, of stockholders' equity and of cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

***Basis for Opinions***

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

***Definition and Limitations of Internal Control over Financial Reporting***

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***Critical Audit Matters***

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

*Interim Goodwill Impairment Assessment – Home Health Reporting Unit*

As described in Notes 1 and 7 to the consolidated financial statements, the Company's goodwill balance was $855.3 million as of December 31, 2025, and the goodwill associated with the Home Health reporting unit was $637.5 million. Absent any triggering events, management tests goodwill for impairment at least annually, as of October 1. During the fourth quarter of 2025, management identified a potential impairment triggering event and performed a quantitative analysis. Based on the quantitative analysis, the Company recorded an impairment charge of $44.7 million to reflect a decrease in the carrying value of the Home Health reporting unit. Management estimated the fair value of the reporting unit using both the income approach and market approach. Fair value under the income approach was determined by management discounting to present value the estimated future cash flows of the reporting unit. Significant assumptions are incorporated by management into the discounted cash flow analysis, such as estimates of revenue growth rates, timing of de novo location openings, forecasted operating margins, the weighted average cost of capital, and the terminal growth rate. Fair value under the market approach utilized the guideline public company methodology, which uses valuation indicators, including market multiples of earnings before interest, taxes, depreciation and amortization, from other businesses that are similar to the reporting unit and an implied control premium.

The principal considerations for our determination that performing procedures relating to the interim goodwill impairment assessment of the Home Health reporting unit is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the Home Health reporting unit; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to revenue growth rates, forecasted operating margins, the weighted average cost of capital, and the terminal growth rate used in the income approach and the market multiples of earnings before interest, taxes, depreciation and amortization (EBITDA) and implied control premium used in the market approach; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management's interim goodwill impairment assessment, including controls over the valuation of the Home Health reporting unit. These procedures also included, among others (i) testing management's process for developing the fair value estimate of the Home Health reporting unit; (ii) evaluating the appropriateness of the income and market approaches used by management; (iii) testing the completeness and accuracy of underlying data used in the income and market approaches; and (iv) evaluating the reasonableness of the significant assumptions used by management related to revenue growth rates, forecasted operating margins, the weighted-average cost of capital, and the terminal growth rate used in the income approach and the market multiples of EBITDA and implied control premium used in the market approach. Evaluating management's assumptions related to revenue growth rates and forecasted operating margins involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the Home Health reporting unit; (ii) the consistency with external market and industry data; and (iii) whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the income and market approaches and (ii) the reasonableness of the weighted average cost of capital, terminal growth rate, market multiples of EBITDA, and implied control premium assumptions.

*Valuation of Accounts Receivable, Net of Allowances for Implicit Price Concessions*

As described in Note 1 to the consolidated financial statements, the Company's accounts receivable balance, net of allowances was $144.0 million as of December 31, 2025, of which a majority relates to accounts receivable, net of

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

allowances for implicit price concessions. Accounts receivable, net of allowances, from services rendered are reported at their estimated transaction price, which takes into account price concessions based on the amounts expected to be due from payers including federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers' compensation programs, employers, and patients. Management estimates the value of accounts receivable, net of allowances, based upon historical experience and other factors, including an aging of accounts receivable, evaluation of expected adjustments, past adjustments, and collection experience in relation to amounts billed, current contract and reimbursement terms, shifts in payers and other relevant information. The evaluation of these factors involves complex, subjective judgments impacting the determination of the implicit price concession assumption.

The principal considerations for our determination that performing procedures relating to the valuation of accounts receivable, net of allowances for implicit price concessions is a critical audit matter are (i) the significant judgment by management when developing the estimate of accounts receivable, net of allowances for implicit price concessions and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the valuation of accounts receivable, net of allowances for implicit price concessions.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management's estimate of accounts receivable, net of allowances for implicit price concessions. These procedures also included, among others (i) testing management's process for developing the estimate of accounts receivable, net of allowances for implicit price concessions; (ii) testing the completeness and accuracy of underlying data used in the estimate; (iii) evaluating the historical accuracy of management's estimate of accounts receivable, net of allowances for implicit price concessions by performing a retrospective comparison to actual cash collections; and (iv) performing a comparison of the remaining uncollected accounts receivable balance as of a date subsequent to year end to expected future cash collections based on the Company's historical collection patterns.

/s/ PricewaterhouseCoopers LLP

Dallas, Texas

March 4, 2026

We have served as the Company's auditor since 2021.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**CONSOLIDATED STATEMENTS OF INCOME**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| **(in millions, except per share data)** | **2025** | **2024** | **2023** |
| Net service revenue | $**1060.0** | $1034.8 | $1046.3 |
| Cost of service, excluding depreciation and amortization | **540.2** | 530.8 | 535.6 |
| General and administrative expenses | **433.5** | 425.9 | 441.6 |
| Depreciation and amortization | **22.5** | 31.5 | 30.9 |
| Impairment of goodwill | **44.7** | 161.7 | 85.8 |
| Impairment of intangible assets | **3.0** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) | **16.1** | (115.1) | (47.6) |
| Interest income | **0.2** |  |  |
| Interest expense and amortization of debt discounts and fees | **34.0** | 42.9 | 43.0 |
| Other (income) expense | **(19.1)** |  | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income (loss) before income taxes and noncontrolling interests | **1.4** | (158.0) | (90.4) |
| Provision for (benefit from) income taxes | **4.0** | (4.0) | (11.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | **(2.6)** | (154.0) | (79.0) |
| Less: Net income attributable to noncontrolling interests | **2.0** | 2.2 | 1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss) attributable to Enhabit, Inc.** | $**(4.6)** | $(156.2) | $(80.5) |
| **Weighted average common shares outstanding:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | **50.8** | 50.2 | 49.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | **50.8** | 50.2 | 49.9 |
| **Earnings (loss) per common share:** |  |  |  |
| Basic earnings (loss) per share attributable to Enhabit, Inc. common stockholders | $**(0.09)** | $(3.11) | $(1.61) |
| Diluted earnings (loss) per share attributable to Enhabit, Inc. common stockholders | $**(0.09)** | $(3.11) | $(1.61) |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| **(in millions)** | **2025** | **2024** | **2023** |
| Net income (loss) | $**(2.6)** | $(154.0) | $(79.0) |
| Other comprehensive income (loss) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on cash flow hedges, net of tax expense (benefit) of $0.1, $0.1, and $0.1, respectively | **0.2** | 0.3 | 0.2 |
| Total other comprehensive income (loss) | **0.2** | 0.3 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss including noncontrolling interests | **(2.4)** | (153.7) | (78.8) |
| Less: Comprehensive income attributable to noncontrolling interests | **2.0** | 2.2 | 1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss attributable to Enhabit, Inc. | $**(4.4)** | $(155.9) | $(80.3) |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| **(in millions, except share and per share data)** | **2025** | **2024** |
| **Assets** |  |  |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**43.6** | $28.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | **1.9** | 1.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **144.0** | 149.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **16.1** | 13.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **205.6** | 192.7 |
| Property and equipment, net | **15.5** | 17.7 |
| Operating lease right-of-use assets | **49.8** | 52.8 |
| Goodwill | **855.3** | 900.0 |
| Intangible assets, net | **38.5** | 58.1 |
| Other long-term assets | **2.4** | 4.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $**1167.1** | $1226.0 |
| **Liabilities and Stockholders' Equity** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | $**22.3** | $22.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | **12.6** | 12.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **9.2** | 6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll | **40.4** | 37.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | **41.8** | 47.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **126.3** | 126.2 |
| Long-term debt, net of current portion | **426.0** | 492.6 |
| Long-term operating lease liabilities, net of current portion | **39.1** | 41.8 |
| Deferred income tax liabilities | **11.5** | 11.5 |
| Other long-term liabilities | **0.1** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | **603.0** | 672.1 |
| Commitments and contingencies (See Note 13) |  |  |
| Redeemable noncontrolling interests | **5.0** | 5.0 |
| **Stockholders' equity:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.10 par value; 1,500,000 shares authorized; no shares issued | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.01 par value; 200,000,000 shares authorized; 51,195,035 and 50,589,768 shares issued; and 50,723,245 and 50,369,917 shares outstanding as of December 31, 2025 and 2024, respectively | **0.5** | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital in excess of par value | **443.6** | 426.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **—** | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | **93.7** | 98.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost, 471,790 and 219,851 shares as of December 31, 2025 and 2024, respectively | **(3.8)** | (1.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Enhabit, Inc. stockholders' equity | **534.0** | 523.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interests | **25.1** | 25.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | **559.1** | 548.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and stockholders' equity** | $**1167.1** | $1226.0 |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Capital in Excess of Par Value** | **Accumulated Other Comprehensive Loss** | **Retained Earnings** | **Number of Treasury Shares Outstanding** | **Treasury Stock** | **Noncontrolling Interests** | **Total** |
| **(in millions)** | **Shares** | **Amount** | **Capital in Excess of Par Value** | **Accumulated Other Comprehensive Loss** | **Retained Earnings** | **Number of Treasury Shares Outstanding** | **Treasury Stock** | **Noncontrolling Interests** | **Total** |
| **December 31, 2022** | 50.1 | $0.5 | $406.9 | $(0.7) | $335.0 |  | $— | $28.4 | $770.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  |  |  |  | (80.5) |  |  | 1.5 | (79.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax |  |  |  | 0.2 |  |  |  |  | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions declared |  |  |  |  |  |  |  | (2.9) | (2.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense |  |  | 8.9 |  |  |  |  |  | 8.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock forfeited, including forfeitures due to net share settlement of income taxes | (0.1) |  |  |  |  | 0.1 | (0.6) |  | (0.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock pursuant to omnibus incentive plan | 0.1 |  |  |  |  |  |  |  |  |
| **December 31, 2023** | 50.1 | 0.5 | 415.8 | (0.5) | 254.5 | 0.1 | (0.6) | 27.0 | 696.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income |  |  |  |  | (156.2) |  |  | 2.2 | (154.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income, net of tax |  |  |  | 0.3 |  |  |  |  | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions declared |  |  |  |  |  |  |  | (3.8) | (3.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense |  |  | 10.8 |  |  |  |  |  | 10.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock forfeited, including forfeitures due to net share settlement of income taxes | (0.1) |  |  |  |  | 0.1 | (1.1) |  | (1.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock pursuant to omnibus incentive plan | 0.4 |  |  |  |  |  |  |  |  |
| **December 31, 2024** | 50.4 | 0.5 | 426.6 | (0.2) | 98.3 | 0.2 | (1.7) | 25.4 | 548.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | **—** | **—** | **—** | **—** | **(4.6)** | **—** | **—** | **2.0** | **(2.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income, net of tax | **—** | **—** | **—** | **0.2** | **—** | **—** | **—** | **—** | **0.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions declared | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **(2.3)** | **(2.3)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | **—** | **—** | **17.0** | **—** | **—** | **—** | **—** | **—** | **17.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock forfeited, including forfeitures due to net share settlement of income taxes | **(0.3)** | **—** | **—** | **—** | **—** | **0.3** | **(2.1)** | **—** | **(2.1)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock pursuant to omnibus incentive plan | **0.6** | **—** | **—** | **—** | **—** | **—** | **—** | **—** | **—** |
| **December 31, 2025** | **50.7** | $**0.5** | $**443.6** | $**—** | $**93.7** | **0.5** | $**(3.8)** | $**25.1** | $**559.1** |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | |
|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Year Ended December 31,** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Year Ended December 31,** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Year Ended December 31,** |
| **(in millions)** | **2025** | **2024** | **2023** |
| **Cash flows from operating activities:** |  |  |  |
| Net income (loss) | $**(2.6)** | $(154.0) | $(79.0) |
| Adjustments to reconcile net loss to net cash provided by operating activities— |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **22.5** | 31.5 | 30.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt related costs | **1.5** | 1.5 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment | **(19.2)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **44.7** | 161.7 | 85.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of intangible assets | **3.0** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | **16.6** | 11.7 | 8.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **—** | (5.7) | (11.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | **0.4** | (0.6) | (0.4) |
| Changes in assets and liabilities, net of acquisitions — |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **5.2** | 15.5 | (14.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | **(2.3)** | 3.1 | 19.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **2.6** | (1.0) | 3.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll | **3.7** | (2.3) | 3.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | **(5.4)** | (10.2) | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | **70.7** | 51.2 | 48.4 |
| **Cash flows from investing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition of businesses, net of cash acquired | **—** |  | (2.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment, including capitalized software costs | **(4.9)** | (3.8) | (3.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of investment | **21.0** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **0.6** | 1.4 | 1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used) in investing activities** | **16.7** | (2.4) | (5.3) |
| **Cash flows from financing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments on term loan facility | **(20.0)** | (20.0) | (20.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments on revolving credit facility | **(45.0)** | (20.0) | (10.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments under finance lease obligations | **(2.7)** | (3.6) | (3.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt issuance costs | **—** |  | (3.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions paid to noncontrolling interests of consolidated affiliates | **(2.3)** | (3.7) | (3.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **(2.2)** | (1.0) | (0.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | **(72.2)** | (48.3) | (40.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Increase in cash, cash equivalents, and restricted cash** | **15.2** | 0.5 | 2.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Cash, cash equivalents, and restricted cash at beginning of year** | **30.3** | 29.8 | 27.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Cash, cash equivalents, and restricted cash at end of year** | $**45.5** | $30.3 | $29.8 |

---

See also Note 16, *Supplemental Cash Flow Information*.

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**1. Summary of Significant Accounting Policies**

***Organization and Description of Business.*** Enhabit, Inc. ("Enhabit" or the "Company"), incorporated in Delaware in 2014, provides a comprehensive range of Medicare-certified skilled home health and hospice services in 34 states, with a concentration in the southern half of the United States. The Company manages its operations and discloses financial information using two reportable segments: (i) Home Health and (ii) Hospice. See Note 14, *Segment Reporting*. References in this Annual Report on Form 10-K to "Enhabit" or "the Company" refer to Enhabit, Inc., and all wholly-owned subsidiaries included in the consolidated financial statements. Prior to July 1, 2022, the Company operated as a reporting segment of Encompass Health Corporation ("Encompass").

***Separation from Encompass.*** On July 1, 2022, Encompass completed the previously announced separation of the Company through the distribution of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit to the stockholders of record of Encompass (the "Distribution") as of the close of business on June 24, 2022 (the "Record Date"). The Distribution was effective at 12:01 a.m. Eastern Time on July 1, 2022. The Distribution was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Distribution, Enhabit is now an independent public company, and its common stock is listed under the symbol "EHAB" on the New York Stock Exchange (the "Separation").

The Separation was completed pursuant to a separation and distribution agreement (the "Separation and Distribution Agreement") and other agreements with Encompass related to the Separation, including, but not limited to, a tax matters agreement (the "Tax Matters Agreement"), an employee matters agreement (the "Employee Matters Agreement"), and a transition services agreement (the "Transition Services Agreement" or "TSA"). Following the Separation, certain functions were provided by Encompass under the TSA. Following the expiration of the TSA, these functions are now performed using the Company's own resources or third-party providers.

See also Note 8, *Long-Term Debt*.

***Basis of Presentation and Consolidation.*** The consolidated financial statements include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which the Company exercises control, and, when applicable, entities in which the Company has a controlling financial interest.

***Reclassification.*** Certain prior period balances have been reclassified to conform to the current period presentation in the audited consolidated financial statements. The reclassifications did not have any effect on the Company's financial position, results of operations, or cash flows.

***Variable Interest Entities.*** Any entity considered a variable interest entity ("VIE") is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. To determine if Enhabit is the primary beneficiary of a VIE, the Company must determine what activities most significantly impact the economic performance of the entity, whether the Company has the power to direct those activities, and if the Company's obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE. See Note 3, *Variable Interest Entities*, for more information.

***Use of Estimates and Assumptions.*** The preparation of Enhabit's consolidated financial statements in conformity with generally accepted accounting principles in the United States of America ("GAAP") requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (i) estimates of net transaction prices to be collected for services and related revenue adjustments; (ii) fair value of acquired assets and assumed liabilities in business combinations; (iii) asset impairments, including goodwill; (iv) depreciable lives of assets; (v) useful lives of intangible assets; (vi) economic lives and fair value of leased assets; (vii) fair value of stock-based compensation; (viii) fair value of derivative instruments; (ix) reserves for self-insured healthcare plans; (x) reserves for professional, workers' compensation, and comprehensive general insurance liability risks; and (xi) income taxes. Future events and their effects cannot be predicted with certainty; accordingly, Management's accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of Enhabit's consolidated financial statements will change as new events

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

occur, as more experience is acquired, as additional information is obtained, and as the Company's operating environment changes. Management evaluates and updates its assumptions and estimates on an ongoing basis and may employ outside experts to assist in its evaluation, as considered necessary. Actual results could differ from those estimates**.**

***Net Service Revenue.*** *Net service revenue* by payer source and segment is as follows (in millions):

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Home Health** | **Home Health** | **Home Health** | **Hospice** | **Hospice** | **Hospice** | **Consolidated &nbsp;&nbsp;&nbsp;&nbsp;** | **Consolidated &nbsp;&nbsp;&nbsp;&nbsp;** | **Consolidated &nbsp;&nbsp;&nbsp;&nbsp;** |
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| Medicare | $**455.2** | $484.6 | $557.4 | $**241.8** | $206.5 | $190.5 | $**697.0** | $691.1 | $747.9 |
| Medicare Advantage | **253.0** | 237.9 | 199.2 | **—** |  |  | **253.0** | 237.9 | 199.2 |
| Managed care | **93.6** | 91.1 | 80.9 | **2.8** | 3.5 | 5.0 | **96.4** | 94.6 | 85.9 |
| Medicaid | **7.4** | 9.4 | 11.8 | **1.5** |  | 0.7 | **8.9** | 9.4 | 12.5 |
| Other | **4.6** | 1.8 | 0.8 | **0.1** |  |  | **4.7** | 1.8 | 0.8 |
| Total | $**813.8** | $824.8 | $850.1 | $**246.2** | $210.0 | $196.2 | $**1060.0** | $1034.8 | $1046.3 |

---

Enhabit records *Net service revenue* on an accrual basis using management's best estimate of the transaction price for the type of service provided to the patient and expect to receive in exchange for providing services directly to patients. Management's estimate of the transaction price includes adjustments for contractual rate and other revenue adjustments, including uncollectible amounts. Contractual rate revenue adjustments are recorded for the excess of the Company's standard rates over the contracted rate applicable to the relevant payer, if any. Management calculates contractual rate adjustments on a patient-by-patient basis based on the rates in effect for each primary third-party payer. Other revenue adjustments include adjustments for self-pay, uninsured patients and other payers and include revenue adjustments arising from billing documentation, face-to-face documentation, authorizations, and adjustments that may arise from payment, and other reviews by third-party payers or their agents. Estimates for other revenue adjustments are determined based on the aging of the Company's accounts receivable, its historical collection experience for each type of payer, its success rate in the claims adjudication process, and other relevant factors.

Management continually reviews the transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payers, which are often subject to interpretation, Enhabit may receive reimbursement for healthcare services authorized and provided that is different from management's estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each home health and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to the Company under these reimbursement programs. If actual results are not consistent with management's assumptions and judgments, the Company may be exposed to adjustments to *Net service revenue* that could be material.

The Centers for Medicare and Medicaid Services ("CMS") has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information concerning an overpayment, fraud, or willful misrepresentation. If CMS suspects payments are being made as the result of fraud or willful misrepresentation, CMS may suspend payment at any time without providing prior notice to the Company. The initial suspension period is limited to 180 days; however, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General or the United States Department of Justice. Therefore, management is unable to predict if or when the Company may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact the Company's financial position, results of operations, and cash flows.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

Enhabit's performance obligations relate to contracts with a duration of less than one year. Therefore, management elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.

The Company is subject to changes in government legislation that could impact Medicare payment levels and changes in payer patterns that may impact the level and timing of payments for services rendered.

***Home Health Revenues***

Under the Medicare home health prospective payment system, the Company is paid by Medicare based on episodes of care. The performance obligation is the rendering of services to the patient during the term of the episode of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal regulation. The base episode payment can be adjusted based on each patient's health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. Medicare reimburses home health providers under the Patient-Driven Groupings Model ("PDGM"). Under the PDGM, the initial certification remains valid for 60 days. If a patient remains eligible for care after the initial period as certified by a physician, a new treatment period may begin.

As the Company provides home health services to its patients on a scheduled basis over the episode of care in a manner that approximates a pro rata pattern, revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode that have been completed as of the period end date.

Enhabit is subject to certain Medicare regulations affecting outlier revenue if its patient care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenues received by each provider during a cost reporting year. Management has reviewed the potential cap. Adjustments to the transaction price for the outlier cap were not material as of December 31, 2025, 2024, and 2023.

For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, the Company recognizes revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, revenue is recorded on an accrual basis based upon the date of service at amounts equal to the Company's estimated per-visit transaction price. Price concessions, including contractual rate and other revenue adjustments are recorded as decreases to the transaction price.

***Hospice Revenues***

Medicare revenues for Hospice are recognized and recorded on an accrual basis using the input method based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The performance obligation is the rendering of services to the patient during each day that he or she is on hospice care. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payer or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the Medicare Administrative Contractors. Adjustments to the transaction price for these caps were $0.2 million, $1.4 million and zero for the years ended December 31, 2025, 2024, and 2023, respectively.

For non-Medicare Hospice revenues, Enhabit records gross revenue on an accrual basis based upon the date of service at amounts equal to the Company's estimated per day transaction price. Price concessions, including contractual and other revenue adjustments are recorded as decreases to the transaction price and thus reduce *Net service revenue*.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

***Cash and Cash Equivalents.*** *Cash and cash equivalents* include highly liquid investments with original maturities of three months or less when purchased. Carrying values of *Cash and cash equivalents* approximate fair value due to the short-term nature of these instruments.

The Company maintains amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the creditworthiness of those institutions, and the Company has not experienced any losses on such deposits.

***Restricted Cash.*** *Restricted cash* represents cash accounts maintained by a joint venture in which the Company's joint venture partner requested, and management agreed, that the joint venture's cash not be commingled with other corporate cash accounts and be used only to fund the operations of the joint venture.

***Accounts Receivable, Net of Allowances.*** *Accounts receivable, net of allowances*, from services rendered are reported at their estimated transaction price, which takes into account price concessions based on the amounts expected to be due from payers including federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers' compensation programs, employers, and patients. Management estimates the value of *Accounts receivable, net of allowances*, based upon historical experience and other factors, including an aging of accounts receivable, evaluation of expected adjustments, past adjustments, and collection experience in relation to amounts billed, current contract and reimbursement terms, shifts in payers and other relevant information. Collection of *Net service revenue* the Company expects to receive is normally a function of providing complete and correct billing information to the payers within the various filing deadlines. The evaluation of these factors involves complex, subjective judgments impacting the determination of the implicit price concession assumption. In addition, management compares the Company's cash collections to recorded *Net service revenue* and evaluates historical allowances, including implicit price concessions, based upon the ultimate resolution of the accounts receivable balance.

*Accounts receivable, net of allowances*, are concentrated by type of payer. The concentration of patient service accounts receivable by payer class, as a percentage of total patient service *Accounts receivable, net of allowances*, is as follows:

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Medicare | **62.1%** | 63.9% |
| Managed care and other discount plans, including Medicare Advantage | **32.4%** | 28.1% |
| Medicaid | **4.8%** | 7.1% |
| Other | **0.7%** | 0.9% |
| Total | **100.0%** | 100.0% |

---

While revenues and accounts receivable from the Medicare program are significant to Enhabit's operations, management does not believe there are significant credit risks associated with this government agency. Management does not believe there are any other significant concentrations of revenues from any particular payer that would subject the Company to any significant credit risks in the collection of accounts receivable.

Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts by patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payer decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When management determines all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.

The collection of outstanding receivables from Medicare and managed care payers is Enhabit's primary source of cash and is critical to the Company's operating performance. While it is Company policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where the Company is unable to obtain verification because the patient's insurance company was unresponsive to attempts to be contacted or a

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, but confirmation of qualification or denial for such benefits may take several days, weeks, or months to be communicated.

If actual results are not consistent with management's assumptions and judgments, the Company may be exposed to adjustments to *Net service revenue* and cash collections that could be material. Changes in general economic conditions, business office operations, payer mix, or trends in federal or state governmental and private employer healthcare coverage could affect the Company's collection of accounts receivable, financial position, results of operations, and cash flows.

Subsequent adjustments to accounts receivable determined to be the result of an adverse change in the payer's ability to pay are recognized as provision for credit losses. The majority of what historically was classified as provision for credit losses under operating expenses is now treated as an implicit price concession factored into the determination of *Net service revenue* discussed above. As of December 31, 2025 and 2024, the allowance for credit losses was $1.2 million and $0.9 million, respectively. See Note 4, *Accounts Receivable, Net of Allowances*, for additional information.

***Prepaid Expenses and Other Current Assets.*** *Prepaid expenses and other current assets* include $6.7 million and $6.8 million, and $5.7 million and $5.6 million of other prepaid expenses and prepaid property and casualty insurance, as of December 31, 2025 and 2024, respectively.

***Property and Equipment.*** Enhabit reports leasehold improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization, as well as any asset impairments. The Company depreciates assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:

---

| | |
|:---|:---|
| | **Years** |
| Leasehold improvements | 2 to 5 |
| Vehicles | 3 to 4 |
| Furniture, fixtures, and equipment | 2 to 5 |

---

Maintenance and repairs of leasehold improvements and equipment are expensed as incurred. The Company capitalizes replacements and betterments that increase the estimated useful life of an asset.

The Company retains fully depreciated assets and the related accumulated depreciation accounts until the assets are removed from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the Consolidated Statements of Income.

***Leases.*** Management determines if an arrangement is a lease, or contains a lease, at the inception of the contract and performs an analysis to determine whether the lease is an operating lease or a finance lease. The Company measures right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most leases do not provide a readily determinable implicit rate, management estimates an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, adjusting this amount based on the impact of collateral over the term of each lease. Management uses this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. The implicit rate is used when readily determinable. Lease expense is recognized for operating leases on a straight-line basis over the lease term. For finance leases, the Company recognizes amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to management's initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. Management does not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.

Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. Lease expense for these leases is recognized on a straight-line basis over the lease term.

***Goodwill and Other Intangible Assets, Net.*** *Goodwill* is required to be tested for impairment at least annually, as of October 1<sup>st</sup>, absent any triggering events that would accelerate an impairment assessment. The Company may perform

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

interim impairment tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or an indefinite lived intangible asset below its carrying amount. Potential impairment of a reporting unit is identified by comparing the reporting unit's estimated fair value to its carrying amount. The Company would recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its fair value.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit-specific operating results, as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative assessment for its reporting units and perform a quantitative test as of the measurement date of the test. Management assesses qualitative factors in the Home Health and Hospice reporting units to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, management believes the quantitative goodwill impairment test must be performed, management would estimate the fair value of the reporting units using generally accepted valuation techniques including the equal weighting of income approach and the market approach. Fair value under the income approach is determined by discounting to present value the estimated future cash flows of each reporting unit. Significant assumptions are incorporated into the discounted cash flow analysis, such as estimates of revenue growth rates, timing of de novo location openings, forecasted operating margins, the weighted average cost of capital, and terminal growth rates. Fair value under the market approach utilizes the guideline public company methodology, which uses valuation indicators, including market multiples of earnings before interest, taxes, depreciation and amortization, from other businesses that are similar to each reporting unit and implied control premiums. Changes in general economic and market conditions impacting these assumptions could result in goodwill impairment charges in future periods. When the Company disposes of a home health or hospice provider location, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.

Intangible assets with finite useful lives are amortized over their respective estimated useful lives to their estimated residual value. As of December 31, 2025, no finite useful lived intangible assets has an estimated residual value. Management reviews these assets for impairment whenever events or changes in circumstances indicate the Company may not be able to recover the asset's carrying amount.

The range of estimated useful lives and the amortization basis for intangible assets, excluding goodwill, are generally as follows:

---

| | |
|:---|:---|
| | **Estimated Useful Life and Amortization Basis&nbsp;&nbsp;&nbsp;&nbsp;** |
| Certificates of need | 10 years using straight-line basis |
| Licenses | 10 to 20 years using straight-line basis |
| Noncompete agreements | 5 years using straight-line basis |
| Internal-use software | 3 years using straight-line basis |

---

Enhabit capitalizes the costs of obtaining or developing internal-use software, including external direct costs of material and services and directly related payroll costs. Amortization begins when the internal-use software is ready for its intended use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.

***Impairment of Long-Lived Assets and Other Intangible Assets.*** Management assesses the recoverability of long-lived assets (excluding goodwill) and identifiable acquired intangible assets with finite useful lives whenever events or changes in circumstances indicate the Company may not be able to recover the asset's carrying amount. Management measures the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. The amount of impairment of other long-lived assets (excluding goodwill) is calculated as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows. Long-lived assets to be disposed of other than by sale are classified as held and used until they are disposed. When long-lived assets are to be disposed of by sale,

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

they are classified as held for sale, recognized in the balance sheet at the lower of their carrying amount or fair value less cost to sell, and depreciation is ceased.

See Note 7, *Goodwill and Other Intangible Assets, Net*, for more information.

***Investments in and Advances to Nonconsolidated Affiliates.*** Investments in entities that the Company does not control, but in which it has the ability to exercise significant influence over the operating and financial policies of the investees, are accounted for under the equity method. Equity method investments are recorded at original cost and adjusted periodically to recognize Enhabit's proportionate share of the investees' net income or loss after the date of investment, additional contributions made, dividends or distributions received, and impairment losses resulting from adjustments to net realizable value. Enhabit records equity method losses in excess of the carrying amount of an investment when the Company guarantees obligations or is otherwise committed to provide further financial support to the affiliate.

The Company uses the measurement alternative to account for equity investments and measures such investments at cost less impairment plus or minus observable price changes in orderly transactions for the identical investment or a similar investment of the same issuer at each reporting period.

***Fair Value Measurements.*** Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.

The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 1* – Observable inputs such as quoted prices in active markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 2* – Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Level 3* – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Market approach* – Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Cost approach* – Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Income approach* – Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).

Financial instruments consist mainly of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, an interest rate swap, and long-term debt. The carrying amounts of *Cash and cash equivalents*, *Restricted cash*, *Accounts receivable, net of allowances*, and *Accounts payable* approximate fair value because of the short-term maturity of these instruments.

There are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of *Intangible assets, net*, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of *Goodwill* is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.

***Noncontrolling Interests in Consolidated Affiliates.*** The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates Enhabit controls. Accordingly, the Company has recorded noncontrolling interests in the earnings and equity of such entities. Adjustments to noncontrolling interests are

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

recorded for the allocable portion of income or loss to which the noncontrolling interest holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interest holders' balance.

***Accrued Other Expenses.*** *Accrued other expenses* include $9.5 million and $13.5 million, $4.4 million and $6.7 million, $6.0 million and $6.6 million, and $7.1 million and $5.5 million of accrued expenses related to hospice-related costs, legal fees, workers' compensation, and medical insurance costs, as of December 31, 2025 and 2024, respectively.

***Redeemable Noncontrolling Interests in Consolidated Affiliates.*** Certain joint venture agreements contain provisions that allow Enhabit's partners to require the Company to purchase their interests in the joint venture at fair value at certain points in the future. Because these noncontrolling interests provide for redemption features that are not solely within the Company's control, they are classified as *Redeemable noncontrolling interests* outside of permanent equity in the Company's Consolidated Balance Sheets and present as redeemable noncontrolling interests at the greater of the carrying amount or redemption value at the end of each reporting period.

The following tables reconcile *Net income attributable to nonredeemable noncontrolling interests*, as recorded in the shareholders' equity section of the Consolidated Balance Sheets, and the *Net income attributable to redeemable noncontrolling interests*, as recorded in the mezzanine section of the Consolidated Balance Sheets, to the *Net income attributable to noncontrolling interests* presented in the Consolidated Statements of Income, and to the *Comprehensive income attributable to noncontrolling interests* presented in the Consolidated Statements of Comprehensive Income (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Balance at beginning of period | $**5.0** | $5.0 | $5.2 |
| Distribution to noncontrolling interests | **—** |  | (0.2) |
| Balance at end of period | $**5.0** | $5.0 | $5.0 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Net income attributable to nonredeemable noncontrolling interests | $**2.0** | $2.2 | $1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interests | $**2.0** | $2.2 | $1.5 |

---

***Stock-Based Payments.*** Enhabit employees participate in the Enhabit, Inc. 2022 Omnibus Performance Incentive Plan (the "2022 Plan") and the 2025 Equity and Incentive Compensation Plan (the "2025 Plan"). Enhabit has stockholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain Company employees. All stock-based payments to employees are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period. Stock-based compensation is included within *General and administrative expenses* on the Consolidated Statements of Income. See Note 9, *Stock-Based Payments*, for more information.

***Advertising Costs.*** Costs of print, radio, television, and other advertisements are expensed as incurred. Advertising expenses, primarily included in *General and administrative expenses* within the accompanying Consolidated Statements of Income, were immaterial in each of the years ended December 31, 2025, 2024, and 2023.

***Income Taxes.*** Enhabit provides for income taxes using the asset and liability method. This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for differences in the book and tax carrying amounts of the Company's assets and liabilities.

Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, management assesses the likelihood of realization of the Company's deferred tax assets considering all available evidence, both positive and negative.

Management evaluates the Company's tax positions and establishes assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes on a quarterly basis.

***Derivative Instrument.*** Enhabit is exposed to certain risks arising from both the Company's business operations and economic conditions. Management managed economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of debt funding and, until its maturity on October 20, 2025, the use of an interest rate swap agreement. The interest rate swap agreement was a derivative financial instrument used to manage differences in the amount, timing, and duration of known or expected cash payments principally related to the Company's borrowings.

Enhabit's objectives in using an interest rate derivative were to add stability to interest expense and to manage the Company's exposure to interest rate movements. To accomplish these objectives, the Company primarily used an interest rate swap as part of its interest rate risk management strategy. An interest rate swap designated as a cash flow hedge involved the receipt of variable amounts from a counter party in exchange for the Company making fixed-rate payments over the life of the agreement without exchange of the underlying notional amount. In accordance with Accounting Standards Codification ("ASC") 815, "Derivatives and Hedging," the derivative was recorded in the Consolidated Balance Sheets as either an asset or a liability measured at fair value. The change in the fair value of the derivative designated and that qualify as a cash flow hedge is recorded on the Consolidated Balance Sheet in *Accumulated other comprehensive loss*, net of tax, and is subsequently reclassified into earnings in the period the hedged forecasted transaction affects earnings. For the year ended December 31, 2025, such a derivative was used to hedge certain variable cash flows associated with existing variable-rate debt, until its maturity in October 2025.

See Note 12, *Derivative Instrument*, for more information.

***Earnings (Loss) per Common Share.*** The following table sets forth the computation of diluted weighted average common shares outstanding for the years ended December 31, 2025, 2024, and 2023 (in millions). A total of 0.3 million, 0.3 million and 0.3 million options to purchase Enhabit's shares and 2.7 million, 2.1 million and 1.7 million restricted stock awards and restricted stock units were excluded from the diluted weighted average common shares outstanding for the years ended December 31, 2025, 2024, and 2023, respectively, because their effects were anti-dilutive.

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Weighted average common shares outstanding: |  |  |  |
| Basic | **50.8** | 50.2 | 49.9 |
| Dilutive effect of options and restricted stock units | **—** |  |  |
| Diluted common shares outstanding | **50.8** | 50.2 | 49.9 |

---

***Recently Issued Accounting Standards Not Yet Adopted.*** In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, "Income Statement *(Topic 220)*: Reporting Comprehensive Income—Expense Disaggregation Disclosures." This standard requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (i) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential impact this standard will have on its consolidated financial statements and related disclosures.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

In December 2025, the FASB issued ASU 2025-11, "Interim Reporting *(Topic 270)*: Improvements to Interim Financial Statement Disclosures." This ASU introduces new requirements and clarifies existing guidance related to the presentation and disclosure of interim financial information. The amendments are intended to enhance the transparency and consistency of interim financial reporting by requiring additional disclosures regarding significant events or transactions that occur between annual reporting periods, as well as more detailed information about changes in estimates, accounting policies, and unusual or infrequent items. ASU 2025-11 is effective for public business entities for interim and annual periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied prospectively to all interim periods presented after the effective date. The amendments may be applied either (i) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential impact this standard will have on its consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-12, "Codification Improvements". This ASU is part of the FASB's ongoing efforts to clarify, correct, and improve the ASC to ensure consistency and ease of application. The amendments in ASU 2025-12 do not create new accounting requirements but instead provide technical corrections, clarifications, and minor improvements to a variety of topics throughout the codification of the ASC. These changes may include updates to references, wording, or examples to better align with existing guidance and to remove inconsistencies. ASU 2025-12 is effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods within those fiscal years. Early adoption is permitted. The amendments may be applied either (i) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

***Recently Adopted Provisions of GAAP.*** In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (*Topic 280*): Improvements to Reportable Segments Disclosures." This standard provides guidance to improve the disclosures about a public entity's reportable segments and address requests from investors for additional, more detailed information about a reportable segment's expenses. The Company adopted this standard as of December 31, 2024. See Note 14, *Segment Reporting*, for more information.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (*Topic 740*): Improvements to Income Tax Disclosures." This standard requires disaggregated income tax disclosures on the effective tax rate reconciliation and income taxes paid. The Company retrospectively adopted this standard as of December 31, 2025. See Note 11, *Income Taxes*, for more information.

**2. Business Combinations**

Enhabit did not complete any acquisitions during the years ended December 31, 2025 and 2024. The Company completed one acquisition during the year ended December 31, 2023 for a total purchase price of $3.1 million using cash on hand. This acquisition was not material to Enhabit's consolidated financial statements. The Company accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from the date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets and an income approach utilizing the relief-from-royalty method for the trade name intangible asset. The aforementioned income methods utilize management's estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. All goodwill recorded reflects management's expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends.

**3. Variable Interest Entities**

As of December 31, 2025, 2024, and 2023 Enhabit consolidated two joint venture entities that are VIEs and of which the Company is the primary beneficiary. The Company's ownership percentages in these entities range from 60% to 90% as of December 31, 2025. Through partnership and management agreements with or governing these entities, Enhabit

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

manages these entities and handles all day-to-day operating decisions. Accordingly, management has the decision-making power over the activities that most significantly impact the economic performance of the VIEs and the Company has an obligation to absorb losses or receive benefits from the VIEs that could potentially be significant to the VIEs. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections and creation and maintenance of medical records. The terms of the agreements governing the VIEs prohibit the Company from using the assets of the VIEs to satisfy the obligations of other entities.

The carrying amounts and classifications of the consolidated VIEs' assets and liabilities, which are included in Enhabit's Consolidated Balance Sheets, are as follows (in millions):

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| **Assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | $**1.7** | $1.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **1.3** | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **3.0** | 3.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | **—** | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | **12.4** | 12.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | **0.6** | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $**16.0** | $16.7 |

---

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| **Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current operating lease liabilities | $**—** | $0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll | **0.2** | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | **0.7** | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **0.9** | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | **—** | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $**0.9** | $1.3 |

---

**4. Accounts Receivable, Net of Allowances**

*Accounts receivable, net of allowances*, consists of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Current patient accounts receivable | $**144.0** | $149.2 |
| Noncurrent patient accounts receivable included within Other long-term assets | **0.5** | 0.5 |
| Current and noncurrent accounts receivable, net of allowances | $**144.5** | $149.7 |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

**5. Property and Equipment**

*Property and equipment, net*, consists of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Leasehold improvements | $**4.0** | $3.2 |
| Vehicles | **26.8** | 26.8 |
| Furniture, fixtures, and equipment | **50.4** | 42.7 |
|  | **81.2** | 72.7 |
| Less: Accumulated depreciation and amortization | **(65.7)** | (55.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | $**15.5** | $17.7 |

---

The amount of depreciation expense is as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Depreciation expense | $**3.4** | $4.2 | $4.3 |

---

**6. Leases**

The Company leases office space, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2035. These operating and finance leases generally have one- to eleven-year terms. Certain leases also include options to purchase the leased property.

The components of lease costs are as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Operating lease cost: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | $**20.9** | $20.7 | $20.5 |
| Finance lease cost: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use assets | **2.5** | 3.4 | 3.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest on lease liabilities | **0.4** | 0.4 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total finance lease cost | **2.9** | 3.8 | 3.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total lease cost | $**23.8** | $24.5 | $23.8 |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

Supplemental Consolidated Balance Sheet information related to leases is as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | | **As of December 31,** | **As of December 31,** |
| |<br>**Classification** | **2025** | **2024** |
| **Assets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease | Operating lease right-of-use assets | $**49.8** | $52.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease<sup>(1)</sup> | Property and equipment, net | **7.7** | 11.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total leased assets |  | $**57.5** | $63.8 |
| **Liabilities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease | Current portion of operating lease liabilities | $**12.6** | $12.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finance lease | Current portion of long-term debt | **2.3** | 2.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncurrent liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease | Long-term operating lease liabilities, net of current portion | **39.1** | 41.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finance lease | Long-term debt, net of current portion | **2.3** | 4.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total leased liabilities |  | $**56.3** | $61.5 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Finance lease assets are recorded net of accumulated amortization of $19.2 million and $21.3 million as of December 31, 2025 and 2024, respectively.

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Weighted Average Remaining Lease Term |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease | **5.2 years** | 5.5 years |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease | **2.1 years** | 2.9 years |
| Weighted Average Discount Rate |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease | **6.8%** | 6.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease | **5.8%** | 5.7% |

---

Maturities of lease liabilities as of December 31, 2025 are as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| **Year Ending December 31,&nbsp;&nbsp;&nbsp;&nbsp;** | **Operating Leases** | **Finance Leases** | **Total**<br>**Leases** |
| 2026 | $15.5 | $2.5 | $18.0 |
| 2027 | 13.5 | 2.1 | 15.6 |
| 2028 | 9.9 | 0.3 | 10.2 |
| 2029 | 6.7 |  | 6.7 |
| 2030 | 4.7 |  | 4.7 |
| 2031 and thereafter | 11.7 |  | 11.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease payments | 62.0 | 4.9 | 66.9 |
| Less: Interest portion | (10.3) | (0.3) | (10.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities | $51.7 | $4.6 | $56.3 |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

Supplemental cash flow information related to leases is as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows from operating leases | $**15.0** | $14.4 | $16.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows from finance leases | $**0.4** | $0.5 | $0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing cash flows from finance leases | $**2.7** | $3.6 | $3.4 |
| Right-of-use assets obtained in exchange for lease obligations: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases | $**12.6** | $11.0 | $31.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance leases | $**0.1** | $5.5 | $3.8 |

---

**7. Goodwill and Other Intangible Assets, Net**

The following table shows changes in the carrying amount of *Goodwill* for the years ended December 31, 2025 and 2024 (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Home Health** | **Hospice** | **Consolidated** |
| **Goodwill as of December 31, 2023** | $843.9 | $217.8 | $1061.7 |
| Impairment | (161.7) |  | (161.7) |
| **Goodwill as of December 31, 2024** | 682.2 | 217.8 | 900.0 |
| Impairment | **(44.7)** | **—** | **(44.7)** |
| **Goodwill as of December 31, 2025** | $**637.5** | $**217.8** | $**855.3** |

---

*Goodwill* decreased because of the impairment charges recorded for the years ended December 31, 2025 and 2024.

The Company is required to test goodwill for impairment at least annually, as of October 1<sup>st</sup>, absent any triggering events that would accelerate an impairment assessment.

During the year ended December 31, 2023, management identified potential impairment triggering events in the second and third quarters and determined a quantitative analysis of the two reporting units should be performed. These triggering events included Enhabit's performance compared to the 2023 forecast and decreases in the Company's share price and market capitalization in each quarter. During the year ended December 31, 2023, the Company recorded an impairment charge of $85.8 million to reflect a decrease in the carrying value of the Hospice reporting unit.

During the third quarter of 2024, management identified potential impairment triggering events and determined a quantitative analysis of the two reporting units should be performed. These triggering events included a decrease in Enhabit's share price and market capitalization. Based on the quantitative analysis performed in the third quarter of 2024, Enhabit recorded an impairment charge of $107.9 million to reflect a decrease in the carrying value of the Home Health reporting unit. We conducted our annual impairment test at October 1, 2024, which resulted in the same values determined as of September 30, 2024.

During the fourth quarter of 2024, management identified potential impairment triggering events and determined a quantitative analysis of the two reporting units should be performed. These triggering events included a decrease in the Home Health reporting unit's performance compared to the 2024 forecast. Based on the quantitative analysis performed in the fourth quarter of 2024, Enhabit recorded an impairment charge of $53.8 million to reflect a decrease in the carrying value of the Home Health reporting unit. Due to improved performance in the Hospice reporting unit in the fourth quarter of 2024, its fair value exceeded its carrying value with adequate headroom as of December 31, 2024.

We conducted our annual impairment test at October 1, 2025 and during the fourth quarter of 2025 identified a potential impairment triggering event and determined a quantitative analysis should be performed. The triggering event was the release of the 2026 final rule for home health, which included a net negative home health payment update. Based on the

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

quantitative analysis performed in the fourth quarter of 2025, Enhabit recorded an impairment charge of $44.7 million to reflect a decrease in the carrying value of the Home Health reporting unit. Due to sustained positive performance in the Hospice reporting unit in 2025, its fair value exceeded its carrying value with adequate headroom as of December 31, 2025.

Management estimated the fair value of the reporting units using equal weighting of the income approach and market approach. The assumptions used in the income approach incorporate several significant estimates and judgments, including the revenue growth rates, timing of de novo location openings, forecasted operating margins, the weighted average cost of capital, and terminal growth rates. The market approach utilizes the guideline public company methodology, which uses valuation indicators, including market multiples of earnings before interest, taxes, depreciation, and amortization, from other businesses that are similar to each reporting unit and implied control premiums.

While management believes the assumptions used are reasonable and commensurate with the views of a market participant, there is also uncertainty in current general economic and market conditions. The result of the analysis is sensitive to changes in key assumptions, such as assumed future reimbursement rates, rising interest rates and labor costs and delays in the Company's ability to complete de novo location openings, which could negatively impact forecasted cash flows and result in an impairment charge in future periods.

As of December 31, 2025 and 2024, *Goodwill* included consolidated accumulated impairment charges of $401.2 million and $356.5 million, respectively.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

The following table provides information regarding other *Intangible assets, net* (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Gross Carrying Amount&nbsp;&nbsp;&nbsp;&nbsp;** | **Accumulated<br>Amortization** | **Net** |
| **Certificates of need:** | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;2025 | $**85.8** | $**(66.3)** | $**19.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;2024 | $89.2 | $(58.6) | $30.6 |
| **Licenses:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;2025 | $**129.5** | $**(112.4)** | $**17.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;2024 | $131.2 | $(107.1) | $24.1 |
| **Noncompete agreements:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;2025 | $**14.8** | $**(14.0)** | $**0.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;2024 | $15.1 | $(13.5) | $1.6 |
| **Trade names:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;2025 | $**7.4** | $**(7.4)** | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;2024 | $7.6 | $(7.6) | $— |
| **Internal-use software:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;2025 | $**32.3** | $**(31.2)** | $**1.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;2024 | $32.1 | $(30.3) | $1.8 |
| **Total intangible assets:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;2025 | $**269.8** | $**(231.3)** | $**38.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;2024 | $275.2 | $(217.1) | $58.1 |

---

Amortization expense for other intangible assets is as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Amortization expense | $**16.6** | $23.9 | $23.5 |

---

The Company performs its annual impairment test for indefinite-lived assets in the fourth quarter, or more frequently if triggering events occur. During the fourth quarter of 2025, management identified two certificates of need, with a total value of $3.0 million, that no longer held value due to its long-term growth assumptions within the associated geographic areas of these assets. These changes in assumptions resulted in the Company recognizing a non-cash impairment charge of $3.0 million for the year ended December 31, 2025, to reduce the carrying value of the intangible assets to fair value.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

**8. Long-Term Debt**

Long-term debt outstanding consists of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Credit Agreement— |  |  |
| &nbsp;&nbsp;Term loan A facility | $**328.7** | $348.0 |
| &nbsp;&nbsp;Advances under revolving credit facility | **115.0** | 160.0 |
| Finance lease obligations | **4.6** | 7.4 |
| &nbsp;&nbsp;Total debt | **448.3** | 515.4 |
| Less: Current portion | **(22.3)** | (22.8) |
| Long-term debt, net of current portion | $**426.0** | $492.6 |

---

The following chart shows scheduled principal payments due on long-term debt for the next five years (in millions):

---

| | |
|:---|:---|
| **Year Ending December 31,** | **Amount** |
| 2026 | $22.3 |
| 2027 | 427.0 |
| 2028 | 0.3 |
| 2029 |  |
| &nbsp;&nbsp;Gross maturities | 449.6 |
| Less unamortized debt issuance costs<sup>(1)</sup> | (1.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $448.3 |

---

(1) &nbsp;&nbsp;&nbsp;&nbsp;These unamortized debt issuance costs do not include $1.0 million of unamortized debt costs associated with the Revolving Credit Facility that are not netted against the outstanding borrowings, and instead are included in non current assets.

In June 2022, the Company entered into a credit agreement (the "Credit Agreement") that consists of a $400.0 million term loan A facility (the "Term Loan A Facility") and a $350.0 million revolving credit facility (the "Revolving Credit Facility" and together with the Term Loan A Facility, the "Credit Facilities"). The Credit Facilities mature in June 2027. Interest on the loans under the Credit Facilities is calculated by reference to the Secured Overnight Financing Rate ("SOFR") or an alternative base rate, plus an applicable interest rate margin. Enhabit may voluntarily prepay outstanding loans under the Credit Facilities at any time without premium or penalty, other than customary breakage costs with respect to SOFR loans. The Term Loan A Facility contains customary mandatory prepayments, including with respect to proceeds from asset sales and from certain incurrences of indebtedness.

On June 30, 2022, the Company drew the full $400.0 million of the Term Loan A Facility and $170.0 million on the Revolving Credit Facility. The net proceeds of $566.6 million were distributed to Encompass prior to the completion of the Distribution. For additional information on the Separation, see Note 1, *Summary of Significant Accounting Policies*, to the accompanying consolidated financial statements.

The Term Loan A Facility amortizes by an amount per annum equal to 5.0% of the outstanding principal amount thereon as of the closing date, payable in equal quarterly installments, with the balance being payable in June 2027. The Revolving Credit Facility provides the ability to borrow and obtain letters of credit, which is subject to a $75.0 million sublimit. Obligations under the Credit Facilities are guaranteed by Enhabit's existing and future wholly-owned domestic material subsidiaries (the "Guarantors"), subject to certain exceptions. Borrowings under the Credit Facilities are secured by first priority liens on substantially all the assets of Enhabit and the Guarantors, subject to certain exceptions. The Credit Facilities contain representations and warranties, affirmative and negative covenants, and events of default customary for secured financings of this type, including limitations with respect to liens, fundamental changes, indebtedness, restricted

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

payments, investments, and affiliate transactions, in each case, subject to a number of important exceptions and qualifications.

On June 27, 2023, Enhabit amended the Credit Facilities (the "First Amendment") to provide for, among other things: (i) a new tier to the pricing grid for interest rate margins when the total net leverage ratio exceeds 4.50 to 1.00; (ii) changes to the conditions concerning the Company's total net leverage ratio that must be met for the Company to borrow incremental ratio-based amounts; (iii) an increase in the maximum permitted total net leverage ratio to 5.25 to 1.00 for the quarters ended June 30, 2023, September 30, 2023, and December 31, 2023, stepping down to 5.00 to 1.00 for the quarter ended March 31, 2024, 4.75 to 1.00 for the quarter ended June 30, 2024, and 4.50 to 1.00 for the quarter ended September 30, 2024 and thereafter; and (iv) modifications to the Company's ability to declare and make certain restricted payments.

On September 29, 2023, Enhabit entered into a Limited Waiver (the "Waiver") with Wells Fargo Bank, National Association, as administrative agent to the other lenders (the "Administrative Agent") under the Credit Agreement and the First Amendment. The Waiver released the Company from the requirement to comply with the total net leverage ratio and the interest coverage ratio covenants for the three months ended September 30, 2023. The Waiver also required that, until such time as the Company certified compliance with the waived financial covenants, the aggregate principal amount of the Company's revolving loans allowed under the Credit Agreement were decreased from $350.0 million to $230.0 million. All other covenants and terms of the Credit Agreement remained unchanged and in effect. Although the Company was not required to be in compliance with the financial covenants as of September 30, 2023, it was in compliance with the financial covenants under the Credit Facilities.

As of September 30, 2023, Enhabit's forecasted results suggested there was uncertainty of meeting the covenants through a period of one year from the issuance date of the September 30, 2023 financial statements. As a result, on November 3, 2023, the Company amended the Credit Facilities (the "Second Amendment") to provide for, among other things: (i) an increase in the maximum permitted Total Net Leverage Ratio (as defined in the Credit Agreement) to 6.75 to 1.00 for the quarters ended December 31, 2023 and March 31, 2024, stepping down to 6.50 to 1.00 for the quarters ended June 30, September 30 and December 31, 2024, 5.75 to 1.00 for the quarter ending March 31, 2025, and 4.50 to 1.00 for the quarter ending June 30, 2025 and thereafter; (ii) the addition of a Fixed Charge Coverage Ratio (as defined in the Credit Agreement) covenant of 1.15 to 1.00 until the end of the Covenant Adjustment Period (as defined below); (iii) no Interest Coverage Ratio (as defined in the Credit Agreement) covenant until the end of the Covenant Adjustment Period; (iv) a permanent reduction in the Revolving Credit Facility commitment from $350.0 million to $220.0 million; (v) an increase in the Applicable Commitment Fee (as defined in the Credit Agreement) during the Covenant Adjustment Period; (vi) suspension of the ability of the Company to request incremental commitments under the Credit Agreement during the Covenant Adjustment Period; (vii) an increase of 0.25% in the applicable interest rate margins on amounts outstanding under the Credit Agreement during the Covenant Adjustment Period; (viii) limits on the amount of cash the Company can keep on hand and outside the lender group during the Covenant Adjustment Period; and (ix) additional limits on permitted indebtedness and acquisitions, permitted liens, restricted payments and permitted investments during the Covenant Adjustment Period. The "Covenant Adjustment Period" begins on the date of the Second Amendment and ends on the earlier of (a) the date the Company provides evidence of compliance with the financial covenants in the Credit Agreement, as amended, for the fiscal quarter ending June 30, 2025 and (b) the date that the Company provides evidence of compliance with the financial covenants in the Credit Agreement as in effect immediately prior to the First Amendment for the applicable quarter.

Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, Enhabit may not be able to borrow under the Revolving Credit Facility. Additionally, violation of the covenants would result in an event of default under the Credit Facilities. A default that occurs, and is not cured within any applicable cure period or is not waived, would permit lenders to accelerate the maturity of the debt under the Credit Facilities and to foreclose upon any collateral securing the debt.

As of December 31, 2025, amounts drawn under both the Term Loan A Facility and the Revolving Credit Facility had an interest rate of 6.1%. On October 20, 2022, Enhabit entered into an interest rate swap to manage the Company's exposure to interest rate movements for a portion of the Term Loan A Facility. The interest rate swap had a $200.0 million notional value and a maturity date of October 20, 2025. Beginning in October 2022, the Company received the one-month SOFR and paid a fixed rate of interest of 4.3%. See also Note 12, *Derivative Instrument*.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

The carrying amounts and estimated fair values for long-term debt are presented in the following table (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** | **As of December 31,** | **As of December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Carrying Amount** | **Estimated Fair Value** | **Carrying Amount** | **Estimated Fair Value** |
| Long-term debt: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Term loan A facility | $**328.7** | $**325.5** | $348.0 | $345.3 |
| &nbsp;&nbsp;&nbsp;Advances under revolving credit facility | $**115.0** | $**115.0** | $160.0 | $160.0 |
| &nbsp;&nbsp;&nbsp;Finance lease obligations | $**4.6** | $**4.6** | $7.4 | $7.4 |

---

Fair values for long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, *Summary of Significant Accounting Policies—Fair Value Measurements*.

In February 2026, the Company entered into an amended and restated credit agreement (the "2026 Credit Agreement") that consists of a $315.0 million senior secured term loan A facility (the "2026 Term Loan A Facility") and a $160.0 million senior secured revolving credit facility (the "2026 Revolving Credit Facility" and together with the 2026 Term Loan A Facility, the "2026 Credit Facilities"). The 2026 Credit Facilities mature on February 26, 2031. The 2026 Credit Facilities refinance by amendment and restatement the Credit Facilities. Interest on the loans under the 2026 Credit Facilities is calculated by reference to the SOFR or an alternative base rate, plus an applicable interest rate margin. The Company may voluntarily prepay outstanding loans under the 2026 Credit Facilities at any time without premium or penalty, other than customary breakage costs with respect to SOFR loans. The 2026 Credit Facilities contain customary mandatory prepayments, including with respect to proceeds from certain asset sales and incurrences of indebtedness.

On February 26, 2026, the Company drew the full $315.0 million of the 2026 Term Loan A Facility and $110.0 million on the 2026 Revolving Credit Facility. Cash on hand and the net proceeds of $425.0 million were used to repay amounts outstanding under the Credit Facilities.

The 2026 Term Loan A Facility amortizes by an amount per annum equal to 7.5% of the outstanding principal amount thereon as of the closing date, payable in equal quarterly installments, with the balance being payable on February 26, 2031. The 2026 Revolving Credit Facility provides the ability to borrow and obtain letters of credit, which is subject to a $40.0 million sublimit. Obligations under the 2026 Credit Facilities are guaranteed by the Guarantors, subject to certain exceptions. Borrowings under the 2026 Credit Facilities are secured by first priority liens on substantially all the assets of Enhabit and the Guarantors, subject to certain exceptions. The 2026 Credit Facilities contain representations and warranties, affirmative and negative covenants, and events of default customary for secured financings of this type, including limitations with respect to liens, fundamental changes, indebtedness, restricted payments, investments, and affiliate transactions, in each case, subject to a number of important exceptions and qualifications.

Enhabit's forecasted results indicate the Company will continue to be in compliance with the financial covenants through a period of one year from the issuance date of the December 31, 2025 financial statements. Management cannot guarantee the Company will be in compliance with the financial covenants for each reporting period through a period of one year from the issuance date of the December 31, 2025 financial statements. As of December 31, 2025, Enhabit was in compliance with the financial covenants under the Credit Facilities. Management continually evaluates the Company's expected compliance with the covenants described above and takes all appropriate steps to proactively renegotiate such covenants when appropriate.

**9. Stock-Based Payments**

In 2022 the Company adopted the Enhabit, Inc. 2022 Omnibus Performance Incentive Plan (the "2022 Plan"), under which employees and non-employee directors could be granted stock options, stock appreciation rights, stock awards, performance stock units ("PSUs"), restricted stock, dividend equivalents, restricted stock units ("RSUs"), other stock-based awards and cash awards. This incentive plan provides for the issuance of up to an aggregate of 7 million shares of the

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

Company's common stock in stock-based compensation awards. Awards granted under the plan vest over the awards' requisite service periods, which are typically three years.

In June 2025, the Company adopted the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan ("the 2025 Plan") under which employees and non-employee directors could be granted stock options rights or appreciation rights, restricted stock, RSUs, performance shares or performance units, dividend equivalents, and other stock-based awards and cash awards. This incentive plan provides for the issuance of up to an aggregate of 3,300,000 shares of common stock, minus (i) as of the effective date, one share of common stock for every one share of common stock subject to an award under the predecessor plan after April 29, 2025 and before the effective date, plus (ii) the shares of common stock that are subject awards granted under this plan or the predecessor plan that are added (or, added back, as applicable) to the aggregate number of shares of common stock available under either plan. The 2025 Plan became effective as of June 26, 2025, when it was approved by the shareholders of the Company.

***Stock Options***

Under the 2022 Plan, one member of management was given the right to purchase shares of Enhabit common stock at a fixed grant price determined on the day the options were granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the Compensation & Human Capital Committee of Enhabit's board of directors. However, no options are exercisable beyond ten years from the date of grant. Granted options vest over the awards' requisite service periods, which are generally three years.

No stock options were granted during the years ended December 31, 2025 and 2024. The grant date fair value of stock options granted during the year ended December 31, 2023 was estimated at the grant date using the Black-Scholes option-pricing model with the following weighted average assumptions:

---

| | |
|:---|:---|
| | **Year Ended December 31,** |
| | **2023** |
| Expected volatility | 53.0% |
| Risk-free interest rate | 4.1% |
| Expected life (years) | 6.0 |
| Dividend yield | —% |

---

The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including the expected stock price volatility. Volatility was estimated using the historical value of Enhabit's peer group for a period of time commensurate with the expected term of the option. The risk-free interest rate was the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. The expected term was estimated using the simplified method outlined in the Securities and Exchange Commission's Staff Accounting Bulletin 120. The dividend yield is zero. Enhabit recognizes forfeitures for all award types as they occur. Under the Black-Scholes option-pricing model, the weighted average grant date fair value per share of employee stock options was $8.35 for the year ended December 31, 2023.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

A summary of stock option activity for the year ended December 31, 2025 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(shares in thousands)** | **Shares** | **Weighted Average Exercise Price per Share** | **Weighted<br>Average Remaining Life (Years)&nbsp;&nbsp;&nbsp;&nbsp;** | **Aggregate Intrinsic Value<br>(In Millions)** |
| Outstanding, December 31, 2024 | 286.3 | $24.44 |  |  |
| &nbsp;&nbsp;Granted |  |  |  |  |
| &nbsp;&nbsp;Expirations |  |  |  |  |
| Outstanding, December 31, 2025 | **286.3** | **24.44** | **4.8** | **—** |
| Exercisable, December 31, 2025 | **265.0** | $**25.17** | **4.6** | $**—** |

---

The Company recognized approximately $0.2 million, $0.3 million, and $0.4 million of compensation expense related to stock options for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, there was no unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted average period of 2 months. No options were exercised during the years ended December 31, 2025, 2024, and 2023. The total fair value of stock options vested during the years ended December 31, 2025, 2024, and 2023 was $0.3 million, $0.4 million, and $0.3 million, respectively.

***Restricted Stock Awards***

A summary of RSA activity for the year ended December 31, 2025 is as follows:

---

| | | |
|:---|:---|:---|
| **(shares in thousands)** | **Shares** | **Weighted<br>Average Grant Date Fair Value** |
| Nonvested shares at December 31, 2024 | 202.6 | $23.26 |
| &nbsp;&nbsp;Granted | **—** | **—** |
| &nbsp;&nbsp;Vested | **(129.0)** | **23.52** |
| &nbsp;&nbsp;Forfeited | **(7.7)** | **23.47** |
| Nonvested shares at December 31, 2025 | **65.9** | $**22.74** |

---

The Company recognized $1.3 million, $2.1 million, and $3.0 million of stock-based compensation related to RSAs for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, there was $0.7 million of unrecognized compensation expense related to unvested RSAs. This cost is expected to be recognized over a weighted average period of 6 months. There were no RSAs granted in the year ended December 31, 2025. The total fair value of RSAs vested during the years ended December 31, 2025, 2024, and 2023 was $3.0 million, $1.9 million, and $4.2 million, respectively.

***Restricted Stock Units***

The RSUs granted in 2025 were service-based and performance-based awards. These awards generally vest over a three-year requisite service period. The fair value of the RSU was determined by the closing price of Enhabit's common stock on the grant date for the free cash flow performance condition and the Monte Carlo simulation model for the total shareholder return performance condition. The performance-based RSUs will vest in an amount between zero and 200% of the target units granted based on two criteria, (i) total shareholder return over the three-year period ending December 31, 2027 as compared to a designated peer group, and (ii) free cash flow generated by the Company over a two-year period ending December 31, 2026. The total shareholder return performance condition represents 40% of the total 2025 performance-based RSU award, and the free cash flow performance condition represents 60% of the total 2025 performance-based RSU award.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

A summary of RSU activity for the year ended December 31, 2025 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Service Based** | **Service Based** | **Performance Based** | **Performance Based** |
| **(shares in thousands)** | **Shares** | **Weighted<br>Average Grant Date Fair Value** | **Shares** | **Weighted<br>Average Grant Date Fair Value** |
| Nonvested shares at December 31, 2024 | 951.5 | $12.28 | 973.5 | $12.12 |
| &nbsp;&nbsp;Granted | **1068.8** | **8.27** | **796.3** | **9.95** |
| &nbsp;&nbsp;Performance factor adjustment | **—** | **—** | **37.1** | **(1.34)** |
| &nbsp;&nbsp;Vested | **(845.4)** | **12.05** | **(344.1)** | **10.50** |
| &nbsp;&nbsp;Forfeited | **(118.5)** | **9.96** | **(168.4)** | **11.57** |
| Nonvested shares at December 31, 2025 | **1056.4** | $**8.67** | **1294.4** | $**10.90** |

---

The Company recognized $15.4 million, $8.3 million, and $5.5 million of stock-based compensation related to RSUs for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, there was $5.5 million of unrecognized compensation expense related to unvested service-based RSUs. This cost is expected to be recognized over a weighted average period of 20 months. As of December 31, 2025, there was $7.6 million of unrecognized compensation expense related to performance-based RSUs. This cost is expected to be recognized over a weighted average period of 23 months. The total compensation expense ultimately recognized for the performance-based RSUs will depend on the outcome of the free cash flow performance condition upon vesting of the award. The weighted average grant-date fair value per share of service-based RSUs granted was $8.27, $8.94, and $12.84 during the years ended December 31, 2025, 2024, and 2023, respectively. The total fair value of service-based RSUs vested during the years ended December 31, 2025, 2024, and 2023 was $10.2 million, $7.1 million, and $4.1 million, respectively. The total fair value of performance-based RSUs vested during the year ended December 31, 2025 was $3.6 million.

Of the $17.0 million of stock-based compensation disclosed above, approximately $1.0 million represents RSUs issued in 2025 for 2024 discretionary bonus awards. Additionally, Enhabit has accrued $0.6 million of stock-based compensation for discretionary bonus awards with service inception dates in 2025 that will be granted in 2026. There is no unamortized expense associated with the awards.

The total tax benefit recognized for all stock-based compensation was $2.1 million, $1.1 million, and $0.9 million for the years ended December 31, 2025, 2024, and 2023, respectively.

**10. Employee Benefit Plans**

Substantially all employees are eligible to enroll in Company-sponsored healthcare plans, including coverage for medical and dental benefits. Enhabit's primary healthcare plans are national plans administered by third-party administrators. The Company is self-insured for these plans. During 2025, 2024, and 2023, costs associated with these plans, net of amounts paid by employees and stop-loss recoveries, approximated $49.7 million, $46.9 million, and $48.1 million, respectively. As of December 31, 2025 and 2024, medical insurance accruals of $7.1 million and $5.5 million, respectively, are included in *Other current liabilities* in the Consolidated Balance Sheets.

The Company offers one qualified 401(k) savings plan, the Home Health Savings Plan (the "HHSP"). The HHSP allows eligible employees to contribute up to 60% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. All Home Health and Hospice full-time and part-time employees are eligible to participate in the HHSP, and all contributions to the plan are in the form of cash. The Company's employer matching contribution under the HHSP is 25% of the first 3% of each participant's elective deferrals, which vest gradually over a six-year service period. Participants are always fully vested in their own contributions.

Employer contributions to the HHSP approximated $2.2 million, $2.3 million, and $2.3 million in 2025, 2024, and 2023, respectively. In 2025, 2024, and 2023, approximately $0.3 million, $0.2 million, and $0.4 million, respectively, from forfeited accounts were used to fund the matching contributions in accordance with the terms of the HHSP.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

**11. Income Taxes**

The significant components of *Provision for (benefit from) income taxes* are as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Current: |  |  |  |
| &nbsp;&nbsp;Federal | $**3.8** | $1.4 | $0.2 |
| &nbsp;&nbsp;State and other | **0.2** | 0.3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current expense | **4.0** | 1.7 | 0.2 |
| Deferred: |  |  |  |
| &nbsp;&nbsp;Federal | **(0.2)** | (5.4) | (9.3) |
| &nbsp;&nbsp;State and other | **0.2** | (0.3) | (2.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred benefit | **—** | (5.7) | (11.6) |
| Total income tax (benefit) expense related to continuing operations | $**4.0** | $(4.0) | $(11.4) |

---

A reconciliation of differences between the U.S. federal statutory tax rate and Enhabit's effective tax rate is presented below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| Tax at U.S. federal statutory rate | $**0.3** | **21.0%** | $(33.2) | 21.0% | $(19.0) | 21.0% |
| State and local income tax, net of federal (national) income tax effect<sup>(1)</sup> | **0.4** | **28.6%** | 0.1 | (0.1)% | (1.9) | 2.1% |
| Effect of changes in tax laws or rates enacted in the current period | **(4.2)** | **(300.0)%** |  | —% |  | —% |
| Tax credits |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General business credit - IRC section 38 | **(0.5)** | **(35.7)%** |  | —% |  | —% |
| Changes in valuation allowances | **2.3** | **164.3%** | 11.7 | (7.4)% |  | —% |
| Nontaxable or nondeductible items |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **4.5** | **321.4%** | 16.2 | (10.2)% | 8.3 | (9.2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | **1.5** | **107.1%** | 1.3 | (0.8)% | 1.1 | (1.2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interest | **(0.4)** | **(28.6)%** | (0.5) | 0.3% | (0.3) | 0.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **0.1** | **7.6%** | 0.4 | (0.3)% | 0.4 | (0.5)% |
| Effective Tax Rate | $**4.0** | **285.7%** | $(4.0) | 2.5% | $(11.4) | 12.6% |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;State taxes in Alabama, Florida, Georgia, and Mississippi made up the majority (greater than 50 percent) of the tax effect in this category.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The significant components of deferred tax assets and liabilities are presented in the following table (in millions):

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Deferred income tax assets: |  |  |
| &nbsp;&nbsp;Operating lease liabilities | $**11.8** | $12.4 |
| &nbsp;&nbsp;Accrued expenses and allowances | **1.5** | 2.9 |
| &nbsp;&nbsp;Stock-based compensation | **4.5** | 3.3 |
| &nbsp;&nbsp;Interest expense | **21.3** | 21.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred income tax assets, gross | **39.1** | 40.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Valuation allowance | **(12.2)** | (14.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred income tax assets, net | **26.9** | 26.2 |
| Deferred income tax liabilities: |  |  |
| &nbsp;&nbsp;Intangible assets | **(21.5)** | (19.1) |
| &nbsp;&nbsp;Operating lease right-of-use assets | **(11.4)** | (12.1) |
| &nbsp;&nbsp;Property, net | **(2.9)** | (3.2) |
| &nbsp;&nbsp;Other deferred income tax liabilities | **(2.6)** | (3.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred income tax liabilities | **(38.4)** | (37.7) |
| Net deferred income tax liabilities | $**(11.5)** | $(11.5) |

---

The deferred tax asset for interest expense is attributable to a carryforward with an indefinite carryforward period. The Company recorded a valuation allowance against a portion of the deferred tax assets of $14.1 million for 2024, of which $5.4 million relates to deferred tax assets arising in a prior year. The Company reduced the valuation allowance by $1.9 million for 2025, relating to deferred tax assets originating in a prior year. The reduction in the valuation allowance is primarily attributable to provisions of the One Big Beautiful Bill Act enacted on July 4, 2025.

At the Distribution, the Company entered into the Tax Matters Agreement with Encompass. The Tax Matters Agreement governs the Company's respective rights, responsibilities and obligations with respect to taxes including taxes, if any, incurred as a result of any failure of the Distribution to qualify as tax-free for U.S. federal income tax purposes. The Tax Matters Agreement provides rules that allocate tax liabilities in the event the Distribution or certain related transactions are not tax-free. In general, under the Tax Matters Agreement, each party is responsible for any taxes imposed on Encompass or the Company that arise from the failure of the Distribution or certain related transactions to qualify as a transaction that is generally tax-free for U.S. federal income tax purposes under Section 355 of the Code, to the extent that the failure to so qualify is attributable to actions, events or transactions relating to such party's respective stock, assets or business, or a breach of the relevant covenants made by that party in the Tax Matters Agreement.

Interest and penalties related to income tax matters are recognized in *Provision for (benefit from) income taxes* in the Consolidated Statements of Income. Interest recorded as part of the income tax provisions for 2025, 2024, and 2023 was not material. Accrued interest related to income taxes as of December 31, 2025 and 2024 was not material.

As of December 31, 2025 and 2024, the Company has not recorded any unrecognized income tax benefits for uncertain tax positions. Enhabit's federal income tax returns have been examined through the date of the Distribution as part of the examinations of the Encompass consolidated federal income tax returns. All subsequent tax years are open for examination.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

*Income taxes paid (net of refunds received) were as follows:*

---

| | | | |
|:---|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** | **2023** |
| Federal | $**1.3** | $— | $(8.4) |
| State | **0.1** | (0.8) | 0.2 |
| Total income taxes paid (net of refunds received) | $**1.4** | $(0.8) | $(8.2) |

---

State activity in 2024 included refunds of $0.2 million from Alabama and Virginia, refunds of $0.1 million from Georgia, Louisiana, and Mississippi, and a refund of less than $0.1 million from Massachusetts. State activity in 2025 included a refund of $0.1 million from Oklahoma.

**12. Derivative Instrument**

In October 2022, Enhabit entered into an interest swap agreement with a notional value of $200.0 million and a maturity of October 20, 2025. See Note 8, *Long-Term Debt*.

The activities of the cash flow hedge included in *Accumulated other comprehensive loss* for the year ended December 31, 2025 are presented in the following table (in millions):

---

| | |
|:---|:---|
| | **Cash Flow Hedge** |
| Balance as of December 31, 2024 | $(0.2) |
| Unrealized gain recognized in other comprehensive income, net of tax | **0.2** |
| Balance as of December 31, 2025 | $**—** |

---

The fair value of derivative assets and liabilities within the Consolidated Balance Sheets are presented in the following table (in millions):

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Other current liabilities | $**—** | $(0.3) |
| Total | $**—** | $(0.3) |

---

The fair value of the Company's derivative instrument was determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, *Summary of Significant Accounting Policies—Fair Value Measurements*.

**13. Contingencies and Other Commitments**

Enhabit operates in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against the Company. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect the Company's financial position, results of operations, and cash flows in a given period.

There were no claims made against the Company that are probable of loss and reasonably estimable as liabilities within *Other current liabilities* in the Consolidated Balance Sheet as of December 31, 2025.

In the first quarter of 2026, the Company, along with Encompass Health Corporation ("EHC"), collected $43.1 million, which, has been divided substantially equally between them, in full satisfaction of their claims for attorney's fees and mitigation damages in the Delaware Court of Chancery against a former officer, a senior partner of Vistria Group and a managing director of Nautic Partners. These amounts related to the December 2024 ruling in favor of Enhabit and EHC, entered by the Delaware Court of Chancery in the lawsuit styled Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al. This settlement will result in the recognition of a gain in the first quarter of 2026.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

***Other Commitments***

Enhabit is a party to service and other contracts in connection with conducting business. Minimum amounts due under these agreements are $40.9 million in 2026, $23.0 million in 2027, and $4.5 million in 2028 and thereafter. These contracts primarily relate to medical and durable medical equipment used in the two reporting segments, and business and software licensing and support. Certain of these agreements include variable arrangements, such as the cost to the supplier plus a designated mark-up percentage, or a fixed rate per average patient count per month in the two reportable segments.

**14. Segment Reporting**

Enhabit's two reportable segments, Home Health and Hospice, are based on the major types of services provided by the Company, as described below. The Chief Executive Officer, who is also the Chief Operating Decision Maker, uses these segment groupings and the results of each segment, measured by adjusted earnings before interest, taxes, depreciation, and amortization ("Segment Adjusted EBITDA") to evaluate performance and allocate resources, primarily during the annual budget process and regular operational performance reviews. Segment assets are not reviewed by the Chief Operating Decision Maker and therefore are not disclosed below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Home Health* - Enhabit operates home health agencies in 33 states, with a concentration in the southern half of the United States. As of December 31, 2025, the Company operates 249 home health agencies. Enhabit is the sole owner of 238 of these locations. The Company retains 50.0% to 81.0% ownership in the remaining 11 jointly owned locations. Home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Hospice* - Enhabit's hospice operations represent one of the nation's largest providers of Medicare-certified hospice services. The Company operates hospice provider locations in 25 states, with a concentration in the southern half of the United States. As of December 31, 2025, the Company operates 117 hospice provider locations. Enhabit is the sole owner of 113 of these locations. The Company retains 50.0% to 90.0% ownership in the remaining four jointly owned locations. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself.

The accounting policies of the reportable segments are the same as those described in Note 1, *Summary of Significant Accounting Policies*. All revenues for services are generated through external customers. See Note 1, *Summary of Significant Accounting Policies—Net Service Revenue*, for the disaggregation of revenues. No corporate overhead is allocated to either of the reportable segments. Other cost of service is comprised of third-party services and other individually insignificant costs in the Home Health segment. Other cost of service is comprised of medical director, skilled nursing facilities and other individually insignificant costs in the Hospice segment. Other general and administrative expenses is comprised of licensing fees and other individually insignificant fees for both the Home Health and Hospice segments.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

Selected financial information for the reportable segments is as follows (in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Home Health** | **Home Health** | **Home Health** | **Hospice** | **Hospice** | **Hospice** |
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| Net service revenue | $**813.8** | $824.8 | $850.1 | $**246.2** | $210.0 | $196.2 |
| Labor | **390.1** | 389.5 | 398.6 | **71.9** | 63.8 | 62.5 |
| Supplies and pharmacy | **9.5** | 9.9 | 10.8 | **21.8** | 19.4 | 17.1 |
| Travel | **20.8** | 21.8 | 22.8 | **5.1** | 4.7 | 4.8 |
| Other cost of service | **6.1** | 7.0 | 6.8 | **14.9** | 14.7 | 12.2 |
| &nbsp;&nbsp;Total cost of service, excluding depreciation and amortization | **426.5** | 428.2 | 439.0 | **113.7** | 102.6 | 96.6 |
| General and administrative salaries | **188.6** | 193.2 | 196.9 | **59.7** | 54.0 | 52.2 |
| Other general and administrative expenses | **48.7** | 42.2 | 43.7 | **12.5** | 11.5 | 11.2 |
| &nbsp;&nbsp;Total general and administrative expenses | **237.3** | 235.4 | 240.6 | **72.2** | 65.5 | 63.4 |
| Other income | **—** |  | (0.2) | **—** |  |  |
| Net income attributable to noncontrolling interests | **1.5** | 1.8 | 1.4 | **0.5** | 0.4 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment Adjusted EBITDA | $**148.5** | $159.4 | $169.3 | $**59.8** | $41.5 | $36.1 |

---

Total segment reconciliations (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| **Total Segment Adjusted EBITDA** | $**208.3** | $200.9 | $205.4 |
| Non-segment general and administrative expenses | **(107.4)** | (113.3) | (128.7) |
| Interest expense, net | **(33.8)** | (42.9) | (43.0) |
| Depreciation and amortization | **(22.5)** | (31.5) | (30.9) |
| Gain (loss) on sale of investment and disposal of assets | **19.1** |  |  |
| Impairment of goodwill | **(44.7)** | (161.7) | (85.8) |
| Impairment of intangible assets | **(3.0)** |  |  |
| Stock-based compensation expense | **(16.6)** | (11.7) | (8.9) |
| Net income attributable to noncontrolling interests | **2.0** | 2.2 | 1.5 |
| &nbsp;&nbsp;**Income (loss) before income taxes and noncontrolling interests** | $**1.4** | $(158.0) | $(90.4) |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

Additional detail regarding the revenues of the operating segments by payer type follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Home Health: |  |  |  |
| &nbsp;&nbsp;Medicare | $**455.2** | $484.6 | $557.4 |
| &nbsp;&nbsp;Non-Medicare | **350.8** | 331.2 | 283.0 |
| &nbsp;&nbsp;Private duty<sup>(1)</sup> | **7.8** | 9.0 | 9.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Home Health | **813.8** | 824.8 | 850.1 |
| Hospice | **246.2** | 210.0 | 196.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total net service revenue** | $**1060.0** | $1034.8 | $1046.3 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Private duty represents long-term comprehensive hourly nursing medical care.

**15. Related Party Transactions**

***Separation From Encompass***

In connection with the Separation, Enhabit entered into several agreements with Encompass that govern the relationship of the parties following the Distribution, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement, and an Employee Matters Agreement. The Separation and Distribution Agreement contains provisions that, among other things, relate to (i) assets, liabilities, and contracts to be transferred, assumed, and assigned to each of Enhabit and Encompass as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of the Enhabit business with Enhabit and financial responsibility for the obligations and liabilities of Encompass's remaining business with Encompass, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation between Enhabit and Encompass of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Distribution, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Enhabit's and Encompass's obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of Enhabit's business and Encompass's business.

***Allocation of Corporate Expenses***

Historically Encompass provided the Company with certain services, including, but not limited to, executive oversight, treasury, legal, accounting, human resources, tax, internal audit, financial reporting, information technology and investor relations. After the Separation, some of these services continued to be provided by Encompass to the Company on a temporary basis under the Transition Services Agreement. As of April 1, 2024, these functions are being performed using the Company's own resources or third-party providers. In addition, the Company's employees have historically participated in Encompass's various stock-based plans as discussed in Note 9, *Stock-Based Payments*.

For information related to the Tax Sharing Agreement with Encompass, see Note 11, *Income Taxes*.

***Data Analytics Investment***

During 2019, Enhabit made a $2.0 million investment in Medalogix, LLC, a healthcare predictive data and analytics company. During 2021, Medalogix became a wholly-owned subsidiary of TVG Logic Holdings, LLC ("TVG"), which resulted in the Company obtaining a minority equity investment in TVG in exchange for its investment in Medalogix. This investment was accounted for under the measurement alternative for investments.

On March 19, 2025 (the "Transaction Date"), Medalogix was combined with Forcura in a private equity-backed transaction (the "Transaction"). In connection with the Transaction, the Company sold its investment interest in TVG for approximately $21.0 million. The Transaction resulted in the Company recording a gain on sale of investment of approximately $19.3 million in *Other (income) expense* on the audited Consolidated Statement of Income. On

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**ENHABIT, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(CONTINUED)

March 31, 2025, the Company used $20.0 million of the proceeds from the Transaction to reduce debt under the Credit Agreement. See also Note 8, *Long-Term Debt*.

As of the Transaction Date, Medalogix was no longer a related party of the Company. During 2025, 2024, and 2023, the Company incurred costs of approximately $1.2 million, $4.9 million, and $4.5 million, respectively, in connection with the usage of Medalogix's analytics platforms. These costs are included in *Cost of service, excluding depreciation and amortization*, and *General and administrative expenses* in the Consolidated Statements of Income.

**16. Supplemental Cash Flow Information**

The following table provides supplemental cash flow information and disclosures of non-cash investing and financing activities for the years ended December 31, 2025, 2024, and 2023 (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Supplemental cash flow disclosures: |  |  |  |
| &nbsp;&nbsp;Income taxes paid (net of refunds received) | $**1.4** | $(0.8) | $(8.2) |
| &nbsp;&nbsp;Cash paid for interest | $**(32.4)** | $(42.7) | $(40.6) |
| Supplemental cash flow disclosures of non-cash investing and financing activities: |  |  |  |
| &nbsp;&nbsp;Property and equipment additions through finance leases | $**0.1** | $5.5 | $3.8 |
| &nbsp;&nbsp;Operating lease additions | $**12.6** | $11.0 | $31.6 |

---

The following table details supplemental cash flow disclosures related to the reconciliation of cash and cash equivalents and restricted cash balances (in millions):

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| Cash, cash equivalents, and restricted cash reconciliation: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $**43.6** | $28.4 |
| &nbsp;&nbsp;Restricted cash | **1.9** | 1.9 |
| Cash, cash equivalents, and restricted cash at end of period | $**45.5** | $30.3 |

---

**17. Subsequent Events**

The Company has evaluated subsequent events through the date at which the consolidated financial statements were issued. The events below occurred subsequent to December 31, 2025, and accordingly are not reflected in the accompanying consolidated financial statements.

In the first quarter of 2026, the Company, along with EHC collected amounts under claims made against certain third parties. See Note 13, *Contingencies and Other Commitments,* for more information.

On February 26, 2026, the Company entered into an amended and restated credit agreement. See Note 8, *Long-Term Debt* for more information.

On February 22, 2026, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which the Company will be acquired by Anchor Parent, LLC, a Delaware limited liability company ("Parent"). Pursuant to the Merger Agreement, Anchor Merger Sub, Inc., a Delaware corporation ("Merger Sub") and a wholly owned subsidiary of Parent, will be merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent (the "Surviving Corporation"). Parent and Merger Sub are affiliates of funds advised by Kinderhook Industries, LLC (or an affiliate thereof). See Enhabit's Current Report on Form 8-K filed on February 23, 2026 for more information regarding the Merger Agreement.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**EXHIBIT INDEX**

The following documents are filed as exhibits hereto:

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit Description** |
| 2.1 | <u>[Separation and Distribution Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc. (incorporated by reference to Exhibit 2.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on July 5, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122025027/ny20003604x14_ex2-1.htm)</u> |
| 2.2 | <u>[Transition Services Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc. (incorporated by reference to Exhibit 2.2 to Enhabit, Inc.'s Current Report on Form 8-K filed on July 5, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122025027/ny20003604x14_ex2-2.htm)</u> |
| 2.3 | <u>[Second Amendment to Transition Service Agreement, dated as of September 1, 2023, by and between Encompass Health Corporation and Enhabit, Inc. (incorporated by reference to Exhibit 2.3 to Enhabit, Inc.'s Annual Report on Form 10-K filed on March 15, 2024).](https://www.sec.gov/Archives/edgar/data/1803737/000180373724000041/exhibit-23xenhabitincxseco.htm)</u> |
| 2.4 | <u>[Tax Matters Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc. (incorporated by reference to Exhibit 2.3 to Enhabit, Inc.'s Current Report on Form 8-K filed on July 5, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122025027/ny20003604x14_ex2-3.htm)</u> |
| 2.5 | <u>[Employee Matters Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc. (incorporated by reference to Exhibit 2.4 to Enhabit, Inc.'s Current Report on Form 8-K filed on July 5, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122025027/ny20003604x14_ex2-4.htm)</u> |
| 2.6 | <u>[Agreement and Plan of Merger, dated February 22, 2026, by and among Enhabit, Inc., Anchor Parent, LLC and Anchor Merger Sub, Inc](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[.](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[(incorporated by reference to Exhibit](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[2](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on February 23, 2026).](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)</u> |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of Enhabit, Inc. (incorporated by reference to Exhibit 3.1.2 to Enhabit, Inc.'s Current Report on Form 8-K filed on July 5, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122025027/ny20003604x14_ex3-12.htm)</u> |
| 3.2 | <u>[Amended and Restated Bylaws of Enhabit, Inc. (incorporated by reference to Exhibit 3.2 to Enhabit, Inc.'s Quarterly Report on Form 10-Q filed on November 14, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000180373722000119/ehab10q9_30x22ex32.htm)</u> |
| 4.1 | <u>[Description of Enhabit, Inc.'s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.1 to Enhabit, Inc.'s Annual Report on Form 10-K filed on April 14, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000051/exhibit-41xenhabitxdescrip.htm)</u> |
| 10.1\* | <u>[Enhabit, Inc. 2022 Omnibus Performance Incentive Plan (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on July 5, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122025027/ny20003604x14_ex10-1.htm)</u> |
| 10.2\* | <u>[Enhabit, Inc. Executive Severance Plan (Amended and Restated as of February 22, 2023) (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on February 28, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000010/enhabit-arexecutiveseveran.htm)</u> |
| 10.3\* | <u>[Enhabit, Inc. Executive Change in Control Benefits Plan (Amended and Restated as of February 22, 2023) (incorporated by reference to Exhibit 10.2 to Enhabit, Inc.'s Current Report on Form 8-K filed on February 28, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000010/enhabit-arexectuivechangei.htm)</u> |
| 10.4\* | <u>[Form of Restricted Stock Unit Agreement pursuant to the Enhabit, Inc. 2022 Omnibus Performance Incentive Plan (incorporated by reference to Exhibit 10.5 to Enhabit, Inc.'s Annual Report on Form 10-K filed on April 14, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000051/exhibit-105xenhabitincxfor.htm)</u> |
| 10.5\* | <u>[Form of Performance-Based Restricted Stock Unit Agreement pursuant to the Enhabit, Inc. 2022 Omnibus Performance Incentive Plan (incorporated by reference to Exhibit 10.6 to Enhabit, Inc.'s Annual Report on Form 10-K filed on April 14, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000051/exhibit-106xenhabitincxfor.htm)</u> |
| 10.6\* | <u>[Form of Non-Qualified Stock Option Agreement pursuant to the Enhabit, Inc. 2022 Omnibus Performance Incentive Plan (incorporated by reference to Exhibit 10.7 to Enhabit, Inc.'s Annual Report on Form 10-K filed on April 14, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000051/exhibit-107xenhabitincxfor.htm)</u> |
| 10.7\* | <u>[Form of Enhabit, Inc. Employee Restricted Stock Award Agreement (Enhabit, Inc. 2022 Omnibus Performance Incentive Plan) (incorporated by reference to Exhibit 10.7 to Enhabit Inc.'s Amendment No. 1 to Form 10 filed on June 9, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122022486/ny20003604x7_ex10-7.htm)</u> |
| 10.8\* | <u>[Form of Enhabit, Inc. Restricted Stock Unit Agreement (Enhabit, Inc. 2022 Omnibus Performance Incentive Plan) (incorporated by reference to Exhibit 10.6 to Enhabit, Inc.'s Amendment No. 1 to Form 10 filed on June 9, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122022486/ny20003604x7_ex10-6.htm)</u> |
| 10.9\* | <u>[Enhabit, Inc. 2025 Equity and Incentive Plan (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on June 26, 2025).](https://www.sec.gov/Archives/edgar/data/1803737/000180373725000121/enhabitinc2025equityandinc.htm)</u> |
| 10.10\* | <u>[Form of Restricted Stock Unit Agreement – Directors pursuant to the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to Enhabit, Inc.'s Quarterly Report on Form 10-Q filed on August 7, 2025).](https://www.sec.gov/Archives/edgar/data/1803737/000180373725000155/exhibit102-formofrestricte.htm)</u> |
| 10.11\* | <u>[Form of Restricted Stock Units Agreement (Special Retention Grant), pursuant to the 2025 Enhabit, Inc. Equity and Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to Enhabit, Inc.'s Current Report on Form 8-K filed on August 6, 2025).](https://www.sec.gov/Archives/edgar/data/1803737/000119312525174474/d26299dex102.htm)</u> |
| 10.12\*† | <u>[Form of Restricted Stock Unit Agreement pursuant to the Enhabit, Inc. 2025 Equity and Incentive Plan.](exhibit-1012enhabitincxfor.htm)</u> |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

---

| | |
|:---|:---|
| 10.13\*† | <u>[Form of Performance-Based Restricted Stock Unit Agreement pursuant to the Enhabit, Inc. 2025 Equity and Incentive Plan.](exhibit-1013xenhabitincxfo.htm)</u> |
| 10.14\* | <u>[Enhabit, Inc. Director Deferred Compensation Plan (incorporated by reference to Exhibit 10.2 to Enhabit, Inc.'s Quarterly Report on Form 10-Q filed on November 8, 2024).](https://www.sec.gov/Archives/edgar/data/1803737/000180373724000194/exhibit102-2024directordef.htm)</u> |
| 10.15\* | <u>[Form of Restrictive Covenants Agreement (incorporated by reference to Exhibit 10.5 to Enhabit, Inc.'s Amendment No. 1 to Form 10 filed on June 9, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122022486/ny20003604x7_ex10-5.htm)</u> |
| 10.16\* | <u>[Transition, Separation and Release Agreement between Advanced Homecare Management, LLC d/b/a Enhabit Home Health & Hospice and Barbara A. Jacobsmeyer, dated August 5, 2025 (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on August 6, 2025).](https://www.sec.gov/Archives/edgar/data/1803737/000119312525174474/d26299dex101.htm)</u> |
| 10.17\* | <u>[Form of Restrictive Covenants Agreement by and between the Company and Ryan Solomon (incorporated by reference to Exhibit 10.3 to Enhabit, Inc.'s Current Report on Form 8-K filed on November 7, 2024).](https://www.sec.gov/Archives/edgar/data/0001803737/000180373724000190/exhibit103-formofrestricti.htm)</u> |
| 10.18 | <u>[Separation and Release Agreement between Advanced Homecare Management, Inc. d/b/a Enhabit Home Health & Hospice and Crissy Carlisle, dated August 6, 2024 (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/1803737/000180373724000154/separationandreleaseagreem.htm)</u> |
| 10.19\* | <u>[Form of Cash Retention Bonus Letter Agreement (Executive Officers) (incorporated by reference to Exhibit 10.3 to Enhabit, Inc.'s Current Report on Form 8-K filed on August 6, 2025).](https://www.sec.gov/Archives/edgar/data/1803737/000119312525174474/d26299dex103.htm)</u> |
| 10.20 | <u>[Credit Agreement, dated as of June 1, 2022, by and among Enhabit, Inc., Wells Fargo Bank, N.A., as administrative agent, collateral agent and swingline lender, and various other lenders from time to time party thereto (incorporated by reference to Exhibit 10.4 to Enhabit, Inc.'s Amendment No. 1 to Form 10 filed on June 9, 2022).](https://www.sec.gov/Archives/edgar/data/1803737/000114036122022486/ny20003604x7_ex10-4.htm)</u> |
| 10.21 | <u>[First Amendment to Credit Agreement, dated as of June 27, 2023, by and among Enhabit, Inc., Wells Fargo Bank, N.A., as administrative agent, collateral agent, and swingline lender, and various other lenders from time to time party thereto (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on June 28, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000110/exhibit101-wellsfargoxenha.htm)</u> |
| 10.22 | <u>[Limited Waiver to the Credit Agreement, dated as of September 29, 2023, by and among Enhabit, Inc., Wells Fargo Bank, as administrative agent, collateral agent, and swingline lender, and various other lenders (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on October 2, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000150/exhibit101-wellsfargoxenha.htm)</u> |
| 10.23 | <u>[Second Amendment to the Credit Agreement, dated as of November 3, 2023, by and among Enhabit, Inc., Wells Fargo Bank, as administrative agent, collateral agent, and swingline lender, and various other lenders (incorporated by reference to Exhibit 10.1 to Enhabit, Inc.'s Current Report on Form 8-K filed on November 7, 2023).](https://www.sec.gov/Archives/edgar/data/1803737/000180373723000158/exhibit101-secondamendment.htm)</u> |
| 10.24 | <u>[Amended and Restated Credit Agreement, dated as of](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[February](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[26](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[, 2026, by and among Enhabit, Inc., Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender, and each issuing bank and lender from time to time party thereto](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[(inc](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[orporated by reference to E](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[xhibit 10.1 to Enhabit, Inc](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)['](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[s Current Report on Form 8-K filed on](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[March 3, 2026)](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)[.](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000009/amendedandrestatedcreditag.htm)</u> |
| 10.25 | <u>[Form of Voting and Support Agreement by and among Anchor Parent, LLC, Anchor Merger Sub, Inc. and the stockholders party thereto (included as Exhibit C in Exhibit 2.1)](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[(incorporated](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[by reference to Exhibit 10.1 to Enhabit, Inc.](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)['](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[s Cu](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[rrent Report o](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[n Form 8-K filed on February 23, 2026)](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)[.](https://www.sec.gov/Archives/edgar/data/1803737/000119312526064210/d29040dex21.htm)</u> |
| 19.1† | <u>[Enhabit, Inc. Insider Trading Policy, amended and restated, February 19, 2025.](exhibit-191xenhabitincxins.htm)</u> |
| 21.1† | <u>[List of Subsidiaries.](exhibit211-enhabitincxlist.htm)</u> |
| 23.1† | <u>[Consent of PricewaterhouseCoopers LLP.](exhibit-231xconsentofprice.htm)</u> |
| 24.1† | <u>[Power of Attorney (included on signature page to this Form 10-K).](#i37ed9800c8d04a6988fc71aea423e4a2_283)</u> |
| 31.1† | <u>[Certification by the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit-311xenhabitincx302.htm)</u> |
| 31.2† | <u>[Certification by the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit-312xenhabitincx302.htm)</u> |
| 32.1+ | <u>[Certification by the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit-321xenhabitincx906.htm)</u> |
| 32.2+ | <u>[Certification by the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit-322xenhabitincx906.htm)</u> |
| 97.1 | <u>[Enhabit, Inc. Incentive Compensation Recoupment Policy, dated December 1, 2023 (incorporated by reference to Exhibit 97.1 to Enhabit, Inc.'s Annual Report on Form 10-K filed on March 15, 2024).](https://www.sec.gov/Archives/edgar/data/1803737/000180373724000041/exhibit971-enhabitincxreco.htm)</u> |
| 101.INS† | Inline XBRL Instance Document. |
| 101.SCH† | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL† | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF† | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB† | Inline XBRL Taxonomy Extension Label Linkbase Document. |

---

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

101. PRE† Inline XBRL Taxonomy Extension Presentation Linkbase Document. <br> 104 Cover Page Interactive Data File.

† Filed herewith as an exhibit.

+ Furnished herewith as an exhibit.

\* Indicates management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

**ITEM 16. FORM 10-K SUMMARY**

None.

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **ENHABIT, INC.** | **ENHABIT, INC.** |
| By: | /s/ Ryan Solomon |
| Name: | Ryan Solomon |
| Title: | Chief Financial Officer |
| Date: | March 4, 2026 |

---

[Signatures continue on the following page]

------

<u>[**Table of Contents**](#i37ed9800c8d04a6988fc71aea423e4a2_10)</u>

---

| | | |
|:---|:---|:---|
| **POWER OF ATTORNEY** | **POWER OF ATTORNEY** | **POWER OF ATTORNEY** |
| &nbsp;&nbsp;&nbsp;&nbsp; Each person whose signature appears below hereby constitutes and appoints Dylan C. Black his or her true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments and supplements to this Annual Report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof. | &nbsp;&nbsp;&nbsp;&nbsp; Each person whose signature appears below hereby constitutes and appoints Dylan C. Black his or her true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments and supplements to this Annual Report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof. | &nbsp;&nbsp;&nbsp;&nbsp; Each person whose signature appears below hereby constitutes and appoints Dylan C. Black his or her true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments and supplements to this Annual Report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof. |
| &nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated: | &nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated: | &nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated: |
| **Signature** | **Title** | **Date** |
| /s/ Barb Jacobsmeyer | President and Chief Executive Officer and Director<br>(Principal Executive Officer) |  |
| /s/ Barb Jacobsmeyer | President and Chief Executive Officer and Director<br>(Principal Executive Officer) | March 4, 2026 |
| Barb Jacobsmeyer |  |  |
| /s/ Ryan Solomon | Chief Financial Officer<br>(Principal Financial Officer) |  |
| /s/ Ryan Solomon | Chief Financial Officer<br>(Principal Financial Officer) | March 4, 2026 |
| Ryan Solomon |  |  |
| /s/ Collin McQuiddy | Chief Accounting Officer<br>(Principal Accounting Officer) |  |
| /s/ Collin McQuiddy | Chief Accounting Officer<br>(Principal Accounting Officer) | March 4, 2026 |
| Collin McQuiddy |  |  |
| /s/ Jeffrey W. Bolton | Director, Chairperson |  |
| /s/ Jeffrey W. Bolton | Director, Chairperson | March 4, 2026 |
| Jeffrey W. Bolton |  |  |
| /s/ Tina L. Brown-Stevenson | Director |  |
| /s/ Tina L. Brown-Stevenson | Director | March 4, 2026 |
| Tina L. Brown-Stevenson |  |  |
| /s/ Charles M. Elson | Director |  |
| /s/ Charles M. Elson | Director | March 4, 2026 |
| Charles M. Elson |  |  |
| /s/ Erin P. Hoeflinger | Director |  |
| /s/ Erin P. Hoeflinger | Director | March 4, 2026 |
| Erin P. Hoeflinger |  |  |
| /s/ Stuart McGuigan | Director |  |
| /s/ Stuart McGuigan | Director | March 4, 2026 |
| Stuart McGuigan |  |  |
| /s/ Mark W. Ohlendorf | Director |  |
| /s/ Mark W. Ohlendorf | Director | March 4, 2026 |
| Mark W. Ohlendorf |  |  |
| /s/ Stephan S. Rodgers | Director |  |
| /s/ Stephan S. Rodgers | Director | March 4, 2026 |
| Stephan S. Rodgers |  |  |
| /s/ Greg S. Rush | Director |  |
| /s/ Greg S. Rush | Director | March 4, 2026 |
| Greg S. Rush |  |  |
| /s/ Barry Schochet | Director |  |
| /s/ Barry Schochet | Director | March 4, 2026 |
| Barry Schochet |  |  |

---

## Exhibit 10.12

**Exhibit 10.12**

**ENHABIT, INC.**

**NOTICE OF GRANT OF RESTRICTED STOCK UNITS**

**(Employees)**

&nbsp;&nbsp;&nbsp;&nbsp;Enhabit, Inc. (the "<u>Company</u>") hereby grants to the Participant the number of Restricted Stock Units ("<u>RSUs</u>") set forth below under the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan (the "<u>Plan</u>"). The RSUs are subject to all of the terms and conditions in this Notice of Grant of Restricted Stock Units (this "<u>Grant Notice</u>"), in the Restricted Stock Units Agreement attached hereto (the "<u>Agreement</u>") and in the Plan. Capitalized terms used, but not otherwise defined, in this Grant Notice will have the meanings given to such terms in the Plan or the Agreement, and the Plan and the Agreement are hereby incorporated by reference into this Grant Notice. If there are any inconsistencies between this Grant Notice or the Agreement and the Plan, the terms of the Plan shall govern.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Participant:** | ________________________ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Type of Grant:** | Restricted Stock Units |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Date of Grant:** | ________________________ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Number of RSUs:** | ________________________ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Vesting Schedule:** | Subject to the conditions set forth in the Agreement, including but not limited to the Participant's continuous employment with the Company or a Subsidiary until the applicable vesting date, the RSUs shall vest as follows: [<u>__________</u>], [<u>__________</u>] and [<u>__________</u>] (each such date, a "Vesting Date"). |

---

&nbsp;&nbsp;&nbsp;&nbsp;

NAI-5001863123v4

------

**ENHABIT, INC.**

**<u>Restricted Stock Units Agreement</u>**

Enhabit, Inc. (the "<u>Company</u>") has granted, pursuant to the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan (the "<u>Plan</u>"), to the Participant named in the Notice of Grant of Restricted Stock Units (the "<u>Grant Notice</u>") to which this Restricted Stock Units Agreement is attached (together with the Grant Notice, this "<u>Agreement</u>") an award of Restricted Stock Units as set forth in such Grant Notice, subject to the terms and conditions set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Certain Definitions</u>**. Capitalized terms used, but not otherwise defined, in this Agreement will have the meanings given to such terms in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Grant of RSUs</u>**. Subject to and upon the terms, conditions and restrictions set forth in this Agreement and in the Plan, the Company has granted to the Participant, as of the Date of Grant, the number of RSUs set forth in the Grant Notice. Each RSU shall represent the right of the Participant to receive one share of Common Stock subject to and upon the terms and conditions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Restrictions on Transfer of RSUs</u>**. Subject to Section 15 of the Plan, neither the RSUs evidenced hereby nor any interest therein or in the shares of Common Stock underlying such RSUs shall be transferable prior to payment to the Participant pursuant to **<u>Section 6</u>** hereof other than by will or pursuant to the laws of descent and distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Vesting of RSUs</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The RSUs shall vest in accordance with the Vesting Schedule set forth in the Grant Notice (the period from the Date of Grant until the last applicable Vesting Date, the "<u>Vesting Period</u>"). Any RSUs that do not so become vested will be forfeited, including, except as provided in **<u>Sections</u> <u>4(b)</u>**, **<u>4(c)</u>** or **<u>4(d)</u>** below, if the Participant ceases to be continuously employed by the Company or a Subsidiary for any reason prior to the end of the Vesting Period. For purposes of this Agreement, "continuously employed" (or substantially similar terms) means the absence of any interruption or termination of the Participant's employment with the Company or a Subsidiary. Continuous employment shall not be considered interrupted or terminated in the case of transfers between locations of the Company and its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding **<u>Section 4(a)</u>** above, upon any termination of the Participant's employment as a result of the Participant's death or Disability, in each case prior to the end of the Vesting Period, the RSUs (to the extent not previously vested) shall vest in full.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding **<u>Section 4(a)</u>** above, if the Participant's employment terminates as a result of Retirement prior to the end of the Vesting Period, then a pro-rata portion of the RSUs shall vest, with such pro-rata portion determined by multiplying (i) the total number of RSUs by (ii) a fraction, the numerator of which is the number of

&nbsp;&nbsp;&nbsp;&nbsp;

------

full months that have elapsed from the Date of Grant until the date of such termination and the denominator of which is the number of full months in the Vesting Period, and subtracting from such amount the number of RSUs (if any) that previously vested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding **<u>Section 4(a)</u>** above, in the event of a Change in Control that occurs prior to the end of the Vesting Period, the RSUs shall become vested and payable in accordance with **<u>Section 5</u>** below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Effect of a Change in Control</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding **<u>Section 4(a)</u>** above, if at any time before the end of the Vesting Period or forfeiture of the RSUs, and while the Participant is continuously employed by the Company or a Subsidiary, a Change in Control occurs, then all of the RSUs (to the extent not previously vested) will become vested, except to the extent that a Replacement Award is provided to the Participant in accordance with **<u>Section 5(b)</u>** to continue, replace or assume the RSUs covered by this Agreement (the "<u>Replaced Award</u>"), immediately prior to (and contingent upon) the Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, a "<u>Replacement Award</u>" means an award (i) of the same type (*i.e*., time-based restricted stock units) as the Replaced Award, (ii) that has a value at least equal to the value of the Replaced Award, (iii) that relates to publicly traded equity securities of the Company or its successor in the Change in Control or another entity that is affiliated with the Company or its successor following the Change in Control, (iv) if the Participant is subject to U.S. federal income tax under the Code, the tax consequences of which to such Participant under the Code are not less favorable to such Participant than the tax consequences of the Replaced Award, and (v) the other terms and conditions of which are not less favorable to the Participant than the terms and conditions of the Replaced Award (including the provisions that would apply in the event of a subsequent termination of employment or change in control). A Replacement Award may be granted only to the extent it does not result in the Replaced Award or Replacement Award failing to comply with or be exempt from Section 409A of the Code. Without limiting the generality of the foregoing, the Replacement Award may take the form of a continuation of the Replaced Award if the requirements of the two preceding sentences are satisfied. The determination of whether the conditions of this paragraph are satisfied will be made by the Committee, as constituted immediately before the Change in Control, in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;If, within two years after receiving a Replacement Award, the Participant experiences a termination of employment with the Company or a Subsidiary (or any of their successors) (as applicable, the "<u>Successor</u>") by reason of a termination by the Successor without Cause or by the Participant for Good Reason during the remaining vesting period for the Replacement Award, the Replacement Award shall immediately vest.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Form and Time of Payment of RSUs</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the RSUs, after and to the extent they have become vested, shall be made in the form of one share of Common Stock for each vested RSU. Except as provided in **<u>Section 6(b)</u>**, such payment shall be made within thirty (30) days after the applicable Vesting Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding **<u>Section 6(a)</u>**, to the extent the RSUs are vested on the dates set forth below and have not previously been settled, payment for such vested RSUs shall be made within thirty (30) days after such date:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;the date of a Change in Control, provided such Change in Control qualifies as a permissible date of distribution under Section 409A(a)(2)(A)(v) of the Code; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;subject to Section 17 of the Plan, the date of the Participant's "separation from service" for purposes of Section 409A(a)(2)(A)(i) of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Except to the extent permitted by Section 409A of the Code and approved by the Committee, no shares of Common Stock may be issued to the Participant at a time earlier than otherwise expressly provided in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;The Company's obligations to the Participant with respect to the RSUs will be satisfied in full upon the issuance of shares of Common Stock corresponding to such RSUs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;**<u>No Dividend Equivalents; Voting and Other Rights</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Participant shall have no rights of ownership in the shares of Common Stock underlying the RSUs, no rights to dividends with respect to such shares, and no right to vote the shares of Common Stock underlying the RSUs until the date on which the shares of Common Stock underlying the RSUs are issued or transferred to the Participant pursuant to **<u>Section 6</u>** above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The obligation of the Company under this Agreement will be merely that of an unfunded and unsecured promise of the Company to deliver shares of Common Stock in the future, and the rights of the Participant will be no greater than that of an unsecured general creditor. No assets of the Company will be held or set aside as security for the obligations of the Company under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Adjustments</u>**. The number of shares of Common Stock issuable for each RSU and the other terms and conditions of the grant evidenced by this Agreement are subject to mandatory adjustment, including as provided in Section 11 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Taxes</u>**. To the extent that the Company is required to withhold federal, state, local, or foreign taxes or other amounts in connection with any payment made or benefit realized by the Participant under this Agreement, and the amounts available to the Company for such withholding are insufficient, it shall be a condition to the receipt of such

------

payment or the realization of such benefit that the Participant make arrangements satisfactory to the Company for payment of the balance of such taxes or other amounts required to be withheld. If the Participant's benefit is to be received in the form of shares of Common Stock, then, unless otherwise determined by the Committee, the Company will withhold shares of Common Stock having a value equal to the amount required to be withheld. The shares of Common Stock used for tax or other withholding will be valued at an amount equal to the fair market value of such shares of Common Stock on the date the benefit is to be included in the Participant's income. The market value of Common Stock to be withheld pursuant to this **<u>Section 9</u>** to satisfy applicable withholding taxes or other amounts may exceed the minimum amount of taxes required to be withheld in accordance with procedures established by the Company, including pursuant to the aggregate method of withholding. Notwithstanding any other provision of this Agreement, the Company shall not be obligated to guarantee any particular tax result for the Participant with respect to any payment provided to the Participant hereunder, and the Participant shall be responsible for any taxes imposed on the Participant with respect to any such payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Compliance with Law</u>**. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws; <u>provided</u>, <u>however</u>, that notwithstanding any other provision of the Plan and this Agreement, the Company shall not be obligated to issue any shares of Common Stock pursuant to this Agreement if the issuance thereof would result in a violation of any such law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Compliance With Section 409A of the Code</u>**. To the extent applicable, it is intended that this Agreement and the Plan comply with the provisions of Section 409A of the Code. This Agreement and the Plan shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of the Participant). Notwithstanding the foregoing, the Company is not guaranteeing any particular tax outcome, and the Participant shall remain solely liable for any and all tax consequences associated with the RSUs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Interpretation</u>**. Any reference in this Agreement to Section 409A of the Code will also include any proposed, temporary or final regulations, or any other guidance, promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;**<u>No Right to Future Awards or Employment</u>.** The grant of the RSUs under this Agreement to the Participant is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards. The grant of the RSUs and any payments made hereunder will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law. Nothing contained in this Agreement shall confer upon the Participant any right to be employed or remain employed by the Company or any of its Subsidiaries, nor limit or affect in any manner the right of the Company or any of its Subsidiaries to terminate the employment or adjust the compensation of the Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Relation to Other Benefits</u>**. Any economic or other benefit to the Participant under this Agreement or the Plan shall not be taken into account in determining any benefits to

------

which the Participant may be entitled under any other compensatory arrangement maintained by the Company or any of its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Amendments</u>**. Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; <u>provided</u>, <u>however</u>, that no amendment shall adversely affect the rights of the Participant under this Agreement without the Participant's written consent, and the Participant's consent shall not be required to an amendment that is deemed necessary by the Company to ensure compliance with Section 409A of the Code or Section 10D of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Severability</u>**. In the event that one or more of the provisions of this Agreement shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Relation to Plan</u>**. The RSUs granted under this Agreement and all of the terms and conditions hereof are subject to all of the terms and conditions of the Plan. In the event of any inconsistency between this Agreement and the Plan, the terms of the Plan will govern. The Committee acting pursuant to the Plan, as constituted from time to time, shall, except as expressly provided otherwise herein or in the Plan, have the right to determine any questions which arise in connection with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Compensation Recovery Policy</u>**. Notwithstanding anything in this Agreement to the contrary, the Participant acknowledges and agrees that this Agreement and the award described herein are subject to the terms and conditions of the Company's clawback policy (if any) as may be in effect from time to time and applicable to the Participant and the RSUs, including specifically to implement Section 10D of the Exchange Act and any applicable rules or regulations promulgated thereunder (including applicable rules and regulations of any national securities exchange on which the Common Stock may be traded) (the "<u>Compensation Recovery Policy</u>"), and that applicable sections of this Agreement and any related documents shall be superseded by and subject to the terms and conditions of the Compensation Recovery Policy from and after the effective date thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Electronic Delivery</u>**. The Company may, in its sole discretion, deliver any documents related to the RSUs and the Participant's participation in the Plan, or future awards that may be granted under the Plan, by electronic means or request the Participant's consent to participate in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Governing Law</u>**. This Agreement shall be governed by and construed with the internal substantive laws of the State of Delaware, without giving effect to any principle of law that would result in the application of the law of any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Successors and Assigns</u>**. Without limiting **<u>Section 3</u>** hereof, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs,

------

legal representatives and assigns of the Participant, and the successors and assigns of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Acknowledgement</u>**. The Participant acknowledges that the Participant (a) has received a copy of the Plan, (b) has had an opportunity to review the terms of this Agreement and the Plan, (c) understands the terms and conditions of this Agreement and the Plan and (d) agrees to such terms and conditions. Nothing in this Agreement prevents the Participant from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Counterparts</u>**. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same agreement.

## Exhibit 10.13

**Exhibit 10.13**

**ENHABIT, INC.**

**NOTICE OF GRANT OF PERFORMANCE-BASED RESTRICTED STOCK UNITS**

&nbsp;&nbsp;&nbsp;&nbsp;Enhabit, Inc. (the "<u>Company</u>") hereby grants to the Participant the target number of performance-based Restricted Stock Units ("<u>PRSUs</u>") set forth below under the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan (the "<u>Plan</u>"). The PRSUs are subject to all of the terms and conditions in this Notice of Grant of Performance-Based Restricted Stock Units (this "<u>Grant Notice</u>"), in the Performance-Based Restricted Stock Units Agreement attached hereto (the "<u>Agreement</u>") and in the Plan. Capitalized terms used, but not otherwise defined, in this Grant Notice will have the meanings given to such terms in the Plan or the Agreement, and the Plan and the Agreement are hereby incorporated by reference into this Grant Notice. If there are any inconsistencies between this Grant Notice or the Agreement and the Plan, the terms of the Plan shall govern.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Participant:** | ________________________________ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Type of Grant:** | Performance-based Restricted Stock Units |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Date of Grant:** | ________________________________ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Target Number of PRSUs:** | ________________________________ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Performance Period:** | [________________________________] |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Potential Payout %:** | From 0% to 200% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Vesting Terms:** | Subject to the terms and conditions set forth in the Agreement and in the Statement of Management Objectives delivered to Participant in connection with the award, the PRSUs shall become earned ("<u>Earned PRSUs</u>") to the extent that the Management Objectives for the PRSUs are achieved, as set forth or contemplated in the Statement of Management Objectives, provided (except as otherwise provided in the Agreement) that the Participant has remained in continuous employment with the Company or a Subsidiary through the last day of the Performance Period. |

---

------

**ENHABIT, INC.**

**<u>Performance-Based Restricted Stock Units Agreement</u>**

Enhabit, Inc. (the "<u>Company</u>") has granted, pursuant to the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan (the "<u>Plan</u>"), to the Participant named in the Notice of Grant of Performance-Based Restricted Stock Units (the "<u>Grant Notice</u>") to which this Performance-Based Restricted Stock Units Agreement is attached (together with the Grant Notice, this "<u>Agreement</u>") an award of performance-based Restricted Stock Units as set forth in such Grant Notice, subject to the terms and conditions set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Certain Definitions</u>**. Capitalized terms used, but not otherwise defined, in this Agreement will have the meanings given to such terms in the Grant Notice, or, if not defined therein, then in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Grant of PRSUs</u>**. Subject to and upon the terms, conditions and restrictions set forth in this Agreement and in the Plan, the Company has granted to the Participant, as of the Date of Grant, the target number of performance-based Restricted Stock Units set forth in the Grant Notice (the "<u>PRSUs</u>"). Each earned and vested PRSU shall represent the right of the Participant to receive one share of Common Stock subject to and upon the terms and conditions of this Agreement, the Plan and the achievement of the Management Objectives approved by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Restrictions on Transfer of PRSUs</u>**. Subject to Section 15 of the Plan, neither the PRSUs evidenced hereby nor any interest therein or in the shares of Common Stock underlying such PRSUs shall be transferable prior to payment to the Participant pursuant to **<u>Section 6</u>** hereof other than by will or pursuant to the laws of descent and distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Vesting of PRSUs</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>General Rule</u>. The PRSUs shall be subject to the terms of the Statement of Management Objectives provided to the Participant with respect to the PRSUs and approved by the Committee. As set forth in the Grant Notice, Earned PRSUs will be determined for the PRSUs in accordance with the Statement of Management Objectives on the date on which the Committee determines the level of attainment of the Management Objectives for the PRSUs (the "<u>Determination Date</u>"). The Determination Date for the PRSUs shall occur as soon as reasonably practicable, but in any event within 90 days, following the last day of the Performance Period. Provided that the Participant remains continuously employed with the Company or a Subsidiary through the last day of the Performance Period, the total Earned PRSUs shall vest on the Determination Date. Any PRSUs that do not so become vested will be forfeited, including, except as provided in **<u>Section 4(b)</u>** below, if the Participant ceases to be continuously employed by the Company or a Subsidiary for any reason prior to the end of the Performance Period. For purposes of this Agreement, "continuously employed" (or substantially similar terms) means the absence of any interruption or termination of the Participant's employment with the Company or a Subsidiary. Continuous employment shall not be considered

------

interrupted or terminated in the case of transfers between locations of the Company and its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Special Circumstances</u>. Notwithstanding **<u>Section 4(a)</u>** above:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;Upon any termination of the Participant's employment as a result of the Participant's death or Disability, in each case prior to the end of the Performance Period, the PRSUs shall remain outstanding and eligible to vest in full on the applicable Determination Date for such PRSUs (based on the actual achievement of any applicable Management Objectives, as determined by the Committee on such Determination Date).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;If the Participant's employment terminates as a result of Retirement prior to the end of the Performance Period, then a pro-rata portion of the PRSUs shall remain outstanding and eligible to vest on the applicable Determination Date for such PRSUs (based on the actual achievement of the applicable Management Objectives, as determined by the Committee on such Determination Date), with such pro-rata portion determined by multiplying (i) the total number of PRSUs by (ii) a fraction, the numerator of which is the number of full months that have elapsed from the first day of the Performance Period until the date of such termination and the denominator of which is the number of full months in the Performance Period, and subtracting from such amount the number of PRSUs (if any) that previously vested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Change in Control that occurs prior to the end of the Performance Period, the PRSUs shall become vested and payable in accordance with **<u>Section 5</u>** below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Effect of a Change in Control</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding **<u>Section 4(a)</u>** above, if at any time before the vesting or forfeiture of the PRSUs, and while the Participant is continuously employed by the Company or a Subsidiary, a Change in Control occurs, then all of the PRSUs will become immediately vested at the Change in Control Performance Level (as defined below), except to the extent that a Replacement Award is provided to the Participant in accordance with **<u>Section 5(c)</u>** to continue, replace or assume the PRSUs covered by this Agreement (the "<u>Replaced Award</u>") immediately prior to (and contingent upon) the Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, "<u>Change in Control Performance Level</u>" means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;if the Change in Control occurs on or before the last day of the Performance Period, the greater of (A) the "target" performance level and (B) the actual performance level measured as of the date of such Change in Control (as reasonably determined by the Committee, as constituted immediately prior to the Change in Control, in its sole discretion); or

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;if the Change in Control occurs after the last day of the Performance Period, the actual performance level measured as of the end of the Performance Period (as determined by the Committee, as constituted immediately prior to the Change in Control, in its sole discretion).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, a "<u>Replacement Award</u>" means an award (i) of time-based restricted stock units, (ii) that has a value at least equal to the value of the Replaced Award determined based on the Change in Control Performance Level, (iii) that relates to publicly traded equity securities of the Company or its successor in the Change in Control or another entity that is affiliated with the Company or its successor following the Change in Control, (iv) if the Participant is subject to U.S. federal income tax under the Code, the tax consequences of which to such Participant under the Code are not less favorable to such Participant than the tax consequences of the Replaced Award, and (v) the other terms and conditions of which are not less favorable to the Participant than the terms and conditions of the Replaced Award (including the provisions that would apply in the event of a subsequent termination of employment or change in control). A Replacement Award may be granted only to the extent it does not result in the Replaced Award or Replacement Award failing to comply with or be exempt from Section 409A of the Code. Without limiting the generality of the foregoing, the Replacement Award may take the form of a continuation of the Replaced Award if the requirements of the two preceding sentences are satisfied. The determination of whether the conditions of this paragraph are satisfied will be made by the Committee, as constituted immediately before the Change in Control, in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;If, within two years after receiving a Replacement Award, the Participant experiences a termination of employment with the Company or a Subsidiary (or any of their successors) (as applicable, the "<u>Successor</u>") by reason of a termination by the Successor without Cause or by the Participant for Good Reason during the remaining vesting period for the Replacement Award, the Replacement Award shall immediately vest in full upon such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Form and Time of Payment of PRSUs</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the PRSUs, after and to the extent they have become vested, shall be made in the form of shares of Common Stock. Except as provided in **<u>Section 6(b)</u>**, payment of the PRSUs shall be made in the calendar year following the calendar year in which the Performance Period ends.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding **<u>Section 6(a)</u>**, to the extent the PRSUs are not subject to a "substantial risk of forfeiture" (as defined for purposes of Section 409A of the Code) on the dates set forth below and have not previously been settled, payment for such vested PRSUs shall be made within thirty (30) days after such date:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;the date of a Change in Control, provided such Change in Control qualifies as a permissible date of distribution under Section 409A(a)(2)(A)(v) of the Code (a "<u>409A Change in Control</u>"); and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;subject to Section 17 of the Plan, the date of Participant's "separation from service" for purposes of Section 409A(a)(2)(A)(i) of the Code that occurs within two years after a 409A Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Except to the extent permitted by Section 409A of the Code and approved by the Committee, no shares of Common Stock may be issued to the Participant at a time earlier than otherwise expressly provided in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;The Company's obligations to the Participant with respect to the PRSUs will be satisfied in full upon the issuance of shares of Common Stock corresponding to such PRSUs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;**<u>No Dividend Equivalents; Voting and Other Rights</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Participant shall have no rights of ownership in the shares of Common Stock underlying the PRSUs, no rights to dividends with respect to such shares, and no right to vote the shares of Common Stock underlying the PRSUs until the date on which the shares of Common Stock underlying the PRSUs are issued or transferred to the Participant pursuant to **<u>Section 6</u>** above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The obligation of the Company under this Agreement will be merely that of an unfunded and unsecured promise of the Company to deliver shares of Common Stock in the future, and the rights of the Participant will be no greater than that of an unsecured general creditor. No assets of the Company will be held or set aside as security for the obligations of the Company under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Adjustments</u>**. The PRSUs and the number of shares of Common Stock issuable for each PRSU and the other terms and conditions of the grant evidenced by this Agreement are subject to mandatory adjustment, including as provided in Section 11 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Taxes</u>**. To the extent that the Company is required to withhold federal, state, local, or foreign taxes or other amounts in connection with any payment made or benefit realized by the Participant under this Agreement, and the amounts available to the Company for such withholding are insufficient, it shall be a condition to the receipt of such payment or the realization of such benefit that the Participant make arrangements satisfactory to the Company for payment of the balance of such taxes or other amounts required to be withheld. If the Participant's benefit is to be received in the form of shares of Common Stock, then, unless otherwise determined by the Committee, the Company will withhold shares of Common Stock having a value equal to the amount required to be withheld. The shares of Common Stock used for tax or other withholding will be valued at an amount equal to the fair market value of such shares of Common Stock on the date the benefit is to be included in the Participant's income. The market value of Common Stock to be withheld pursuant to this **<u>Section 9</u>** to satisfy applicable withholding taxes or other amounts may exceed the minimum amount of taxes required to be withheld in accordance with procedures established by the Company, including pursuant to the aggregate method of withholding. Notwithstanding any other provision of this Agreement, the Company shall not be obligated to guarantee any particular tax result for the Participant with respect to any payment provided to the

------

Participant hereunder, and the Participant shall be responsible for any taxes imposed on the Participant with respect to any such payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Compliance with Law</u>**. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws; <u>provided</u>, <u>however</u>, that notwithstanding any other provision of the Plan and this Agreement, the Company shall not be obligated to issue any shares of Common Stock pursuant to this Agreement if the issuance thereof would result in a violation of any such law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Compliance With Section 409A of the Code</u>**. To the extent applicable, it is intended that this Agreement and the Plan comply with the provisions of Section 409A of the Code. This Agreement and the Plan shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of the Participant). Notwithstanding the foregoing, the Company is not guaranteeing any particular tax outcome, and the Participant shall remain solely liable for any and all tax consequences associated with the PRSUs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Interpretation</u>**. Any reference in this Agreement to Section 409A of the Code will also include any proposed, temporary or final regulations, or any other guidance, promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;**<u>No Right to Future Awards or Employment</u>**. The grant of the PRSUs under this Agreement to the Participant is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards. The grant of the PRSUs and any payments made hereunder will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law. Nothing contained in this Agreement shall confer upon the Participant any right to be employed or remain employed by the Company or any of its Subsidiaries, nor limit or affect in any manner the right of the Company or any of its Subsidiaries to terminate the employment or adjust the compensation of the Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Relation to Other Benefits</u>**. Any economic or other benefit to the Participant under this Agreement or the Plan shall not be taken into account in determining any benefits to which the Participant may be entitled under any other compensatory arrangement maintained by the Company or any of its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Amendments</u>**. Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; <u>provided</u>, <u>however</u>, that no amendment shall adversely affect the rights of the Participant under this Agreement without the Participant's written consent, and the Participant's consent shall not be required to an amendment that is deemed necessary by the Company to ensure compliance with Section 409A of the Code or Section 10D of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Severability</u>**. In the event that one or more of the provisions of this Agreement shall be invalidated for any reason by a court of competent jurisdiction, any provision so

------

invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Relation to Plan</u>**. The PRSUs granted under this Agreement and all of the terms and conditions hereof are subject to all of the terms and conditions of the Plan. In the event of any inconsistency between this Agreement and the Plan, the terms of the Plan will govern. The Committee acting pursuant to the Plan, as constituted from time to time, shall, except as expressly provided otherwise herein or in the Plan, have the right to determine any questions which arise in connection with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Compensation Recovery Policy</u>**. Notwithstanding anything in this Agreement to the contrary, the Participant acknowledges and agrees that this Agreement and the award described herein are subject to the terms and conditions of the Company's clawback policy (if any) as may be in effect from time to time, including specifically to implement Section 10D of the Exchange Act and any applicable rules or regulations promulgated thereunder (including applicable rules and regulations of any national securities exchange on which the Common Stock may be traded) (the "<u>Compensation Recovery Policy</u>"), and that applicable sections of this Agreement and any related documents shall be superseded by and subject to the terms and conditions of the Compensation Recovery Policy from and after the effective date thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Electronic Delivery</u>**. The Company may, in its sole discretion, deliver any documents related to the PRSUs and the Participant's participation in the Plan, or future awards that may be granted under the Plan, by electronic means or request the Participant's consent to participate in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Governing Law</u>.** This Agreement shall be governed by and construed with the internal substantive laws of the State of Delaware, without giving effect to any principle of law that would result in the application of the law of any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Successors and Assigns</u>**. Without limiting **<u>Section 3</u>** hereof, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of the Participant, and the successors and assigns of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Acknowledgement</u>**. The Participant acknowledges that the Participant (a) has received a copy of the Plan, (b) has had an opportunity to review the terms of this Agreement and the Plan, (c) understands the terms and conditions of this Agreement and the Plan and (d) agrees to such terms and conditions. Nothing in this Agreement prevents the Participant from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Counterparts</u>**. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same agreement.

## Exhibit 19.1

**Exhibit 19.1**

**ENHABIT, INC. INSIDER TRADING POLICY**

(as amended and restated February 19, 2025)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Purpose and Scope</u>. This Insider Trading Policy (this "**Policy**") provides guidelines with respect to transactions in the securities of Enhabit, Inc., a Delaware corporation (including its direct and indirect subsidiaries, the "**Company**" or "**Enhabit**"). The Company has adopted this Policy to promote compliance with applicable laws that prohibit certain persons who are aware of material nonpublic information (as defined below) about a company from: (i) trading in securities of that company; or (ii) providing material nonpublic information to other persons who may trade on the basis of that information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Persons Covered under this Policy</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.This Policy applies to all employees, officers and directors of the Company and its subsidiaries. This Policy also applies to certain family members of persons covered by this Policy-- specifically, their spouses, any minor child or minor step-child, and any other family member who lives in their households or who lives elsewhere but whose transactions are directed by or are subject to their influence or control (e.g., parents or adult children who consult with persons covered by this Policy before they trade in Enhabit stock) ("**Family Members**"). For purposes of this Policy, Family Members may include a person's parent, step-parent, grandparent, grandchild, sibling, mother- or father-in law, son- or daughter-in-law, and brother- or sister-in law. This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual's own account.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.This Policy includes certain requirements that apply only to directors and executive officers (collectively called "**Section 16 Persons**"), and to certain other designated individuals called "**Other Insiders**" whom the Company has determined are likely to have access to the Company's non-public quarterly financial information. The Company will periodically update its list of Section 16 Persons and Other Insiders, and will notify affected individuals when they have been added to or removed from the list.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Prohibition Against Trading on Material Nonpublic Information</u>. During the course of your service at Enhabit, you may become aware of material nonpublic information. If you are aware of material nonpublic information regarding Enhabit, you are prohibited from trading in Enhabit stock or derivative securities relating to Enhabit stock, unless such trade is made pursuant to a properly qualified, adopted and approved Rule 10b5-1 trading plan. Rule 10b5-1 trading plans are discussed in Section 5 of this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.*Material*. It is difficult to describe exhaustively what constitutes "**material**" information, but you should assume that any information, positive or negative, which might be of significance to an investor, as part of the total mix of available information, in determining whether to purchase, sell or hold Enhabit stock would be material. Information may be significant for this purpose even if it would not alone determine the investor's decision. Examples include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• earnings and related financial performance information and operating results

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• internal financial information which departs in any way from what the market would expect

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• significant changes in volumes, market share, payor-mix, strategic plans, or liquidity

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an important financing transaction

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• stock splits or other transactions relating to Enhabit stock

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• mergers, tender offers or acquisitions of other companies, or major purchases or sales of assets

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in senior management

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• sales or purchases by Enhabit of its own stock

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• major litigation

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• major transactions with other companies, such as joint ventures or Medicare Advantage contracts

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a major cybersecurity incident

**Note that this list is merely illustrative and not exhaustive.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.*Nonpublic*. "**Nonpublic**" *information* is any information which has not yet been disclosed generally to the marketplace. *Information* received about a company under circumstances which indicate that it is not yet in general circulation should be considered nonpublic. As a rule, you should be able to point to some fact to show that the information is generally available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.*Trading Day*. "**Trading Day**" shall mean any day on which the New York Stock Exchange is open for *trading*. Even after nonpublic information has been disclosed generally to the marketplace—for example, by the Company issuing a press release—at least one full Trading Day must elapse after the day the information has been generally disclosed before you can trade in Enhabit stock. For example, if Enhabit issues a press release containing material information at 1:00 p.m. on a Tuesday, and the New York Stock Exchange is open for trading on Wednesday, persons subject to this Policy shall not be permitted to trade in Enhabit stock until Thursday. If Enhabit issues a press release containing material information at 6:00 p.m. on a Friday, and the New York Stock Exchange is open for trading on Monday, persons subject to this Policy shall not be permitted to trade in Enhabit stock until Tuesday.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.You also are prohibited from giving "tips" on material nonpublic information. That means you shall not, *directly* or indirectly, disclose material nonpublic information to any other person, including without limitation Family Members, that could inform their trades in Enhabit stock or derivative securities relating to Enhabit stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.Furthermore, if you learn material nonpublic information about another company with which Enhabit does business, such as a supplier, customer or joint venture partner, or you learn that Enhabit is planning a major transaction with another company (such as an acquisition), you must not (i) "tip" or disclose the material nonpublic information to anyone or (ii) trade in the securities of the other company until such information has been made public for at least one full Trading Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f.This means, if you are aware of material nonpublic information, you must forego a transaction in Enhabit stock or the securities of another company even though

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• you planned the transaction before learning of the material nonpublic information,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• you may lose money or a potential profit by not completing the transaction, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the transaction may be necessary or seem justifiable for independent reasons (including a need to raise money for a personal financial reason).

Remember that anyone scrutinizing your transactions will be doing so after the fact, with the benefit of hindsight. As a result, before engaging in any transaction you should carefully consider how your transaction may be construed by enforcement authorities and others in hindsight.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Trading Blackout Periods</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*Quarterly Recurring Blackout*. Section 16 Persons and Other Insiders and their Family Members may only trade Enhabit stock during the period commencing one full Trading Day following a release of Enhabit's quarterly results, and ending at the close of business on the 15<sup>th</sup> calendar day of the third month of each quarter (provided that if the 15<sup>th</sup> calendar day is a Saturday, Sunday or weekday on which the New York Stock Exchange is closed for trading, the trading widow will close at the close of business on the immediately preceding Trading Day). Nonetheless, as mentioned above, no trade of Enhabit stock may be made during these periods if the person covered by this Policy possesses material nonpublic information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*Special Blackout*. From time to time, upon prior notice to the persons affected, the Company may *impose* event-specific special blackout periods during which other specific individuals are prohibited from trading in Enhabit stock. The fact of the special blackout period and the identity of persons affected by it shall be kept confidential and shall not be disclosed to others not subject to it.

------

The trading restrictions set forth in this Section 4 do not apply to any trades made pursuant to properly qualified, adopted and approved Rule 10b5-1 trading plans.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Rule 10b5-1 Trading Plans</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Rule 10b5-1 under the Securities Exchange Act of 1934 provides an affirmative defense against a *claim* of insider trading if an insider's trades are made pursuant to a written plan that was adopted in good faith at a time when the insider was not aware of material nonpublic information. It is the Company's policy that employees and directors may make trades pursuant to a Rule 10b5-1 plan provided that (i) such plan meets the requirements of Rule 10b5-1, (ii) such plan was adopted at a time when the employee or director would otherwise have been able to trade under Sections 3 and 4 of this Policy and (iii) adoption of the plan was expressly authorized by the Company's General Counsel or by his or her designee. No trade under a Rule 10b5-1 plan may be triggered earlier than the later to occur of (x) 90 days after the date the Rule 10b5-1 plan is executed, or (y) 2 business days after the filing of the Company's Form 10-Q (or Form 10-K for any plan executed during the fourth fiscal quarter) for the fiscal quarter in which the plan was executed, up to a maximum of 120 days after the date the plan is executed. In addition, any Rule 10b5-1 plan must be (I) the sole outstanding Rule 10b5-1 plan for such insider, unless an exception is approved in advance by the Company's General Counsel, after evaluating whether any such additional plan would be permitted by Rule 10b5-1, and (II) if such Rule 10b5-1 plan is a single-trade plan, the sole single-trade plan within any consecutive 12-month period. Note that trades made pursuant to Rule 10b5-1 plans by Section 16 Persons must still be reported to the General Counsel pursuant Section 6(b) below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*Outside* of blackout periods and subject to this Policy, trades differing from trading plan instructions that are already in place are allowed as long as the trading plan continues to be followed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>Additional Restrictions and Obligations for Directors and Officers</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*Pre-clearance*. In addition to complying with the prohibition on trading during scheduled and event-specific special blackout periods, Section 16 Persons must first obtain pre-clearance from the Company's General Counsel or his or her designee in the Legal Department before engaging in any *transaction* in Enhabit stock. A request for pre-clearance should be submitted to the General Counsel at least 48 hours in advance of the proposed transaction in a form prescribed by the General Counsel. If the General Counsel seeks pre-clearance, he or she shall request it from the Chief Executive Officer in consultation with counsel. If a proposed transaction receives pre-clearance, the pre-cleared trade must be effected no later than the close of the third Trading Day after the date of receipt of pre-clearance. If the requesting person becomes aware of material nonpublic information before the trade is executed, the pre-clearance is void and the trade must not be completed. Transactions not effected within the time limit become subject to pre-clearance again. If a requesting person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in Enhabit stock and should not inform any other person of the restriction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*Reporting Trades and Short Swing Liability*. Section 16 Persons must also comply with the *reporting* obligations and limitations on short-swing profit transactions set forth in federal securities laws. Section 16 Persons must report the purchase or sale of Enhabit stock to the Company's General Counsel as soon as reasonably practical but no later than one day after any such transaction. Section 16 Persons may be required to disgorge to the Company all profits of purchases and sales that occurred within the same six- month period, whether or not such individual had knowledge of any material nonpublic information. For this reason, it is important that Section 16 Persons contact the General Counsel prior to any trade in Enhabit stock. Your adherence to this Policy is vital to your protection as well as Enhabit's.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<u>Transactions Under Company Plans</u>. This Policy does not apply in the case of the following transactions, except as specifically noted:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*Restricted Stock Awards*. This Policy does not apply to the acquisition of shares of common stock upon vesting of restricted stock or the exercise of a tax withholding right pursuant to which the Company withholds shares of stock to satisfy tax withholding requirements upon the vesting of any restricted stock. The Policy does apply, however, to any market sale of vested shares of restricted stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*Stock Option Exercises*. This Policy does not apply to the exercise of stock options acquired pursuant to the Company's plans or to the exercise of a tax withholding right pursuant to which the Company withholds shares subject to an option to satisfy tax withholding requirements. This Policy does apply, however, to any sale of stock

------

as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)*Other Similar Transactions*. Any other purchase of Enhabit stock from the Company or sales of Enhabit stock to the Company are not subject to this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.<u>Gifts of Enhabit Stock</u>. All persons subject to this Policy must make gifts of Enhabit stock only at times when they could transact in Enhabit stock in compliance with this Policy. Any person subject to this Policy wishing to make a gift of Enhabit stock is also subject to the trading blackout periods and pre-clearance requirements referenced above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.<u>Prohibition Against Short Sales</u>. You and your Family Members may not, under any circumstances, trade options for, or sell "short," Enhabit stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.<u>Prohibition Against Hedging Transactions</u>. Hedging transactions may insulate you from upside or downside price movement in Enhabit stock which can result in the perception that you no longer have the same interests as the Company's other stockholders. Accordingly, you and your Family Members may not enter into hedging or monetization transactions such as zero-cost collars, equity swaps, exchange funds, forward sale contracts, or similar arrangements with respect to Enhabit stock, including the purchase or sale of puts or calls or the use of any other derivative instruments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.<u>Margin Accounts and Pledging</u>. Securities held in a margin account or pledged as collateral for a loan may be sold without your consent by the broker if you fail to meet a margin call or by the lender in foreclosure if you default on the loan. A margin or foreclosure sale that occurs when you are aware of material nonpublic information may, under some circumstances, result in unlawful insider trading. Because of this danger, you and your Family Members may not hold Enhabit stock in a margin account nor pledge Enhabit stock as collateral for a loan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.<u>Policy Interpretations and Amendments</u>. The General Counsel is responsible for interpreting and updating this Policy as required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.<u>Company Transactions</u>. From time to time, the Company may engage in transactions in its own securities. It is the Company's policy to comply with all applicable securities and state laws (including appropriate approvals by the Board of Directors or appropriate committee, if required) when engaging in transactions of its securities.

\* \* \*

THESE ARE VERY SERIOUS MATTERS. INSIDER TRADING IS ILLEGAL AND CAN RESULT IN JAIL SENTENCES AS WELL AS CIVIL PENALTIES, INCLUDING TRIPLE DAMAGES. EMPLOYEES WHO VIOLATE THIS POLICY MAY BE SUBJECT TO DISCIPLINARY ACTION BY THE COMPANY, INCLUDING DISMISSAL FOR CAUSE. IF YOU HAVE ANY QUESTION OR DOUBT ABOUT THE APPLICABILITY OR INTERPRETATION OF THIS POLICY OR THE PROPRIETY OF ANY DESIRED ACTION, PLEASE SEEK CLARIFICATION FROM OUR GENERAL COUNSEL. DO NOT TRY TO RESOLVE UNCERTAINTIES ON YOUR OWN.

## Exhibit 21.1

**Exhibit 21.1**

---

| | |
|:---|:---|
| **Enhabit, Inc. Subsidiaries** | **Enhabit, Inc. Subsidiaries** |
| **<u>Name</u>** | **<u>Jurisdiction</u>** |
| A&B Home Health Solutions, LLC | Delaware |
| Abba Home Health, L.P. | Texas |
| Advanced Homecare Home Office, LLC | Delaware |
| Advanced Homecare Management, LLC | Delaware |
| AHM Action Home Health, LP | Texas |
| AHM Texas GP, LLC | Delaware |
| AHM Texas Holdings, Inc. | Delaware |
| AHM Texas LP, Inc. | Delaware |
| Apex Hospice LLC | Texas |
| Best Home Care LP | Texas |
| Camellia Home Health of Alabama, LLC | Alabama |
| Camellia Home Health of East Tennessee, LLC | Delaware |
| Camellia Home Health of the Gulf Coast, LLC | Mississippi |
| Camellia Hospice of Central Mississippi, LLC | Mississippi |
| Camellia Hospice of East Louisiana, LLC | Delaware |
| Camellia Hospice of Louisiana, LLC | Delaware |
| Camellia Hospice of North Mississippi, LLC | Mississippi |
| Camellia Hospice of Northeast Alabama LLC | Alabama |
| Camellia Hospice of Northeast Mississippi, LLC | Mississippi |
| Camellia Hospice of South Alabama, LLC | Mississippi |
| Camellia Hospice of Southwest Mississippi, LLC | Mississippi |
| Camellia Hospice of the Gulf Coast, LLC | Mississippi |
| Camellia Medical Systems, Inc. | Mississippi |
| CareServices of Bethesda, LLC (100% Ownership – EH Health Home Health of South Florida, LLC) | Florida |
| CareServices of the Treasure Coast, LLC | Florida |
| CareSouth Health System, Inc. | Delaware |
| CareSouth HHA Holdings of Columbus, LLC | Georgia |
| CareSouth HHA Holdings of Dothan, LLC | Georgia |
| CareSouth HHA Holdings of Gainesville, LLC | Georgia |
| CareSouth HHA Holdings of Greensboro, LLC | Georgia |
| CareSouth HHA Holdings of Lexington, LLC | Georgia |
| CareSouth HHA Holdings of North Florida, LLC | Georgia |
| CareSouth HHA Holdings of Panama City, LLC | Florida |
| CareSouth HHA Holdings of Richmond, LLC | Delaware |
| CareSouth HHA Holdings of South Carolina, LLC | Georgia |
| CareSouth HHA Holdings of Tallahassee, LLC | Florida |
| CareSouth HHA Holdings of the Bay Area, LLC | Georgia |
| CareSouth HHA Holdings of Valley, LLC | Georgia |
| CareSouth HHA Holdings of Virginia, LLC | Georgia |
| CareSouth HHA Holdings of Washington, LLC | Georgia |
| CareSouth HHA Holdings of Western Carolina, LLC | Georgia |
| CareSouth HHA Holdings of Winchester, LLC | Georgia |
| CareSouth HHA Holdings, LLC | Georgia |
| CareSouth Hospice, LLC | Georgia |
| Continental Home Care, LLC | Delaware |
| CS Health & Wellness, LLC | Georgia |

---

------

---

| | |
|:---|:---|
| Day-By-Day Staff Relief, LLC | Delaware |
| DOSIK, INC. | Texas |
| DRC Health Systems, L.P. | Texas |
| EH Health Home Health of Alabama, LLC | Delaware |
| EH Health Home Health of Birmingham, LLC | Delaware |
| EH Health Home Health of Central Virginia, LLC | Delaware |
| EH Health Home Health of Florida, LLC | Delaware |
| EH Health Home Health of Kentucky, LLC | Delaware |
| EH Health Home Health of Miami, LLC (100% Ownership-EH Health Home Health of South Florida, LLC) | Florida |
| EH Health Home Health of New England, LLC | Delaware |
| EH Health Home Health of Ohio, LLC | Delaware |
| EH Health Home Health of the Northwest, LLC | Delaware |
| EH Health Home Health of the Southwest, LLC | Delaware |
| EH Health Hospice of Alabama, LLC | Delaware |
| EH Health Hospice of Pennsylvania, LLC | Delaware |
| EH Health Hospice of the Midwest, LLC | Delaware |
| EH Health Hospice of the Northwest, LLC | Delaware |
| EH Health Hospice of the Southwest, LLC | Delaware |
| EH Health Ventures Boise, LLC | Delaware |
| EH Health Ventures Bozeman, LLC | Delaware |
| EH Health Ventures Salida, LLC | Delaware |
| EH Home Health of Austin, LLC | Texas |
| EH Home Health of Colorado, LLC | Delaware |
| EH Home Health of DFW, LLC | Texas |
| EH Home Health of East Texas, LLC | Delaware |
| EH Home Health of New England, LLC | Delaware |
| EH Home Health of the Mid Atlantic, LLC | Delaware |
| EH Home Health of the Midwest, LLC | Delaware |
| EH Home Health of the Southeast, LLC | Florida |
| EH Home Health of the West, LLC | Idaho |
| EH Hospice of Central Florida, LLC | Delaware |
| EH Hospice of Colorado, LLC | Delaware |
| EH Hospice of North Texas, LLC | Delaware |
| EH Hospice of Northern Florida, LLC | Delaware |
| EH Hospice of Southern Florida, LLC | Delaware |
| EH Hospice of the Mid Atlantic, LLC | Delaware |
| EH Hospice of the West, LLC | Idaho |
| EH of Fort Worth, LP | Texas |
| EH of West Texas, LP | Texas |
| EHHH Support Companies, LLC | Delaware |
| Enhabit Holdings, Inc. | Delaware |
| EXCELLA ASSOCIATES, L.L.C. | Massachusetts |
| EXCELLA HEALTHCARE, INC. | Massachusetts |
| EXCELLA HOME HEALTH AGENCY, LLC | Massachusetts |
| EXCELLA HOMECARE, INC. | Massachusetts |
| Guardian Home Care, Inc. | Idaho |
| Hallmark Homecare, L.P. | Texas |
| HealthCare Innovations of Oklahoma, L.L.C. | Texas |
| HEALTHCARE INNOVATIONS OF WESTERN OKLAHOMA, LLC | Texas |

---

------

---

| | |
|:---|:---|
| HealthCare Innovations-Travertine Health Services, L.L.C. | Texas |
| Home Health Care of Bogalusa, Inc. | Delaware |
| Home Health Care Systems, Inc. | Mississippi |
| Hospice Care of Mississippi, LLC | Mississippi |
| Idaho Homecare Holdings, Inc. | Idaho |
| Orion Homecare, LLC | Idaho |
| Preferred Home Health, L.P. | Texas |
| Saad Healthcare of St. Clair County LLC | Delaware |
| Texas Senior Care, L.P. | Texas |
| TH of San Antonio LLC | Texas |
| WellCare, Inc. | New Mexico |
| Wellmark Healthcare Services of El Paso, Inc. | Texas |
| West Mississippi Home Health Services, Inc. | Mississippi |
| ***Joint Ventures*** |  |
| CareSouth HHA Holdings of Middle Georgia, LLC (81% Ownership) | Georgia |
| CareSouth HHA Holdings of the Treasure Coast, LLC (60% Ownership) | Florida |
| EH Health Home Health of South Florida, LLC (80% Ownership) | Florida |
| EH Home Health of Roanoke – (50% Ownership) | Delaware |
| Encompass Health Home Health of Talladega, LLC (75% Ownership) | Delaware |
| Encompass Health Hospice of Talladega, LLC (75% Ownership) | Delaware |
| Heart of the Rockies Home Health, LLC (50% Ownership) | Delaware |
| Hospice of Southwest Montana, LLC (90% Ownership) | Delaware |
| Saint Alphonsus Home Health and Hospice, LLC (50% Ownership) | Delaware |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (Nos. 333-288360 and 333-265957) of Enhabit, Inc. of our report dated March 4, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

Dallas, Texas

March 4, 2026

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) OF THE**

**SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

<br> I, Barbara A. Jacobsmeyer, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Annual Report on Form 10-K of Enhabit, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. <br>

Date: March 4, 2026

---

| | |
|:---|:---|
| By: | /s/ Barbara A. Jacobsmeyer |
|  | Barbara A. Jacobsmeyer |
|  | President and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) OF THE**

**SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

<br> I, Ryan Solomon, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Annual Report on Form 10-K of Enhabit, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 4, 2026

---

| | |
|:---|:---|
| By: | /s/ Ryan Solomon |
|  | Ryan Solomon |
|  | Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED** 

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

<br> In connection with the Annual Report of Enhabit, Inc. (the "Company") on Form 10-K for the period ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Barbara A. Jacobsmeyer, President and Chief Executive Officer of Enhabit, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.<br>

---

| | | | |
|:---|:---|:---|:---|
| Date: | March 4, 2026 |  |  |
|  |  | By: | /s/ Barbara A. Jacobsmeyer |
|  |  | Name: | Barbara A. Jacobsmeyer |
|  |  | Title: | President and Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED** 

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Enhabit, Inc. (the "Company") on Form 10-K for the period ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ryan Solomon, Chief Financial Officer of Enhabit, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Date: | March 4, 2026 |  |  |
|  |  | By: | /s/ Ryan Solomon |
|  |  | Name: | Ryan Solomon |
|  |  | Title: | Chief Financial Officer |

---

<br>